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Chances of quitting 
tobacco can more 
than double 
with the right 
support. 
 Quitting tobacco has 
major and immediate 
health benefits.
. We will not reach 
global targets to 
reduce tobacco use 
and related deaths if 
we do not help people 
to quit now.
WHO report on the global tobacco epidemic, 2019: 
Offer help to quit tobacco use  is the seventh in a series 
of  WHO reports that tracks the status of the tobacco 
epidemic and interventions to combat it.
Monitor
Protect
Offer
Warn
Enforce
Raise
Monitor tobacco use and 
prevention policies
Protect people from 
tobacco smoke 
Offer help to quit tobacco use
Warn about the 
dangers of tobacco
Enforce bans on tobacco 
advertising, promotion and 
sponsorship
Raise taxes on tobacco
 Helping people to quit has 
more impact when efforts are 
combined with other tobacco 
control strategies.
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tobacco cessation interventions must be 
a priority for countries. at the same time, 
innovation is to be encouraged and mobile 
technologies should be fully harnessed to 
improve access to large and hard-to-reach 
populations.  
The importance of tobacco control and 
cessation for global health are reflected in 
the Sustainable Development Goals, which 
call for strengthened implementation of 
the WHO FCTC. The mPOWEr measures 
can assist governments by providing 
key tools to combat the global tobacco 
epidemic. Only if we help people quit 
tobacco now will we be able to reach our 
global targets to reduce the prevalence of 
tobacco use and avert years of debilitating 
illness and millions of preventable deaths. 
Dr Tedros Adhanom Ghebreyesus
Director-General
World Health Organization
THE NuMBER Of PEOPLE PROTECTED By AT LEAsT ONE MPOWER 
MEAsuRE HAs MORE THAN QuADRuPLED sINCE 2007
“Providing access to, and encouraging the use of, 
effective cessation interventions greatly increases 
the likelihood of successfully quitting tobacco.”
Dr Tedros Adhanom Ghebreyesus, WHO Director-General
“Tobacco control is a perfect example of what
can be achieved in global health through
global commitments.”
Tobacco control is a perfect example of 
what can be achieved in global health 
through global commitments. Since 
the adoption of the WHO Framework 
Convention on Tobacco Control (WHO 
FCTC) in 2003, most countries have 
made great strides in implementing 
tobacco control measures. In 2008, WHO 
introduced the six mPOWEr measures to 
help countries implement the WHO FCTC 
using effective interventions that are 
proven to reduce demand for tobacco. 
Since the introduction of mPOWEr, the 
number of countries that have adopted 
at least one measure at best-practice 
level has more than quadrupled. We can 
now report that 136 countries covering 
5 billion people have implemented at 
least one of the key policy interventions 
to reduce tobacco demand. more than 
ever, people are aware of tobacco’s harms 
and consequences. Due in part to these 
successes, many tobacco users now want 
to quit; and we know how to help them. 
This seventh WHO report on the global 
tobacco epidemic focuses on the “O” of 
mPOWEr: “Offer help to quit tobacco 
use”. Today’s tobacco users will make up 
the majority of future tobacco-related 
deaths, which will disproportionately 
affect low- and middle-income countries. 
Providing access to, and encouraging the 
use of, effective cessation interventions 
greatly increases the likelihood of 
successfully quitting tobacco. 
article 14 of the WHO FCTC calls for 
tobacco cessation services to be put in 
place at country level. recommended 
approaches include: brief advice at primary 
care level, national toll-free tobacco quit 
lines, cost-covered nicotine replacement 
therapies and the use of digital and mobile 
technologies to empower those who want 
to quit. These interventions work best in 
combination but can be introduced in a 
step-wise approach where resources are 
limited. 
Help to quit tobacco can and should be 
incorporated into any universal health 
coverage strategy. Over the past decade 
there has been a dramatic increase in 
middle-income countries incorporating 
partially or fully cost-covered quit 
interventions into some or most of 
their primary care services – population 
coverage rose from 16% in 2007 to 78% 
in 2018. among high-income countries, 
the rate has increased from 61% to 97%. 
Implementation of a full package of 
cessation services at best-practice levels 
however, remains remarkably uncommon 
in most countries. as of 2018 only 23 
countries (including only six middle-income 
countries and one low-income country) 
offered comprehensive cessation support 
for tobacco users seeking help to quit. 
Governments must recognize this unmet 
need and act on it immediately as part 
of a comprehensive tobacco control 
strategy. Population-level, cost-effective 
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and global support for effective policies 
is growing. But the fight against an 
aggressive and ever evolving industry is 
far from over. more national governments 
can focus greater attention on the scourge 
of tobacco. more can take strong, life-
saving action. and together, by working 
to replicate proven strategies across the 
world, we can save millions more lives.
Michael R. Bloomberg
WHO Global ambassador for 
Noncommunicable Diseases and Injuries
Founder, Bloomberg Philanthropies
fIvE BILLION PEOPLE NOW COvERED By MPOWER POLICIEs sHOWING 
COuNTRIEs CAN WIN fIGHT AGAINsT THE TOBACCO EPIDEMIC
“Together, by working
to replicate proven strategies across the
world, we can save millions more lives.”
Michael R. Bloomberg, WHO Global Ambassador for Noncommunicable Diseases
Founder of Bloomberg Philanthropies
Tobacco use poses an enormous threat 
to public health worldwide, killing more 
than eight million people every year. more 
countries are making tobacco control a 
priority and saving lives, but there is much 
more work to be done. 
The World Health Organization and 
Bloomberg Philanthropies are committed to 
accelerating the reduction of tobacco use 
worldwide. The challenges are daunting, 
but together, we are proving that this is a 
winnable fight. 
WHO tracks the implementation of the 
six mPOWEr strategies to reduce tobacco 
use, and by showing their impact we 
help spur more countries to adopt them. 
The mPOWEr measures, in line with the 
WHO Framework Convention on Tobacco 
Control, have helped countries make 
unprecedented progress. Since 2007, the 
share of the global population covered 
by at least one mPOWEr policy has more 
than quadrupled. The result is that today, 
five billion people are protected from the 
harmful effects of tobacco use, and the 
number of countries with best-practice 
cessation policies has more than doubled 
from 10 to 23. In addition to advice from 
primary care providers and toll-free quit 
lines, digital technology is transforming 
how people access cessation services and 
get help quitting.
This report shines a spotlight on global 
efforts to help people quit tobacco, and it 
details some of our most important gains. 
India, for example, has greatly increased 
access to services through an innovative 
program that allows participants to enroll 
and receive tailored support to quit on 
their mobile phones. and Brazil is now 
the second country in the world that has 
passed all mPOWEr policies at the highest 
level.
 
Noncommunicable diseases (NCDs) 
cause more than two thirds of deaths in 
developing countries, and tobacco use is a 
major risk factor for NCDs such as cancer 
and heart disease. yet, programs to reduce 
NCDs remain chronically underfunded. Only 
2% of development funding goes toward 
their prevention.
 
Bloomberg Philanthropies works in close 
partnership with Director-General Tedros 
Ghebreyesus and WHO to combat NCDs, 
“WHO tracks the implementation of the six 
MPOWER strategies to reduce tobacco use, and 
by showing their impact, we help spur more 
countries to adopt them.” 
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TOBACCO CONTROL Is A KEy PART Of THE susTAINABLE 
DEvELOPMENT GOALs, MAKING sWIfT AND fuLL IMPLEMENTATION 
Of THE WHO fCTC MORE uRGENT THAN EvER
Dr Vera Luiza da Costa e Silva
Head of the WHO FCTC Secretariat
 
“The overarching objective of the treaty is to protect 
present and future generations from the devastating 
health, economic, social and environmental 
impact of tobacco.”
“It goes without saying that strong tobacco cessation 
support is needed to achieve the SDG targets 
on tobacco control.”
Dr Vera Luiza da Costa e Silva, Head of the WHO FCTC Secretariat
commitment to implementing the WHO 
FCTC.
Published every 2 years since 2008, the 
WHO report on the global tobacco epidemic 
provides comparable data to enable analysis 
of progress towards protecting the world’s 
people from what is now globally the 
biggest single preventable cause of death. 
as this latest edition shows, there is much 
to applaud. already 5 billion people are 
now covered by at least one core demand 
reduction measure of the WHO FCTC at 
the highest level of achievement. and 136 
countries now protect their populations 
by having one or more of these policies 
adopted at best-practice level (as defined in 
the report). However, while some Parties are 
making steady progress, many are lagging, 
and more needs to be done.
It is no secret that the tobacco industry is 
our greatest obstacle to ending the tobacco 
epidemic. This industry makes vast profits 
from selling tobacco and making people 
dependent upon it – and they do not want 
anything to change. But for the sake of 
public health, and in the interests of our 
children and future generations, things must 
change. We are deeply concerned by the fact 
that the tobacco epidemic is shifting to the 
developing world, where less-well resourced 
countries find themselves unable to counter 
tobacco industry exploitation of new 
markets – often through blatant interference 
with public health policy-making. 
Implementing article 5.3 of the WHO FCTC, 
which requires Parties to protect public 
health policy from the tobacco industry, is a 
critical step to preventing tobacco industry 
interference in public health policy-making. 
This report focuses on tobacco cessation 
and outlines progress to date on the 
implementation of article 14 of the WHO 
FCTC. reducing demand for tobacco 
through cessation support is one of the 
WHO FCTC’s core demand reduction 
strategies. article 14 of the WHO FCTC and 
its Guidelines call upon Parties to implement 
a series of measures to assist tobacco users 
to quit. When countries implement such 
measures they could ensure, at the same 
time, that these interventions become 
integral parts of universal health coverage. 
The Convention Secretariat of the WHO 
Framework Convention on Tobacco Control 
(WHO FCTC) and the Protocol to Eliminate 
Illicit Trade in Tobacco Products welcomes 
the publication of the seventh WHO report 
on the global tobacco epidemic. 
The 181 Parties to the WHO FCTC have 
committed themselves to saving lives 
through tobacco control. Based on strong 
evidence, the WHO FCTC sets minimum 
standards to guide Parties in adopting 
strong tobacco control policies and 
legislation to tackle the tobacco epidemic, 
which causes 8 million deaths a year 
worldwide. The overarching objective of 
the treaty is to protect present and future 
generations from the devastating health, 
economic, social and environmental impact 
of tobacco.
In the past year we have seen two major 
achievements in tobacco control. The first 
was the entering into force of the Protocol 
to Eliminate Illicit Trade in Tobacco Products 
on 25 September 2018. Fifty-five Parties 
to the WHO FCTC had already adhered to 
the Protocol by June 2019 – a sign of their 
deepening commitment to tackle the issue. 
The second major achievement was the 
adoption by the Conference of the Parties 
(COP, the governing body of the WHO 
FCTC) of the Global Strategy to accelerate 
Tobacco Control: advancing Sustainable 
Development through the Implementation 
of the WHO FCTC 2019–2025 in October 
2018. This strategy guides implementation 
of the WHO FCTC for the next 7 years, 
including the work of the Parties, 
the Convention Secretariat and other 
stakeholders, and serves as the basis for 
work planning and budgeting for the next 
three biennia. 
Since entering into force in 2005, the WHO 
FCTC has benefitted from the mandatory 
biannual Global progress report on 
implementation of the WHO Framework 
Convention on Tobacco Control, which 
reports on all provisions of the WHO FCTC. 
This report is submitted to every COP 
session and is published by the Convention 
Secretariat on its website. The last report, 
published in 2018, sets out Parties’ growing 
What this report further highlights is that 
cessation policies are still among the least 
implemented of all WHO FCTC demand 
reduction measures, with only 23 countries 
in total providing best-practice cessation 
services, the majority of which are high-
income countries. Clearly there is room 
for greater action and the reason speaks 
for itself: if tobacco cessation measures 
had been adopted at the highest level of 
achievement in 14 countries between 2007 
and 2014, 1.5 million lives could have been 
saved.
Successful case-studies for implementation 
of this article have also recently been 
documented by the Convention Secretariat 
in relation to comorbidities where tobacco 
use impacts on the diseases burden (e.g. 
tuberculosis and HIv/aIDS interventions as 
well as noncommunicable diseases).
Today we have over a decade of experience 
and expertise in tackling tobacco use. Our 
role in promoting sustainable development 
is now recognized within the Sustainable 
Development Goals (SDGs) 2030 agenda, 
as Target 3a calls for strengthening the 
implementation of the WHO FCTC in all 
countries. It goes without saying that strong 
tobacco cessation support is needed to 
achieve the SDG targets on tobacco control.
We welcome this new report for providing 
quality information and comparable data on 
progress in implementing selected demand 
reduction measures. Quitting tobacco has 
an immediate impact on health outcomes, 
and ensuring that strong cessation services 
are part of any tobacco control strategy will 
maximize the potential of these services to 
save lives. 
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Summary
place adding at least one more. This means 
a total of 36 countries introduced one or 
more mPOWEr measures at the highest 
level of achievement between 2016 and 
2018. 
Tobacco cessation needs 
attention
Offering help to quit – the focus of this 
seventh WHO report on the global tobacco 
epidemic – is an essential component 
of any tobacco control strategy. Global 
targets for reducing tobacco use will not be 
reached unless current tobacco users quit, 
and indeed, many tobacco users report that 
they want to quit. With the help of cost-
effective population-based interventions, as 
outlined in the “O” measure of mPOWEr 
(Offer help to quit tobacco use), tobacco 
users greatly increase their chances of 
successfully quitting. 
unfortunately, only 13 new countries have 
started providing comprehensive cessation 
programmes since 2007. There are now 
23 countries protected by this measure, up 
from 10 countries in 2007.  
 
However, in terms of population coverage, 
progress is still promising. One third 
of the world’s population – 2.4 billion 
people in 23 countries – have access 
to cessation services provided at best-
practice level. This is 2 billion more people 
(26% of the world’s population) protected 
by comprehensive cessation support 
programmes since 2007, meaning that 
cessation programmes are now the second 
most adopted mPOWEr measure in terms 
of population coverage. This is thanks 
to two large countries, India and Brazil, 
adopting comprehensive cessation support 
at best-practice level.
Significant progress has 
been made in low- and 
middle-income countries
Of the 5 billion people protected by at 
least one complete mPOWEr measure, 
3.9 billion live in low- and middle-income 
countries. Brazil and Turkey, the only two 
countries that have adopted all mPOWEr 
measures at the highest level, are both 
middle-income countries. In all, 61% of 
the population living in low- and middle-
income countries are protected by at 
least one complete mPOWEr measure, 
and 44% are protected by at least two 
complete mPOWEr measures.
There has been great improvement in 
low-income countries since 2007, when 
only three of the 34 countries in this 
income group had a single measure 
adopted. Today, half (17) of all low-income 
countries have at least one mPOWEr 
measure in place at best-practice level. 
There are now eight low-income countries 
that have one best-practice measure in 
place, five that have two, three (Chad, 
Nepal, Senegal) that have three and one 
(madagascar) that has four measures in 
place. Disappointingly, of the 17 low-
income countries with no measures in 
place at best-practice level, only three run 
a tobacco control programme from their 
ministry of Health with at least five full-
time equivalent staff.
Progress in global tobacco control 
has been strong since mPOWEr was 
introduced in 2007 as a tool to help 
countries implement WHO FCTC demand 
reduction measures. Five billion people 
– about 65% of the world’s population 
– are now covered by at least one 
mPOWEr measure at the highest level of 
achievement. This number has more than 
quadrupled since 2007 when only 1 billion 
people – 15% of the world’s population – 
were protected by at least one mPOWEr 
measure (not including monitoring 
or mass media campaigns, which are 
assessed separately).
 
Since the last  WHO report on the global 
tobacco epidemic, two years ago, progress 
has been steady, with 15 countries that 
previously had no best-practice measures 
taking action to reach best-practice level 
on one or more measures, and a further 21 
countries that had at least one measure in 
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Countries in all regions are 
adopting new measures
Each mPOWEr measure has been 
adopted at best-practice level by new 
countries since the last report:
  n Seven countries (antigua and 
Barbuda, Benin, Burundi, Gambia, 
Guyana, Niue and Tajikistan) newly 
adopted complete smoke-free laws 
covering all indoor public places and 
workplaces. 
  n Four countries (Czechia, Saudi arabia, 
Slovakia and Sweden) advanced to 
best-practice level with their tobacco 
use cessation services. However, 
during the same time period, six other 
countries dropped from the highest 
group, resulting in a net loss of two 
countries.  
aT LEaST TWO mPOWEr POLICIES aT HIGHEST LEvEL OF aCHIEvEmENT (2007–2018)
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  n Fourteen countries (Barbados, 
Cameroon, Croatia, Cyprus, Georgia, 
Guyana, Honduras, Luxembourg, 
Pakistan, Saint Lucia, Saudi arabia, 
Slovenia, Spain and Timor-Leste) 
adopted large graphic pack warnings, 
including plain packaging for Saudi 
arabia. 
  n Ten countries (antigua and Barbuda, 
azerbaijan, Benin, Congo, Democratic 
republic of the Congo, Gambia, 
Guyana, Niue, Saudi arabia and 
Slovenia) introduced comprehensive 
bans on tobacco advertising, 
promotion and sponsorship (TaPS), 
including at point-of-sale. 
  n Ten countries (andorra, australia, 
Brazil, Colombia, Egypt, mauritius, 
montenegro, New Zealand, North 
macedonia and Thailand) moved to 
the top group for taxes so that they 
comprise at least 75% of retail prices. 
 
Over half of the world’s population – 3.9 
billion people living in 91 countries – 
benefit from large graphic pack warnings 
featuring all recommended characteristics, 
making it the mPOWEr measure with 
both the highest population coverage 
and the most countries covered. It is also 
important to note that by the end of 2018, 
10 countries had adopted legislation 
mandating plain packaging of tobacco 
products and had issued regulations with 
implementation dates (australia, France, 
Hungary, Ireland, New Zealand, Norway, 
Saudi arabia, Thailand, united Kingdom 
and uruguay). Plain packaging legislation 
is also in progress in at least nine other 
countries.
There are 1.6 billion people living in the 
62 countries that have completely banned 
smoking in public places and workplaces, 
making this the second most realised 
mPOWEr measure in terms of country 
adoption.
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INCrEaSE IN THE SHarE OF THE WOrLD POPuLaTION COvErED By SELECTED TOBaCCO 
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While only 38 countries levy taxes as 
high as the WHO-recommended 75% of 
the retail price of a pack of cigarettes, 
another 62 countries levy taxes comprising 
between 50% and 75% of the price, and 
a further 61 levy taxes between 25% 
and 50%. Essentially, these countries are 
well-positioned to further raise taxes as 
tobacco taxation gains more widespread 
support.
The population covered 
by protective measures is 
growing 
Since 2016, 14 new countries have 
adopted large graphic warning laws at 
best-practice level, making it the most 
adopted mPOWEr measure over the last 2 
years. advertising bans also saw double-
digit growth at best-practice level, with 10 
additional countries adopting complete 
TaPS bans. Two mPOWEr measures – 
creating smoke-free environments and 
raising taxes – saw seven countries begin 
covering their population at best-practice 
level.
The greatest growth in population 
coverage since 2016 was seen in taxation. 
The population coverage from this 
mPOWEr measure has almost doubled 
from 8% in 2016 to 14% in 2018. Even 
so, taxation, although the most effective 
way to reduce tobacco use, is still the 
mPOWEr measure with the lowest 
population coverage. The population 
covered by pack warnings increased 
by 4%, and the population covered 
by advertising bans increased by 2%. 
although seven countries advanced their 
smoke-free environment laws to best-
practice levels, the population coverage 
did not change visibly because the 
countries were not populous.
The population covered by measures on 
monitoring tobacco use and prevention 
policies, Cessation programmes and mass 
media campaigns have all decreased since 
2016. Coverage of cessation programmes 
declined by 1% owing to the net loss 
of two countries from the best-practice 
group. The decline in monitoring coverage 
is most likely not a true decline, as it 
typically takes 1–3 years for surveys to 
Incomplete or partial 
policies are a stepping stone 
to complete policies 
Even where best-practice levels have not 
yet been achieved, each of the mPOWEr 
measures has received some level of 
attention in the majority of the world’s 
countries. In addition to the 62 countries 
with a complete law on smoke-free 
environments, 70 countries have minimal 
to moderate laws that ban smoking 
in some but not all public spaces and 
workplaces, laying the groundwork for 
establishing a fully effective law in the 
future. This means that although the
partial bans do not currently effectively 
protect these populations from the 
harms of second-hand smoke, growing 
public support will mean that, for most 
countries, only amendments to the law 
will be needed in some of these countries, 
whereas the adoption of a new law will be 
necessary in others.
While only 23 countries have cessation 
support policies that meet the criteria 
for best-practice adoption, there are an 
additional 116 countries that provide 
fully or partially cost-covered services in 
health facilities, and 32 more that provide 
services but do not provide cost-coverage 
for them. This makes a total of 171 
countries in which tobacco users wanting 
to quit can find some level of support.
In addition to the 91 countries that 
mandate strong graphic health warnings 
on cigarette packs, 61 other countries 
have minimal to moderate laws that 
require some kind of warning on packs. 
These less-prominent warnings, while 
not as effective as the best-practice 
warnings, show some effort is being made 
to communicate the dangers of tobacco 
use to consumers, and provide an avenue 
for these 61 countries to strengthen their 
mandated warnings to best-practice level 
in the future.
In addition to the 48 countries that 
have adopted a TaPS ban, another 103 
countries have partial TaPS bans in place, 
so at least some forms of advertising, 
promotion and sponsorship are already 
illegal – and once the principle of a ban 
is established and accepted, it becomes 
easier to extend it to best-practice level. 
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be published after fieldwork is completed 
and only then will they be reported here. 
Some surveys that were conducted in 
2017 and 2018 therefore will not be 
captured until the next WHO report on 
the global tobacco epidemic in 2021. The 
21% decline in the population coverage 
of mass media campaigns is concerning, 
since the maintenance of regular mass 
media campaigns is crucial to keeping the 
conversation open with the public about 
the harms of tobacco and the need for 
tobacco control efforts to continue.
It is inspiring that 91 countries have large 
graphic warning requirements, making 
it the most adopted measure to date. 
more countries have adopted the graphic 
warning requirement since mPOWEr 
began than any other measure, with 82 
additional countries now covered at best-
practice level, up from just nine in 2007. It 
is followed by the adoption of smoke-free 
requirements in public and workplaces, 
which has 52 additional countries at best-
practice level, up from just 10 in 2007, and 
advertising, promotion and sponsorship 
bans, adopted by an additional 
41 countries, up from just 7 in 2007.
Some countries have yet 
to adopt a single MPOWER 
measure
all countries have the ability to implement 
strong tobacco control policies to 
protect their populations from tobacco 
use and second-hand smoke exposure, 
and the illness, disability and death that 
they cause. although the adoption of 
comprehensive tobacco control policies 
has advanced steadily since 2007, there 
is much work to be done. There are 59 
countries that have yet to adopt a single 
mPOWEr measure at the highest level of 
achievement – and 49 of them are low- 
and middle-income countries. additionally, 
the pace of progress for adopting some 
mPOWEr measures has been slower than 
for others. For example, the adoption of 
complete TaPS bans and the raising of 
tobacco taxes to sufficiently high levels is 
much too slow in the majority of countries. 
There are 59 countries that have yet to adopt a 
single MPOWER measure at the highest level of 
achievement.
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The WHO Framework Convention 
on Tobacco Control and the 
Protocol to Eliminate Illicit Trade 
in Tobacco Products
By ratifying the WHO FCTC, countries have firmly 
articulated their commitment to curbing the 
tobacco epidemic. 
In may 2003, WHO member States 
made history by adopting the WHO 
Framework Convention on Tobacco 
Control (WHO FCTC) (1) – the first 
modern treaty specifically related to public 
health. Today 181 parties are signatories 
to the WHO FCTC, enabling it to cover 
more than 90% of the global population. 
It is one of the most widely adopted 
united Nations instruments.
In negotiating the WHO FCTC, countries 
took a brave and forward-looking stand 
against an industry that, as admitted in 
its own internal documents, manufactures 
addictive, deadly products in the pursuit 
of profit. For decades the industry has 
targeted the most vulnerable people 
– women, children, and those on low 
incomes – with sophisticated advertising 
campaigns to ensure they capture the full 
market. They have also manipulated their 
product design to maximize addictiveness. 
The WHO FCTC has also established a 
forum for discussions to address new 
challenges as they emerge, for example 
the promotion in new markets of tobacco 
products from traditional cultures such 
as narghiles and smokeless tobacco, and 
hundreds of categories and brands of 
novel products such as electronic nicotine 
delivery systems and heated tobacco. 
These new challenges point to the need 
for further regulation.    
By ratifying the WHO FCTC, countries have 
firmly articulated their commitment to 
curbing the tobacco epidemic. as strong 
as the WHO FCTC is, its Parties recognize 
that there are aspects of tobacco control 
that need highly tailored responses. One 
of these areas is the illicit (often cross-
border) trade in tobacco products. This 
trade poses a serious threat to public 
health because it undermines strong 
measures such as pictorial health warnings 
and increases access to often cheaper 
tobacco products, thus fueling the tobacco 
epidemic and undermining tobacco 
control policies. It also causes substantial 
losses in government revenues, and at 
the same time contributes to the funding 
of international criminal activities. This 
matter is so serious that the Parties to the 
Convention negotiated a new international 
treaty that complements the WHO FCTC.
The Protocol to Eliminate 
Illicit Trade in Tobacco 
Products 
The Protocol to Eliminate Illicit Trade in 
Tobacco Products (2) is the first protocol 
to the WHO FCTC. The Protocol was 
adopted by consensus of the Fifth Session 
of the Conference of the Parties in 2012 
and currently has 55 Parties. as a legally 
binding instrument, the Protocol sets out 
binding legal obligations in much the 
same way as the WHO FCTC itself.
The Protocol aims at eliminating all forms 
of illicit trade in tobacco products. It 
provides tools for preventing illicit trade 
by securing the supply chain, including 
licensing and establishing an international 
tracking and tracing system for tobacco 
products and countering illicit trade 
through dissuasive law enforcement 
measures and a suite of actions to enable 
international cooperation. This new treaty 
in its own right entered into force in 2018. 
The first session of the meeting of the 
Parties (mOP1) to the Protocol was held 
in Geneva, just after its entering into force 
(3, 4).  
reflecting the WHO FCTC itself, the 
Protocol has 10 parts. It contains an 
introduction and general obligations (Parts 
I and II), substantive parts comprising 
supply chain control, offences and 
international cooperation (Parts III, Iv and 
v), and reporting (Part vI).  Parts vII, vIII, 
IX and X cover institutional arrangements, 
settlement of disputes, development of the 
Protocol and final provisions.
Examples of the topics addressed in the 
47 provisions of the Protocol include 
licensing or an equivalent approval 
or control system (article 6); tracking 
and tracing (article 8); duty free sales 
(article 12); unlawful conduct including 
criminal offences (article 14); assistance 
and cooperation including mutual 
administrative (article 28) and mutual 
legal assistance (article 29).  
Parts of the WHO Framework 
Convention on Tobacco 
Control 
The WHO FCTC is unique among 
framework conventions in the depth and 
breadth of the substantive obligations it 
contains on both the demand and supply 
sides. 
Demand reduction
  n article 6. Price and tax measures to 
reduce the demand for tobacco
  n article 7. Non-price measures to 
reduce the demand for tobacco
  n article 8. Protection from exposure to 
tobacco smoke
  n article 9. regulation of the contents 
of tobacco products
Global Progress in the WHO Framework Convention on Tobacco Control (WHO FCTC) (5)
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  n article 10. regulation of tobacco 
product disclosures
  n article 11. Packaging and labelling of 
tobacco products
  n article 12. Education, communication, 
training and public awareness
  n article 13. Tobacco advertising, 
promotion and sponsorship
  n article 14. Demand reduction 
measures concerning tobacco 
dependence and cessation
Supply reduction
  n article 15. Illicit trade in tobacco 
products
  n article 16. Sales to and by minors
  n article 17. Provision of support 
for economically viable alternative 
activities
as part of its general obligations, the 
WHO FCTC obliges Parties to protect their 
policy-making and implementation from 
the influence of tobacco interests (article 
5.3). With this inclusion, the WHO FCTC 
addresses the full chain of tobacco product 
production, distribution and sale.  
Parties have also adopted, by consensus, 
guidelines for implementation of key 
provisions of the WHO FCTC, which help 
them meet their legal obligations through 
recommended actions that elaborate 
on the provisions. They were developed 
through intergovernmental processes and 
adopted by the Parties at different sessions 
of the COP.
Governance of the WHO 
Framework Convention on 
Tobacco Control and the 
Protocol to Eliminate Illicit 
Trade in Tobacco Products 
The WHO FCTC’s governing body is the 
Conference of the Parties (COP) and it 
comprises all 181 Parties. Similarly, the 
meeting of the Parties (mOP) provides 
governance for the Protocol to Eliminate 
Illicit Trade in Tobacco Products and 
includes all Parties to the Protocol. Both 
bodies meet every 2 years, with the last 
sessions taking place in late 2018. 
The work of the COP and mOP is governed 
by their respective rules of Procedure 
(3, 4) and keeps under regular review 
the implementation of the WHO FCTC 
and the Protocol, and takes decisions 
necessary to promote their effective 
execution, including the establishment of 
subsidiary bodies such as working groups 
and expert groups (6). Focused on their 
respective instruments, the COP and the 
mOP monitor implementation progress, 
identify challenges and opportunities, 
and review ongoing business. Housed 
at WHO headquarters, the Convention 
Secretariat supports the Parties to both 
treaties, working closely with WHO and 
the observers to ensure complementarity 
and synergy.
Article 14 – Demand 
reduction measures 
concerning tobacco 
dependence and cessation  
 
The WHO FCTC directly speaks to the 
importance of reducing the number of 
current tobacco users through cessation 
measures in article 14 – Demand 
reduction measures concerning tobacco 
dependence and cessation (7). This article 
states:
1. Each Party shall develop and 
disseminate appropriate, 
comprehensive and integrated 
guidelines based on scientific evidence 
and best practices, taking into account 
national circumstances and priorities, 
and shall take effective measures to 
promote cessation of tobacco use 
and adequate treatment for tobacco 
dependence. 
2. Towards this end, each Party shall 
endeavour to: 
(a) design and implement effective 
programmes aimed at promoting 
the cessation of tobacco use, in 
such locations as educational 
institutions, health care facilities, 
workplaces and sporting 
environments;
(b) include diagnosis and treatment 
of tobacco dependence and 
counselling services on cessation 
of tobacco use in national health 
and education programmes, 
plans and strategies, with the 
participation of health workers, 
community workers and social 
workers as appropriate;
(c) establish in health care facilities 
and rehabilitation centres 
programmes for diagnosing, 
counselling, preventing and 
treating tobacco dependence; and 
(d) collaborate with other Parties 
to facilitate accessibility and 
affordability for treatment of 
tobacco dependence including 
pharmaceutical products pursuant 
to article 22. Such products 
and their constituents may 
include medicines, products used 
to administer medicines and 
diagnostics when appropriate. 
although article 14 is the only article 
dedicated to cessation, a number of 
provisions in the WHO FCTC refer 
indirectly to cessation – for instance, all 
demand reduction measures will implicitly 
impact cessation. additionally, article 12, 
Education, communication, training and 
public awareness, includes a number of 
references to raising awareness of the 
dangers of tobacco use across sectors 
and the health benefits of cessation. This 
includes a direct reference in paragraph 
(b), which commits each Party to adopt 
and implement effective legislative, 
executive, administrative or other 
measures to promote “public awareness 
about the health risks of tobacco 
consumption and exposure to tobacco 
smoke, and about the benefits of the 
cessation of tobacco use and tobacco-free 
lifestyles as specified in article 14.2”(8).
Article 14 of the WHO FCTC speaks directly
to the importance of reducing the number
of current tobacco users
through cessation measures.
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The 2018 Global progress 
report on implementation 
of the WHO Framework 
Convention on Tobacco 
Control: a report based on 
information from the WHO 
FCTC reporting system
Based on the implementation reports of 
the Parties submitted to the Conference 
of the Parties in accordance with article 
21 of the Convention, the Convention 
Secretariat regularly prepares biennial 
global progress reports. The 2018 Global 
progress report was launched at COP8 (9). 
Guidelines for 
implementation of Article 14 
of the Convention
adopted by COP4 in 2010 as decision 
FCTC/COP4(8), Guidelines for 
Implementation of article 14 are intended 
to “assist Parties in meeting their 
obligations under article 14 of the WHO 
FCTC, consistent with their obligations 
under other provisions of the Convention 
and with the intentions of the Conference 
of the Parties, on the basis of the best 
available scientific evidence and taking 
into account national circumstances and 
priorities”.
To this end, the guidelines: 
(i) encourage Parties to strengthen or 
create a sustainable infrastructure 
that motivates attempts to quit, 
ensures wide access to support for 
tobacco users who wish to quit, and 
provides sustainable resources to 
ensure that such support is available;
 (ii) identify the key, effective measures 
needed to promote tobacco cessation 
and incorporate tobacco dependence 
treatment into national tobacco 
control programmes and health care 
systems; and
(iii) urge Parties to share experiences 
and collaborate in order to facilitate 
the development or strengthening 
of support for tobacco cessation and 
tobacco dependence treatment.
as the foundation for the guidelines, 
the Parties drafted a set of underlying 
considerations for implementing cessation 
programmes. The principles that Parties 
should follow when integrating cessation 
into their health systems include:
  n recognizing that tobacco use is 
highly addictive 
  n Tobacco dependence treatment 
measures should be implemented 
synergistically with other tobacco 
control measures 
  n Tobacco cessation and tobacco 
dependence treatment strategies 
should be based on the best available 
evidence of effectiveness 
  n Treatment should be accessible and 
affordable 
  n Tobacco cessation and tobacco 
dependence treatment should be 
inclusive 
  n monitoring and evaluation are 
essential 
  n active partnership with civil society 
  n Development and implementation 
of tobacco control cessation policies 
should be protected from all 
commercial and vested interests 
  n Sharing experiences among Parties 
greatly enhances Parties’ abilities to 
implement the guidelines 
  n Strengthening existing health care 
systems to promote tobacco cessation 
and tobacco dependence treatment is 
essential.
In addition to a set of defined terms, each substantive section 
of the Guidelines includes recommendations to assist Parties in 
their implementation of article 14 of the Convention. The key 
recommendations are the following:
Developing an infrastructure to support tobacco 
cessation and treatment of tobacco dependence 
Suggested actions include conducting a national situation analysis; 
creating or strengthening national coordination; developing and 
disseminating comprehensive guidelines; addressing tobacco use 
by health care workers and others involved in tobacco cessation; 
developing training capacity; using existing systems and resources 
to ensure the greatest possible access to services; making the 
recording of tobacco use in medical notes mandatory; encouraging 
collaborative working; and establishing a sustainable source of 
funding for cessation help.
Key components of a system to help tobacco users 
quit 
It is recommended that cessation support and treatment is 
provided in all health care settings and by all health care providers. 
Providing cessation support and treatment in non-health care 
settings and by suitably trained non-health care providers should 
also be considered, especially where scientific evidence suggests 
that some groups of tobacco users may be better served in this 
way. 
actions for Parties include establishing population-level 
approaches; establishing more intensive individual approaches; 
making medications available; and considering emerging research 
evidence, novel approaches, and mass media.
Developing cessation support: a stepwise approach 
Guidelines recommend that Parties should implement measures 
to promote tobacco cessation and increase demand for tobacco 
dependence treatment contained in other articles of the WHO 
FCTC. They should also use existing infrastructure, in both health 
care and other settings, to ensure that all tobacco users are 
identified and provided with at least brief advice. 
actions to achieve this include creating an infrastructure and 
environment that prompts quit attempts by establishing health 
system components that support cessation (including through 
adequate funding and training); addressing cessation among 
health care workers themselves; and integrating brief advice 
into existing health care systems.  
Monitoring and evaluation 
The Guidelines recommend that Parties monitor and evaluate 
all tobacco cessation and tobacco dependence treatment 
strategies and programmes, including process and outcome 
measures, to observe trends. additionally, Parties should benefit 
from the experience of other countries through the exchange of 
information.
To ensure that robust monitoring and evaluation takes 
place, Parties should formulate measurable objectives, 
determine the resources required, and identify indicators to 
enable the assessment of progress towards each objective. 
additionally, they should encourage health care workers and 
service providers to participate in the monitoring of service 
performance through clearly defined indicators, taking account 
of national circumstances and priorities. Lastly, Parties should 
use data collection systems that are practical and efficient, 
built on strong methodologies, and appropriate to local 
circumstances. 
International cooperation 
The Guidelines recommend that Parties collaborate 
internationally to ensure that they are able to implement the 
most effective tobacco cessation measures.
To this end, Parties should share their tobacco cessation and 
treatment experiences with other Parties, including strategies 
to develop and fund support for cessation of tobacco use, 
national treatment guidelines, training strategies, and data and 
reports from evaluations of tobacco dependence treatment 
systems. Where appropriate, it is suggested that Parties use 
international reporting mechanisms such as regular reporting 
on the implementation of the WHO FCTC and take advantage 
of bilateral and multilateral contacts and agreements. Finally, 
Parties should review and revise these guidelines periodically 
to ensure they continue to provide effective guidance and 
assistance. 
Guidelines for implementation of Article 14.
As the foundation for the guidelines, the Parties 
drafted a set of underlying considerations for 
implementing cessation programmes.
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FCTC 2030
Through a development assistance project called FCTC 
2030 (10), the Convention Secretariat is supporting 
15 low- and middle-income countries to strengthen 
implementation of the WHO FCTC by integrating tobacco 
control with other health and development activities. 
many of the FCTC 2030 countries are working to develop 
and implement tobacco cessation programmes in line 
with article 14 of the WHO FCTC and the Convention 
Secretariat has been working with the governments 
of FCTC 2030 countries to promote the integration of 
tobacco cessation into primary health and care systems. 
Examples of outcomes of the project include the 
development of an online course on tobacco cessation 
in Colombia and the provision of Trainings of Trainers to 
health professionals in all seven provinces in Nepal. 
Through FCTC 2030, the Convention Secretariat has 
also partnered with the united Nations Development 
Programme (uNDP) to develop an Issue Brief that aims 
to build awareness of the options to incorporate tobacco 
cessation activities into grants from The Global Fund to 
Fight aIDS, Tuberculosis and malaria (11). The document 
outlines how tobacco consumption worsens tuberculosis 
and HIv outcomes, and how the integration of tobacco 
control into these grants could increase health benefits 
and efficiencies. 
Group activity as part of the El Salvador cessation programme of the ‘addiction Prevention and Treatment Centers’
 Global commitment to the WHO FCTC
Each of the outcome documents of the three High-level 
meetings held by the united Nations’ General assembly 
(uNGa) on noncommunicable diseases has endorsed and 
encouraged countries to implement the WHO FCTC. The 
same approach was taken by uN member States when 
adopting the Sustainable Development Goals (SDG) 
agenda, streamlining through uNGa the implementation 
of the WHO FCTC through Target 3a: to “strengthen the 
implementation of the WHO FCTC in all countries, as 
appropriate”. additionally, the Eighth Conference of the 
Parties to the WHO FCTC adopted the Global Strategy 
to accelerate Tobacco Control: advancing Sustainable 
Development through the Implementation of the WHO 
FCTC 2019–2025 (12).
Target 3.4
By 2030, reduce by one third
premature mortality from NCDs
Target 3A
Strengthen the implementation
of the WHO FCTC
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Offering help to quit tobacco use 
Cessation support can more than double the 
chance of successfully quitting
four cigarettes, and after smoking five 
packs, nearly 60% are dependent (18). 
most people who use tobacco regularly do 
so because they are addicted to nicotine 
and can therefore benefit greatly from 
a range of effective tobacco cessation 
interventions. For example, the highest-
level cessation policies, adopted in 14 
countries from 2007 to 2014, will result 
in about 1.5 million fewer future tobacco-
related deaths up to the year 2030 (19). 
The health benefits of 
quitting tobacco are 
immediate 
People start to reap the health benefits 
within hours or even minutes of quitting 
tobacco use. In the course of just a day, 
quitting tobacco can be expected to help 
reduce a person’s heart rate and blood 
pressure, and blood carbon monoxide 
levels can be expected to return to normal 
(20). Within 3 months of quitting smoking, 
the circulation and lung function of a 
quitter improves. Coughing and shortness 
of breath will generally decrease within 
1–9 months of quitting smoking (20). 
The risk of death due to tobacco use also 
begins to decrease soon after quitting. 
Current evidence suggests that the risk 
of death due to ischemic heart disease is 
halved within 5 years of quitting, and the 
risk of stroke returns to that of a never 
smoker within 5–15 years. Even the risk 
of death due to lung cancer is reduced 
by 30–50% within 10 years of quitting 
smoking (20).  
The success of tobacco control 
policies has increased demand 
for support to quit tobacco use. 
Tobacco cessation support should be 
made readily accessible in order to 
have a greater impact on reducing 
the prevalence of tobacco use.
Many tobacco users want to 
quit and need help to quit
There are 1.1 billion adult smokers globally 
and at least 367 million smokeless tobacco 
users (13), many of whom say they want 
– or intend – to quit (14, 15). While this is 
encouraging, tobacco cessation support 
worldwide remains low and many people 
do not have adequate cessation support 
available to them. Currently, about 30% 
of the world’s population have access to 
appropriate tobacco cessation services 
(16).
Over the past decade, countries have 
made substantial progress in establishing 
evidence-based and cost-effective tobacco 
control measures. In numerous countries, 
many indoor public spaces are now 
smoke-free, warnings of the dangers of 
tobacco use appear on packaging and 
mass media messages, higher tobacco 
product prices and taxes have reduced 
the affordability of tobacco products, and 
tobacco product advertising, promotion 
and sponsorship have been prohibited.
all of these efforts have contributed to 
reduced demand for tobacco products and 
increased existing tobacco users’ intention 
to quit. On average, across countries 
where the Global adult Tobacco Survey 
HOW QuITTING TOBaCCO HELPS yOur BODy  (20–25)
Source: Global adult Tobacco Survey (14)
a  Proportions include those who indicated they were thinking of quitting in the next month, within the next 12 months or sometime in the future.
has been conducted, over 60% of smokers 
indicated that they intend to quit, and 
over 40% had attempted to quit in the 
12 months preceding the survey. Tobacco 
cessation support services complement 
countries’ tobacco control measures and 
can contribute to reducing the prevalence 
of tobacco use.
Cessation support helps 
tobacco users to quit
Nicotine, a pharmacologically active 
drug that naturally occurs in the tobacco 
plant, is highly addictive and delivered 
rapidly to the brain following inhalation 
or ingestion of tobacco products, or the 
use of non-tobacco products that contain 
nicotine (17). Nicotine is so addictive that 
the autonomy of a quarter of teens starts 
to diminish after smoking just three or 
There are immediate
and long-term health
benefits in quitting
for all tobacco users
Within 20 minutes
the heart rate and blood pressure drop (22).
Within 12 hours
the carbon monoxide level in the blood drops to normal (23). 
2–12 weeks after quitting tobacco use
the circulation improves and lung function increases (20). 
6 weeks after quitting smokeless tobacco use
97% of oral leukoplastic lesions are completely resolved (24).
1–9 months after quitting smoking
coughing and shortness of breath decrease (20).
1 year after quitting smoking
the risk of coronary heart disease is about half that of a smoker (20).
1–4 years after quitting smokeless tobacco use
the risk of death falls to nearly half that of a person who 
continues to use it (25).
5–15 years after quitting smoking
the risk of death due to ischemic heart disease is halved
the risk of stroke is reduced to that of a non-smoker (20).
10 years after quitting smoking
the risk of lung cancer falls to about half that a of a 
smoker, and the risk of cancer of the mouth, throat, 
oesophagus, bladder, cervix and pancreas decreases (20).
15 years after quitting smoking
the risk of coronary heart disease is that of a person who
never smoked (20).
PrOPOrTION OF CurrENT SmOKErS WHO INTEND TO QuIT (COuNTrIES WITH GLOBaL 
aDuLT TOBaCCO SurvEy DaTa, varIOuS yEarS)a
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Strong cessation services 
save lives, improve health 
and save money 
People who quit tobacco can live longer, 
healthier and more productive lives. 
Quitting smoking at any time in life is 
likely to extend life expectancy – for 
example, quitting as a 30-year-old can 
add up to 10 years of life expectancy. 
Even at the age of 50 years, quitting 
results in an average of 6 years of life 
expectancy gained (21). In other words, 
it is never too late to gain the health 
benefits from quitting tobacco use. Life 
years gained can also be expected to be 
lived in better health, as the diseases 
caused by tobacco use are commonly 
chronic and debilitating, and lead to years 
of diminished quality of life. Quitting can 
therefore reduce the health care costs 
associated with long-term illness while 
also increasing the years of economically 
and socially productive lives. 
Increasing the number of people who 
quit tobacco will also benefit economies. 
In 2012, health care expenditures due to 
smoking-attributable diseases totaled uS$ 
422 billion globally. If loss of productivity 
due to smoking-attributable illnesses 
and deaths are taken into account, this 
cost is estimated to be as high as uS$ 
1436 billion, with almost 40% of these 
costs incurred in low- and middle-income 
countries (26). Therefore, reducing 
tobacco consumption through the 
implementation of comprehensive tobacco 
control measures – including offering 
help to quit – can ensure large savings for 
countries as well as for ex-tobacco users. 
In one Danish study, the estimated total 
lifetime health cost savings to society of 
a moderate smoker quitting at the age of 
35 was €24 800 for men and €34 100 for 
women (27).
Supporting tobacco users 
to quit is embedded in the 
global health agenda
Following the Political Declaration on 
noncommunicable diseases adopted 
by the uN General assembly in 2011, 
WHO developed nine voluntary global 
targets to reduce global mortality from 
the four main noncommunicable diseases 
(NCDs) – cardiovascular diseases, cancer, 
chronic lung diseases and diabetes – and 
accelerate action against the leading 
risk factors for NCDs. The agreed target 
for tobacco control is a 30% relative 
reduction in the prevalence of current 
(daily and occasional) tobacco use in 
persons aged 15 years and above between 
2010 and 2025, which was endorsed 
by the World Health assembly in may 
2013. To achieve this target, it is not only 
essential to prevent the uptake of tobacco, 
but also to ensure that more tobacco users 
quit. Today, a number of highly effective 
and inexpensive interventions exist to help 
make this happen. 
The importance of helping current tobacco 
users quit is reflected in the WHO Global 
action Plan for the Prevention and Control 
of NCDs 2013–2020 (28). The Global 
action Plan lists a menu of “best-buys” 
and cost-effective policy options for 
countries to address the NCD burden. 
These include the recommendation that 
countries should “provide cost-covered, 
effective and population-wide cessation 
support (including brief advice, national 
toll-free quit line services and mCessation) 
to all those who want to quit” (28).
The Sustainable Development Goals 
(SDGs) reinforce the need for all countries 
to act decisively to reduce tobacco use 
by calling for – as a specific target under 
SDG 3 on good health and well-being – 
the strengthening of WHO Framework 
Convention on Tobacco Control (FCTC) 
implementation globally. article 14 of the 
WHO FCTC clarifies both the need for, 
and the means to achieve, implementation 
of tobacco cessation policies and cost-
covered services.
Despite these commitments, progress 
towards best-practice cessation support 
in countries is slow compared to progress 
on other mPOWEr measures (such as 
smoke-free places, and bans on tobacco 
advertising, promotion and sponsorship). 
Effective cessation 
interventions are available
There is a wide choice of 
behavioural and pharmacological 
tobacco cessation interventions 
Without cessation assistance, 4% of 
attempts to quit tobacco succeed (29). 
Proven cessation medications and 
professional support can double a tobacco 
user’s chance of successfully quitting 
(30). a number of different approaches 
have been developed to help people stop 
using tobacco. These range in terms of 
intensity, cost and effectiveness, and can 
broadly be categorized as behavioural or 
pharmacological interventions. 
 
Behavioural interventions
While behavioural interventions for 
tobacco cessation are generally low cost, 
they can be very effective. Brief advice 
from health professionals as part of their 
routine consultations or interactions is 
an approach that makes use of existing 
health care systems. When a tobacco user 
visits a primary or specialized care service 
it presents an opportunity for the health 
care worker to offer and provide them 
with personalized counselling. Brief advice 
is a key means of motivating people who 
might not otherwise seek tobacco cessation 
Population-level 
approaches
Brief advice Advice to stop using tobacco, usually taking only a few minutes, 
is given to all tobacco users during the course of a routine 
consultation and/or interaction with a physician or health care 
worker.
Quit lines A national toll-free quit line is a telephone counselling service that 
can provide both proactive and reactive counselling. A reactive 
quit line provides an immediate response to a call initiated by the 
tobacco user, but only responds to incoming calls. A proactive quit 
line involves setting up a schedule of follow-up calls to tobacco 
users to provide ongoing support.
mTobacco 
cessation 
Tobacco cessation interventions are delivered via mobile phone text 
messaging. Mobile technologies provide the opportunity to expand 
access to a wider population, and text messaging can provide 
personalized tobacco cessation support in an efficient and cost-
effective manner.
Individual specialist 
approaches
Intensive 
behavioural 
support
Behaviour support refers to multiple sessions of individual or 
group counselling aimed at helping people stop their tobacco use. 
It includes all cessation assistance that imparts knowledge about 
tobacco use and quitting, and provides support and resources to 
develop skills and strategies for changing behaviour.
Cessation 
clinics
In many countries, clinics specializing in tobacco cessation services 
are available. These clinics offer intensive behavioural support, 
and where appropriate, medications or advice on the provision of 
medications, delivered by specially trained practitioners. 
NRTs are available in several forms including gum, lozenges, 
patches, inhalers and nasal spray. These cessation tools reduce 
craving and withdrawal symptoms by providing a low, controlled 
dose of nicotine without the toxins found in cigarettes. The doses of 
NRT are gradually reduced over time to help the tobacco user wean 
off nicotine by getting used to less and less stimulation.
These include medications such as bupropion, varenicline and 
cytisine. These pharmacotherapies reduce cravings and withdrawal 
symptoms and decrease the pleasurable effects of cigarettes and 
other tobacco products.
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support and encouraging them to quit, 
and as such is an essential component 
of tobacco cessation services. Countries 
can easily train physicians and health care 
workers to provide brief advice effectively to 
the population they serve.  
 
Toll-free quit lines are a convenient way 
for tobacco users who are ready to quit 
to access brief and potentially intensive 
behavioural counselling. Those that use 
quit lines increase their absolute quit rate 
by 4 percentage points, which represents a 
doubling of success compared to those who 
attempt to quit without assistance (30). This 
rate can be further increased if the quit line 
is “proactive” and counsellors make follow-
up calls to potential tobacco quitters. 
 
With the advent and spread of mobile 
phone technologies, people who want 
to quit can now be accessed not only 
through telephone calls but also via text 
messages. a major development in recent 
years has been the mobile phone-based 
interventions for cessation which have 
been shown to be very promising. Text 
message interventions can increase the 
absolute quit rate by 4% (31).
nicotine replacement therapies (nRTs)
non-nicotine pharmacotherapies
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Behavioural Interventionsa
Pharmacological interventionsa
Source: West et al (33)
a  Each bar represents the findings of a meta-analysis and the strength of evidence associated with each study will vary.
b  This represents the “projected percentage point increase in 6–12 month abstinence compared with no intervention”. The authors adjusted the published 
percentage point increase in 6–12 month abstinence to allow for direct comparison between each intervention where the meta-analyses did not use a 
comparator equivalent to “no intervention”. assessments were based upon the published effectiveness of the comparison intervention through a consensus 
Cessation interventions that work alongside other 
tobacco control measures, Brazil and USA
When implemented together, tobacco control measures can work synergistically to increase the impact of each 
intervention. For example, when the united States raised the federal cigarette tax by uS$ 0.62 in early 2009, the 
number of calls to the quit line almost trebled – from 171 570 calls during January–may 2007 to 533 508 calls during 
the same period in 2009. 
and when Brazil became the first large country to include its national quit line number in graphic health warnings on 
cigarette packaging, the quit line received unprecedented call volumes – reaching up to 6 million calls in the first year, 
and more than all other quit lines globally at that time (35).
Pharmacological interventions 
Pharmacotherapy cessation interventions 
include nicotine replacement therapies 
(NrTs), as well as medications that do 
not contain nicotine but act to alleviate 
tobacco withdrawal symptoms. Both 
forms of therapy are effective aids to help 
people to quit tobacco use. Efficacy of 
pharmacotherapies is generally high, and 
compared to people who do not use an 
intervention, absolute quit rate increases 
can range from 6% for a single type 
of NrT to almost 15% for varenicline. 
Combining more than one NrT (patches 
and a faster-acting form) can also increase 
the effectiveness of NrTs (see Combined 
NrT in graph).
  
Both behavioural cessation support and 
pharmacotherapies are effective in helping 
people to quit tobacco use. Combining 
both behavioural and pharmacotherapy 
interventions, however, is more effective 
and can double the chances of successfully 
quitting (33). 
Mechanisms for developing 
tobacco cessation support
Implementing tobacco 
cessation measures alongside 
other tobacco control policies 
maximizes their impact 
Tobacco cessation support has optimal 
effect when implemented in conjunction 
with other demand-reduction tobacco 
control policies, such as raising 
tobacco taxes, establishing smoke-
free environments, banning tobacco 
advertising, promotion and sponsorship, 
printing large pictorial health warning 
labels on tobacco packages, and 
delivering anti-tobacco mass media 
campaigns. In turn, these tobacco 
control measures promote tobacco 
cessation by encouraging quitting and 
creating a supportive environment. a 
good example of synergising efforts is 
to include the local mCessation register 
portal/number, or quit line number, on 
cigarette and tobacco packs and on mass 
media anti-tobacco campaigns, which 
can significantly increase the demand for 
tobacco cessation services (36).
using existing infrastructure 
to develop cessation support is 
feasible and affordable 
Integrating brief advice into existing 
primary health care systems is one of the 
first actions countries can take to develop 
tobacco cessation support. WHO FCTC 
article 14 Guidelines recommend that 
countries adopt a stepwise approach to 
develop and strengthen national tobacco 
cessation systems as rapidly and cost-
effectively as possible (37). much of the 
needed infrastructure for promoting 
tobacco cessation measures, such as a 
primary health care system, already exists 
in most countries, making such promotion 
not only feasible but also affordable. Every 
country, therefore, can use their existing 
systems and resources to ensure that 
tobacco users at least receive brief advice. 
Every country can use its existing systems and 
resources to ensure that tobacco users at least 
receive brief advice, which can help motivate and 
support successful quit attempts.
mCessation shows huge promise in India
In 2015, a collaboration between WHO and the International 
Telecommunication union’s “Be He@lthy, Be mobile” 
initiative, the Indian ministry of Health and Family Welfare, 
and the ministry of Communication and Information 
Technology led to the development of a short text message-
based “mCessation” programme called QuitNow that 
supports and encourages tobacco users to quit. To evaluate 
the initiative, a total of 12 502 QuitNow subscribers were 
interviewed by telephone between 4–6 months after 
registration. Of those participants who had ever used 
tobacco, 19.1% self-reported that they had abstained in the 
preceding 30 days. Further research is needed to provide a 
more conclusive understanding of the impact of mCessation 
in India, but preliminary results show it has great potential to 
reach people who need support to quit tobacco (31).
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STEPWISE aPPrOaCH TO DEvELOPING aND STrENGTHENING NaTIONaL TOBaCCO 
CESSaTION SySTEmS
STEP 3
Medications
Specialized treatment
Increase the likelihood of quit
attempts succeeding 
Prompt quit
attempts
STEP 1
Establish system components
Address any issues related to health care workers
 Integrate brief advice into existing health systems
STEP 2
Establish free, proactive quit line
and/or mCessation service
Incorporating brief advice into existing 
health care programmes has the potential 
to reach more than 80% of all tobacco 
users in a country each year if delivered 
routinely and widely across a health 
care system (38). Tobacco cessation 
interventions should be integrated into 
any existing health programmes in primary 
care where feasible, as well as disease 
and population-specific programmes 
such as national tuberculosis (TB) 
programmes (39), NCD programmes, 
oral health programmes (40), HIv/aIDS 
programmes, mental health programmes, 
and programmes addressing the needs 
of women’s, children’s and adolescents’ 
health. In particular, there has been 
a major drive globally to integrate 
cessation services into TB programmes 
and into sexual and reproductive health 
programmes. Both of these programmes 
reach populations at particular risk 
from the harms of tobacco and present 
an opportunity to address tobacco 
dependence when people make 
MINIMAL ExPANDED ADvANCED
Brief advice integrated into 
primary care services
Brief advice integrated into primary 
care and hospital services 
Brief advice integrated into 
primary care, hospital and specialized 
services 
Quit line: Toll-free quit line provided Quit line: Toll-free quit line provided
mCessation: Text messaging mCessation: Text messaging
Specialized tobacco dependence 
treatment services: behavioural 
counselling and/or medication
EXamPLES OF mINImaL, EXPaNDED aND aDvaNCED CESSaTION INTErvENTIONSa
a  all countries should implement, at a minimum, brief advice. Once well established, countries can apply expanded and advanced measures, subject to resources.
Both behavioural cessation support and 
pharmacotherapies are effective in helping 
people to quit tobacco use. Combining 
Examples of cessation interventions linked to primary 
he lth care pro rammes
Tobacco and tuberculosis
Tobacco smoking increases the likelihood of acquiring, 
developing and dying from a TB infection. In 2013, the 
World Health assembly passed a resolution to approve the 
End TB Strategy. The strategy is based upon three pillars, 
one of which calls for integrated, patient-centred care and 
prevention. This provides an opportune platform to align 
the efforts against two global epidemics simultaneously, 
tobacco and TB.
South-East asia’s regional response Plan for Integration 
of TB and Tobacco 2017–2021 (41) exists to help member 
States implement cost-effective cessation services through 
TB programmes and screen tobacco users for TB. all 11 
countries in the South-East asia region have a national 
TB programme integrated into primary health care delivery 
systems to which a cessation service component could be 
added. Pilot studies integrating brief advice for tobacco 
cessation in TB patients that have been implemented in 
Bangladesh, India and Indonesia have demonstrated this 
intervention can be effective. India has since developed 
a Joint TB-Tobacco Framework, and is implementing 
the same through its National TB and Tobacco Control 
Programmes.
Tobacco and reproductive health
Tobacco use during pregnancy increases the risk of a large 
number of pregnancy complications including preterm 
delivery and spontaneous abortion, and other long-term 
health risks for both the mother and the unborn child. 
Successful treatment of tobacco use and dependence can 
have a significant effect on pregnancy-related outcomes 
and ongoing health outcomes in general. Integration 
of tobacco cessation services into reproductive health 
programmes is strongly recommended in the WHO 
recommendations for the Prevention and management 
of Tobacco use and Second-hand Smoke Exposure in 
Pregnancy (42). These guidelines state that health care 
providers should routinely offer advice to current tobacco 
users and recent tobacco quitters, as well as provide 
information to expectant mothers and, where possible, 
their partners or other household members about the 
harms of second-hand smoke.
(potentially rare) contact with the health 
system. 
Countries should also consider leveraging 
existing infrastructure to provide wide-
reach intensive behavioural support for 
tobacco users. many countries have 
existing call centres, substance abuse or 
other health-related hotlines that can be 
expanded to provide tobacco quit line 
services.
Provide comprehensive tobacco 
cessation support and treatment 
when resources allow
The cost and effectiveness of different 
cessation approaches vary, and therefore 
the affordability of the different 
approaches varies across low-, middle- 
and high-income countries. Overall, 
almost all population-level behavioural 
interventions are globally affordable, while 
intensive face-to-face therapy is affordable 
for middle- and high-income countries 
(33). If resources allow, countries should 
provide tobacco users with the highest 
level of support to facilitate a successful 
quit attempt. Countries may follow a 
stepwise approach to develop their 
tobacco cessation support systems.
Combining behavioural and 
pharmacological interventions is the 
most effective way to quit, but uptake 
of interventions also relies on people’s 
preferences, which is likely to vary across 
different social and cultural contexts. 
Tobacco users may prefer using multiple 
tobacco cessation interventions, including 
health education materials, advice 
from health professionals, counselling 
(individual, group, or telephone), 
pharmacological therapy and other 
cessation services via text messaging or 
online tools (43, 44). Providing a diverse 
range of tobacco cessation support 
options, as often as possible, is also 
important to ensure maximal uptake and 
effectiveness. 
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Tobacco cessation 
interventions: challenges 
and solutions 
About 30% of the world’s 
population have access to 
appropriate tobacco cessation 
services 
Ensuring cessation interventions reach 
the people who need them is a significant 
challenge. Currently, about 30% of 
the world’s population have access to 
appropriate tobacco cessation services 
(16). a recent study using Global adult 
Tobacco Survey (GaTS) data from low- and 
middle-income countries shows that fewer 
than 50% of smokers who interacted 
with a health care provider in the prior 
12 months were screened for tobacco use 
or advised to quit (45). This represents 
a drastic missed opportunity to reach a 
large number of tobacco users. The impact 
of an intervention largely depends on 
both effectiveness and reach. So, finding 
practical ways to reach as many tobacco 
users as possible is key to achieving the 
impact that tobacco cessation support 
rates and act as a cost-effective marketing 
strategy to motivate large numbers of 
smokers to call a telephone quit line for 
quitting assistance (47, 48)
The efficacy and cost-
effectiveness of cessation 
programmes should be better 
recognized 
Tobacco control policies are, in general, 
highly cost-effective. Policies such as 
raising tobacco taxes can have a large 
impact with relatively few associated 
costs. In comparison, tobacco cessation 
programmes carry costs such as the staff 
time needed to provide brief advice; 
funding for NrTs and medications; and 
the employment of quit line counsellors. 
However, tobacco cessation programmes 
are highly cost-effective relative to other 
health systems activities and clinical 
interventions. The cost-effectiveness of 
quit lines and brief advice programmes 
combined is comparable to that of breast 
cancer screening (49).
INTERvENTION AvERAGE COST-EFFECTIvENESS IN 
LOW- AND LOWER-MIDDLE-INCOME 
COUNTRIES 
AvERAGE COST-EFFECTIvENESS 
IN UPPER-MIDDLE- AND HIGH-
INCOME COUNTRIES
Provision of cost-covered, 
effective and population-wide 
support (including brief advice, 
national toll-free quit line 
services) for tobacco cessation 
to all those who want to quit, 
provided at 95% coverage
Very high High
Screening with mammography 
(once every 2 years for women 
aged 50–69 years) linked to 
timely diagnosis with pathology, 
staging, treatment with surgery 
+/- systemic therapy (endocrine 
therapy or chemotherapy) and 
management of treatment-
related toxicities
Very high High
Source: WHO NCD Global action Plan (28).
Tobacco cessation interventions 
should be responsive to 
vulnerable groups of people  
Cessation support systems are more 
effective if they account for and address 
the different social norms driving tobacco 
consumption as well as the difficulties 
associated with quitting tobacco use. The 
social context of tobacco users, such as 
gender, age, mental health status, and 
language and culture can deeply influence 
an individual’s experience with tobacco, 
including quitting. For example, evidence 
gathered from efficacy and effectiveness 
trials suggests that women may find 
it more difficult to achieve long-term 
abstinence than men. an understanding 
of the many factors that interact with 
gender and sex (including psychological, 
biological, pharmacological, social, 
environmental and cultural factors) and 
how they relate to cessation will likely help 
to design better cessation interventions 
that address these differences (50). 
There are also clear cases where lack 
of attention to particular social factors 
and contexts can decrease the chance of 
quitting. For example, in some countries 
females are less likely to be asked about 
their tobacco use status and less likely 
to be offered brief advice at primary 
care services, which may reflect health 
workers’ expectations of women and 
gender stereotypes (51). Ensuring that 
cessation initiatives are accessible and 
applicable to women, as well as youth, 
those with mental illness, minority ethnic 
groups speaking different languages, 
and other vulnerable groups can improve 
the reach and effectiveness of cessation 
policies.
Few countries carry out regular 
monitoring and evaluation that 
helps them improve tobacco 
cessation services
Evidence is key to providing the rationale 
for decision-makers to implement 
tobacco control policies and improve 
health services. although a great deal 
of evidence on the efficacy of tobacco 
cessation interventions is available, few 
countries carry out regular monitoring and 
evaluation that helps them understand the 
quality, effectiveness, reach, impact and 
cost of their tobacco cessation services. 
Lack of information showing the progress 
and outcome of tobacco cessation 
services at national level may prevent the 
identification of priority areas, quality 
improvement and further investment in 
tobacco cessation services. 
Commitment to tobacco cessation 
must be strengthened in many 
countries
many countries still have no national 
tobacco cessation strategy. Only a few 
countries have dedicated personnel or 
clearly identified budgets for cessation 
programmes (52). Health care systems 
should assume primary responsibility 
for implementing tobacco cessation 
programmes,(37) but cessation support 
incorporated into primary care services 
that provides tobacco users with the 
resources to quit is still not widespread, 
and is especially rare in low-income 
countries. 
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can potentially have on reducing the 
prevalence of tobacco use in a country.
Many countries do not cover 
the costs of tobacco cessation 
services for those using them 
asking tobacco users to pay for tobacco 
cessation services (such as quit lines 
and medications) has proven to be a 
major barrier to service uptake, even in 
high-income countries. although most 
countries make NrT available without 
the need for medical assessment or 
prescription, the cost of purchase may 
limit access, especially for people on low 
incomes (46). Not all cost-coverage or 
insurance mechanisms cover NrTs and 
even when they do, some barriers exist 
where cost-coverage is available. For 
example, it may be that prescriptions by 
certain health professionals, like dentists 
(who can be trained in brief advice), are 
not eligible for reimbursement. It is critical 
for countries to cover the costs of tobacco 
cessation support for their tobacco users.
research in New york City demonstrates 
that offering free NrT can increase quit 
CESSaTION INTErvENTIONS arE COST-EFFECTIvE
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E-cigarettes and other products 
marketed as “cessation aids”
In recent years the tobacco industry (and 
other non-tobacco commercial actors, 
such as those manufacturing e-cigarettes) 
has introduced a wide array of products, 
the majority of which simulate the act of 
smoking while typically delivering nicotine. 
There are currently three broad categories 
of these products:
Heated tobacco products (HTPs) are 
tobacco products that produce aerosols 
containing nicotine and toxic chemicals 
upon heating of the tobacco or activation 
of a device containing the tobacco.  These 
aerosols are inhaled by users during a 
process of sucking or smoking involving a 
device. They contain the highly addictive 
substance nicotine,  non-tobacco additives 
and are often flavoured. The tobacco 
may be in the form of specially designed 
cigarettes (e.g. “heat sticks”, “Neo 
sticks”) or pods or plugs.
 
Electronic nicotine delivery systems 
(ENDS) are devices that heat a liquid to 
create an aerosol that is inhaled by the 
user. The liquid contains nicotine (but not 
tobacco) and other chemicals that may be 
toxic to people’s health.
Electronic non-nicotine delivery systems 
(ENNDS) are similar to ENDS but the 
heated solution delivered as an aerosol 
through the device does not generally 
contain nicotine.
These products are aggressively marketed 
or promoted as cleaner alternatives to 
conventional cigarettes, as smoking 
cessation aids, or as “reduced risk” 
products. They have proliferated in several 
markets around the globe and present 
a unique challenge to regulators. While 
some of these products have lower 
emissions than conventional cigarettes, 
they are not risk free, and the long-
term impact on health and mortality is 
as-yet unknown. There is insufficient 
independent evidence to support the 
use of these products as a population-
level tobacco cessation intervention to 
help people quit conventional tobacco 
use. HTPs contain tobacco, and the use 
of these products constitutes tobacco 
use, thereby contributing to the burden 
of tobacco in countries where they are 
sold. In addition, the available evidence 
does not support the tobacco industry’s 
claim that these products are less harmful 
relative to conventional tobacco products 
(53, 54). 
There remains a great deal of uncertainty 
surrounding the potential toxicity of ENDS. 
although some have been shown to 
help smokers quit conventional smoking 
under certain conditions, when used as 
NrTs (55, 56) the scientific evidence is 
inconclusive (57–59). There have only 
been a limited number of randomized 
control trials and longitudinal studies 
investigating the role of ENDS as potential 
cessation aids offered to a population, and 
their conclusions are equivocal (57, 59). 
Two reviews, in 2016 and 2017, 
established that no credible conclusions 
could be drawn from the available studies 
(57, 59). This is consistent with the 
conclusion of the National academy of 
Sciences in its 2018 review of evidence 
on ENDS (referred to as e-cigarettes 
in this and the subsequent reports), in 
which it stated that “overall, there is 
limited evidence that e-cigarettes may 
Given the scarcity and low quality of scientific 
evidence, it cannot be determined whether ENDS 
may help most smokers to quit or prevent them 
from doing so (FCTC/COP7/11).
be effective aids to promote smoking 
cessation” (60).
By contrast, a randomized control trial of 
e-cigarettes versus nicotine replacement 
therapy concluded that “e-cigarettes were 
more effective for smoking cessation 
than nicotine replacement therapy when 
both products were accompanied by 
behavioural support” (61). However, the 
study has several limitations and any 
consideration of the results must be done 
with caution. For example, although 
those who were assigned e-cigarettes 
were more likely to abstain from using 
traditional cigarettes as compared to 
those who were assigned NrT, 80% of 
the e-cigarette user group continued 
to use e-cigarettes one year after the 
study started. This is compared to a very 
small percentage of people in the NrT 
arm of the study who continued to use 
NrTs. In most countries where they are 
available, the majority of e-cigarette 
users continue to use e-cigarettes and 
cigarettes concurrently, which has little 
to no beneficial impact on health risk and 
effects (62).
at the same time, some reviews have 
also suggested that e-cigarettes could 
in fact hinder smoking cessation (63). 
Further, beyond the scope of cessation, 
novel and emerging tobacco and nicotine 
products are increasingly being taken 
up by never users of tobacco (64). These 
products therefore play an important 
role in expanding the market of nicotine 
users, with a high associated risk for 
addiction, particularly among children and 
adolescents.   
Misinformation by the tobacco 
industry about e-cigarettes is a 
present and real threat
The scientific evidence on e-cigarettes 
as cessation aids is inconclusive and 
there is a lack of clarity as to whether 
these products have any role to play in 
smoking cessation. There are also real 
concerns about the risk they pose to 
non-smokers who start to use them, 
especially young people. unlike the tried 
and tested nicotine and non-nicotine 
pharmacotherapies that are known to help 
people quit tobacco use, WHO does not 
endorse e-cigarettes as cessation aids. 
as ENDS are increasingly introduced to the 
market, careful monitoring of cessation 
rates is vital. The possibility of tobacco 
industry interference in tobacco cessation 
efforts through misinformation about the 
potential benefits of these products – 
which are presented as alternatives but in 
most cases are complementary to the use 
of conventional tobacco products – is a 
present and real threat. 
This issue and other concerns surrounding 
ENDS and HTPs are discussed in further 
detail in the following sections of this 
report.
Maximizing cessation efforts
Governments should make 
greater political and financial 
commitments to promote tobacco 
cessation
Implementing tobacco cessation 
measures can help significantly reduce the 
prevalence of tobacco use and save lives 
(65, 66). It is estimated that if tobacco 
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cessation measures had been adopted 
at the highest level of achievement in 14 
countries between 2007 and 2014, 1.5 
million lives could have been saved (19). If 
the tobacco-related global NCD and SDG 
targets are to be achieved, governments 
need to rank tobacco cessation as an 
important public health priority and 
invest in it accordingly. article 14 of the 
WHO FCTC identifies a blueprint for 
more assertive support for cessation. Key 
recommendations include the following 
activities.
 
Promote tobacco cessation 
support as part of a 
comprehensive tobacco control 
programme
Cessation programmes are more effective 
when they are part of a comprehensive 
tobacco control programme. Countries 
should accelerate full implementation of 
the WHO FCTC, including the provisions 
in article 14, which relates to tobacco 
cessation and treatment. 
Recognize tobacco cessation 
support as an essential 
component of universal health 
coverage
Helping tobacco users to quit is one of the 
most cost-effective preventive services 
in primary care. WHO recommends 
tobacco cessation as one of the essential 
noncommunicable disease interventions 
for primary care in low-resource 
settings (WHO PEN: https://www.who.
int/ncds/management/pen_tools/en/) 
because of its importance in prevention 
and management of NCDs such as 
cardiovascular diseases, cancer, chronic 
respiratory diseases and diabetes. 
Countries should include tobacco 
cessation support in their universal health 
coverage intervention package in order 
to provide people-centred health services 
in primary care. at a minimum, countries 
should ensure that health care workers 
are trained to offer brief advice as part 
of all existing health care programmes in 
primary care and make the documentation 
of tobacco use mandatory in patients’ 
medical records. Training in tobacco 
cessation should be part of all health care 
professional training curricula and part of 
a mandatory training programme across 
health care professions. Training health 
care workers to routinely deliver brief 
advice can be achieved through a one-day 
workshop or even using an online training 
course. To assist countries in their efforts 
to integrate brief advice into primary care, 
WHO has developed a comprehensive 
training package, Strengthening health 
systems for treating tobacco dependence 
in primary care (67), and an e-Learning 
course, Training for primary care providers: 
brief tobacco interventions (available at 
https://www.who.int/tobacco/quitting/
training-for-primary-care-providers/en/), 
which are accessible to anyone free of 
charge.
Earmarking tobacco taxes for cessation: an innovative 
programme in Thailand
Funded by revenue from tobacco and alcohol 
excise taxes, the Thai Health Promotion Foundation 
(ThaiHealth) has supported several smoking cessation 
projects. For example, it has continuously funded the 
National Tobacco Quit Line since 2009, treating up to 
22,000 smokers a year with a success rate of 33% (70). 
Since 2016 it has funded the ministry of Public Health to 
improve tobacco cessation services in all its hospitals. 
ThaiHealth – together with the ministry of Public Health 
and all other stakeholders – has also created and 
launched a project called “Three million smoking quitters 
in three years”. This project, which started in June 2016 
and which finished at the end of may 2019, encouraged 
the ministry of Public Health’s 1 million village volunteers 
in the health service system to help one smoker per year 
successfully quit smoking for at least 6 months (through 
asking people to give up completely at the community 
level and/or referring them for support from the 
ministry’s tobacco cessation services if needed). 
If successful, this project will get 1 million people to 
quit each year, totaling 3 million quitters in 3 years. In 
November 2018 the minister of Public Health announced 
that the project will be one of the indicators used to 
evaluate the performance of all high-level ministry 
administrators – an announcement that spurred the 
project to redouble its efforts. The ministry announced in 
January 2019 that about 1.7 million smokers had started 
to quit tobacco with the programme. 
Establish a sustainable source 
of funding for tobacco cessation 
support
The strengthening or creation of national 
infrastructure to promote and provide 
tobacco cessation support and services 
requires both financial and technical 
resources, so it is essential to identify a 
sustainable funding source. Countries 
should consider placing the cost of 
tobacco cessation support on the tobacco 
industry and other retailers through 
measures such as designated tobacco 
taxes; tobacco manufacturing and/or 
import licence fees; a tobacco-selling 
licence for distributors and retailers; and 
noncompliance fees levied on the tobacco 
industry and retailers.
Offering a level of reimbursement or 
financial incentive can have a significant 
impact on both the uptake of cessation 
treatment as well as the likelihood of 
patients adhering to the treatment (68). 
Interventions that reduce the cost of 
cessation treatment to smokers not only 
increase the number of people who 
attempt to quit, but also increase the 
likelihood of their success in quitting (69).
Promote public-private 
partnerships and engage 
different stakeholders 
It is essential that governments and 
nongovernmental organizations 
work in partnership to accelerate the 
implementation of cessation measures 
and curb the harms of tobacco use. The 
public-private partnerships (which exclude 
the tobacco industry and its funded 
foundations) could extend the depth and 
breadth of funding and tobacco cessation 
services to be offered in countries. For 
example, many national or provincial 
quit lines are resourced by a combination 
of governmental and nongovernmental 
funding. Private insurers and employers 
can also offer incentives (such as reduced 
insurance premiums or access to employee 
benefits) to help motivate successful use 
of cessation services, given the reduction 
in health care costs and improvements 
in productivity that can be expected 
following cessation of tobacco use.
Prioritize population-level 
tobacco cessation approaches 
resources are finite. In order for tobacco 
cessation interventions to reach as many 
tobacco users as possible at the lowest 
achievable cost and have the most impact, 
governments should prioritize population-
wide tobacco cessation approaches and 
consider adopting the three population-
wide approaches as recommended by 
WHO Global Noncommunicable Disease 
action Plan 2013–2020: integrating 
brief advice into primary care, providing 
national toll-free quit line services, and 
making mCessation support available.
Embrace innovative approaches 
to improve the reach of tobacco 
cessation interventions 
an important aspect of SDG 9 on 
industry, innovation and infrastructure is 
the recognized need for people to have 
adequate access to information and 
50 51WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC, 2019 WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC, 2019
and wearable technology for example, 
can help to bring about major impacts 
on reducing prevalence of tobacco use 
globally.
Build effective communication 
strategies
Public awareness campaigns should be 
designed to make clear the efficiency and 
cost-effectiveness of tobacco cessation 
interventions among the general public 
and the tobacco control community. 
It is also essential to build effective 
communication that informs people about 
the different forms of support available, 
and where to access it. Consistent 
messages from health care professionals 
carries weight. Campaigns should be 
carefully designed to target specific 
audiences in different contexts so they 
maximize understanding and gain the 
popular support needed for success.
Monitor and evaluate all 
tobacco cessation strategies and 
programmes
monitoring and evaluation are essential to 
ensure that the best means are employed 
to formulate evidence-based and cost-
effective tobacco cessation interventions 
that help users quit tobacco. The ability to 
learn from the experiences of developing 
and implementing tobacco cessation 
programmes has been hampered by the 
limited availability and quality of data, 
especially in low- and middle-income 
countries. Countries should continue to 
monitor and evaluate current tobacco 
cessation strategies and programmes, 
including process and outcome measures, 
to observe trends and impacts over 
time. Building close collaborations with 
academic institutions, national statistics 
offices, nongovernmental organizations 
and other stakeholders will help to 
develop appropriate monitoring and 
evaluation methods, and to design 
stronger and more tailored services.
Maintain caution where novel and 
emerging tobacco and nicotine 
products are concerned
Policy action and health interventions 
should be based upon robust scientific 
evidence. Where evidence is not 
sufficiently available on the potential 
harms of new products, countries must 
maintain caution by ensuring that 
legislation is up-to-date and sufficiently 
protective of population health.
services. Emerging technologies must be 
harnessed to ensure that populations have 
access to information about the dangers 
of tobacco use through popular forums 
such as social media; in addition, the 
further development of interventions using 
mobile phones and other digital platforms 
should continue.
research and development into innovative 
ways to utilize such advances as mobile 
technologies and artificial intelligence in 
cessation interventions should also be 
encouraged. We currently know what 
interventions work but they do not yet 
reach a sufficient number of tobacco 
users. Increasing the reach and access 
to cessation services, through mHealth 
It is essential that governments and 
nongovernmental organizations work in partnership 
to accelerate the implementation of cessation 
measures and curb the harms of tobacco use.
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Heated tobacco products
Heated tobacco products 
contain tobacco 
Heated tobacco products (HTPs) are 
tobacco products that produce aerosols 
containing nicotine and toxic chemicals 
upon heating of the tobacco or activation 
of a device containing the tobacco. These 
aerosols are inhaled by users during a 
process of sucking or smoking involving a 
device. They contain the highly addictive 
substance nicotine,  non-tobacco additives 
and are often flavoured. The tobacco 
may be in the form of specially designed 
cigarettes (e.g. “heat sticks”, “Neo 
sticks”) or pods or plugs.
HTPs differ not only to conventional 
cigarettes, but also to electronic nicotine 
delivery systems (ENDS, some of which 
are called e-cigarettes), as ENDS do not 
contain tobacco, but rather a nicotine 
solution. These boundaries, however, 
are increasingly difficult to define. Today 
there is a growing presence of emerging 
“hybrid” tobacco products that contain 
both nicotine solution and tobacco.  
Examples of HTPs include IQOS from Philip 
morris International (PmI), Ploom TECH 
from Japan Tobacco International (JTI), Glo 
from British american Tobacco (BaT) and 
PaX from PaX Labs. 
The evidence on HTPs is 
inconclusive
While HTP technology has been around 
since the 1980s, new generations of 
products that have become popular in 
the past 5 years have different features 
and operating mechanisms to earlier 
versions. This means that although 
research has been conducted on HTPs 
since their emergence, conclusions on 
earlier products cannot be applied to later 
ones. Given that the newer generations 
of products have not been on the market 
for long enough, evidence on their health 
impacts is sparse. Further, much of the 
existing science on HTPs is industry-
generated, and thus potentially weakened 
by bias arising from a conflict of interest.
HTPs should be regulated as 
a tobacco product
Currently, HTPs are available in more than 
40 countries. While they are banned in 
few countries, there is significant variation 
in how they are regulated in others.
many factors affect a country’s ability 
to control and regulate the use of 
HTPs, including national regulatory 
powers, enforcement capacity regulatory 
frameworks, country capacity and tobacco 
industry interference. 
As with other tobacco 
products, MPOWER measures 
apply to HTPs
HTPs are tobacco products. This means 
that Parties’ obligations under the WHO 
FCTC apply to HTPs in the same way as 
they apply to conventional cigarettes. 
mPOWEr measures help WHO member 
States to implement the demand reduction 
articles of the WHO FCTC and are equally 
applicable to HTPs as they are to other 
tobacco products. This is well articulated 
qUESTION SUMMARy OF THE EvIDENCE
Do HTPs contain harmful 
chemicals?
From available evidence we know that many of the harmful chemicals that are 
generated by HTPs are similar to those generated by conventional cigarettes, 
but generally at lower levels (71, 72).  However, there is also some evidence 
that there are new chemicals in HTPs that are not present in the emissions of 
conventional cigarettes, and which could have some degree of toxicity and 
associated harm (53).    
Are HTPs less harmful than 
cigarettes?
To date, the available evidence demonstrates that exposure to harmful and 
potentially harmful chemicals from these products may be lower relative to 
cigarettes (73) (but higher compared to electronic nicotine delivery systems 
(ENDS), see next section). However, the evidence does not show that these 
products will reduce tobacco-related diseases, or that they are exclusively 
used as substitutes for cigarettes. If they attract users who were not previously 
tobacco users, their overall impact on health would be negative. 
Are HTPs useful as a cessation aid? HTPs are tobacco products and therefore, even if a tobacco user converts from 
the use of conventional cigarettes to HTPs, this would not constitute cessation. 
Claims that smokers switch from conventional cigarettes to exclusive use of 
HTPs are unsubstantiated (74). Further independent studies are needed to 
gather more information and inform policy options.  
in WHO’s information sheet on heated 
tobacco products, which provides 
guidance on how these products should 
be regulated (75), as well as Decision 
FCTC/COP8(22) for novel and emerging 
tobacco products.   
HTP marketing must be 
closely monitored and 
regulated
 
The marketing of HTPs is one of the 
biggest challenges to tobacco control 
efforts. Products are widely promoted 
using messages that explicitly or implicitly 
claim they are safer and less toxic 
alternatives to conventional cigarettes 
(53). manufacturers exploit the lack of 
clear consensus on the specific forms 
of harm caused by HTPs to confuse 
consumers and evade existing regulation 
and avoid the introduction of regulations 
that cover these products. 
 
For example, while HTPs are widely 
marketed as safer alternatives for 
smokers, manufacturers are generally 
careful to qualify their claims or include 
a waiver (76). One claim often made 
by manufacturers is that the aerosol 
produced from HTPs contains lower 
quantities of harmful constituents than 
cigarette smoke and are therefore less 
harmful to health (76).  However, phrases 
such as “likely to cause less harm” or 
“with potential to cause less harm” do not 
mean this demonstrates reduced risk. 
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n	 HTPs contain tobacco and should be regulated like tobacco products.
n	 HTPs produce toxic emissions, many of which are similar to toxicants found in cigarette smoke.
n	 HTP users are exposed to toxic emissions from the products, and bystanders could also be exposed to these toxic second-
hand emissions.
n	 Although the levels of several toxicants in HTPs are lower than those found in conventional cigarettes, the levels of 
others are higher. A lower level of some toxicants does not necessarily mean a reduction in health risk.
n	 HTPs contain nicotine. Nicotine is highly addictive and linked to health harms, particularly in children, pregnant women 
and adolescents.
n	 The long-term health impacts of HTP use and exposure to their emissions remain unknown. There is currently insufficient 
independent evidence on the relative and absolute risk. Independent studies are needed to determine the health risk 
they pose to users and bystanders.
Key information and recommendations for countries
Heated tobacco products (HTPs) 
are tobacco products. This means 
that Parties’ obligations under 
the WHO FCTC apply to HTPs in 
the same way as they apply to 
conventional cigarettes.
most marketing of HTPs deliberately tries 
to position them as different to cigarettes. 
They are promoted as “smoke-free” 
through claims that the aerosols they 
produce are not smoke and that HTPs 
do not produce tar. This means they are 
often marketed as a more environmentally 
friendly and socially acceptable alternative 
to cigarettes. In addition, HTPs are 
extensively promoted as modern, high-
tech and high-end lifestyle products, 
with minimalist designs, a presence 
in flagship stores, and high-profile 
product launches that portray them as 
attractive and harmless luxury consumer 
products. all of these efforts make use of 
social positioning techniques that were 
previously used to market cigarettes, 
and which are particularly effective in 
targeting young people.
ultimately, in line with WHO guidance, 
all forms of tobacco use are harmful, and 
this includes HTPs. Tobacco is inherently 
toxic and contains carcinogens, regardless 
of whether it is consumed as a smoked 
or smokeless product (75). Overall, given 
the information we have and the fact that 
these products contain tobacco, they must 
be regulated as tobacco products. They 
should be subject to the same policy and 
regulatory measures applied to all tobacco 
products, in line with the WHO FCTC.  
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Electronic nicotine delivery 
systems
Electronic nicotine delivery 
systems are diverse and 
increasingly available
Electronic nicotine delivery systems (ENDS) 
are devices that heat a liquid to create an 
aerosol that is inhaled by the user. The 
liquid contains nicotine (but not tobacco) 
and other chemicals that may be toxic to 
people’s health.  
“ENDS” is an all-encompassing term for 
multiple product categories. The most 
common ENDS are “electronic cigarettes”, 
also known as “e-cigarettes”, “vapes”, 
or “vape pens”. Other categories of 
ENDS include “e-hookahs”, “e-pipes” 
and “e-cigars”. Some of the products 
resemble their conventional tobacco 
counterparts: cigarettes, cigars, cigarillos, 
pipes or hookahs; others are shaped more 
generically like pens, uSB memory sticks, 
or basic cylinders. There are also different 
forms of nicotine used in these products. 
recently, nicotine salts have been used to 
deliver high levels of nicotine. The diversity 
of product groups has evolved over time 
and according to different geographic 
and/or demographic markets.
There are other electronic, non-nicotine 
delivery systems (ENNDS,) which are 
essentially the same as ENDS but the 
liquid used generally does not contain 
nicotine (although upon testing many 
“zero-nicotine” solutions are found 
to contain nicotine). This report only 
addresses ENDS and does not cover 
ENNDS. 
 
Examples of ENDS include Juul from Juul 
Labs, vype from British american Tobacco, 
blu from Imperial Brands.
Evidence on the health 
risks associated with EnDS 
remains inconclusive 
 
WHO has extensively reviewed and 
summarized the available evidence on 
ENDS and finds that the evidence to date 
is inconclusive. It is important to note that 
ENDS are a diverse group of products, 
containing a wide variety of nicotine 
dosages, flavours, and emissions.  
 
as a result, the unique characteristics 
of a particular type of ENDS – such as 
chemical content, heat source or how and 
where it is used – will play a major role 
in its effects on people’s health.  a more 
robust determination of the effects of 
ENDS will require vigorous investigation 
into the health outcomes of large cohorts 
of well-characterized users over a longer 
period of time.
qUESTION SUMMARy OF EvIDENCE
What are the consequences of 
taking up ENDS use at a younger 
age?
Recent surveys in the United States of America (USA) and some European 
countries have shown marked increases in ENDS use amongst youth (77).  
Between 2011 and 2018 in the USA, youth e-cigarette use rates have risen from 
1.5% to a staggering 20.8% (78). Young people who use ENDS are exposed 
to nicotine, which can have long-term effects on the developing brain and 
there is a risk of nicotine addiction, given that tobacco product use is primarily 
established in adolescence (79).  Furthermore, there is a growing body of 
evidence in some settings that never-smoker minors who use ENDS at least 
double their chance of starting to smoke cigarettes later in life (80, 81).
What is the harm of ENDS relative 
to conventional cigarettes? 
ENDS’ aerosols are likely to be less toxic than cigarettes but there is insufficient 
evidence to quantify the precise level of risk associated with them (82). Also, 
many factors will impact on the relative risk associated with their use. For 
example, the amount of nicotine and other toxicants in the heated liquid.
What are the health effects 
associated with ENDS? 
ENDS pose risks to users and non-users (82).  There is insufficient evidence 
to quantify this risk and the long-term effects of exposure to ENDS’ toxic 
emissions are unknown (77, 82). In addition to risks associated with emissions 
of ENDS there are also risks of physical injury brought about by fires or 
explosions related to ENDS devices (83).
Do ENDS help smokers quit 
tobacco?
As discussed in the background chapter on “O” – Offer help to quit, the 
scientific evidence regarding the effectiveness of ENDS as a smoking cessation 
aid is still being debated.  To date, in part due to the diversity of ENDS products 
and the low certainty surrounding many studies, the potential for ENDS to play 
a role as a population-level tobacco cessation intervention is unclear (57–59).
The potential impact of ENDS on public 
health has been heavily debated since 
their introduction to consumer markets 
12–15 years ago.  
EnDS are not harmless and 
must be regulated
 
according to WHO, member States that 
have not banned ENDS should consider 
regulating them as harmful products, 
and governments should implement 
the regulatory measures for ENDS that 
they determine are most appropriate 
for their domestic context. This may 
entail, for example, regulating ENDS as 
tobacco products, products imitating 
tobacco, or as a specifically defined 
category. although the specific level of 
risk associated with ENDS has not yet 
been conclusively estimated, ENDS are 
undoubtedly harmful and should therefore 
be subject to regulation. 
 
MPOWER measures can be 
applied to EnDS
Like any product that can cause harm and 
damage health, all ENDS products should 
be regulated and existing and effective 
policy toolkits, like mPOWEr, can be 
applied productively to ENDS. Guidance 
provided by the WHO report to the 2014 
Conference of the Parties (FCTC/COP/6/10 
rev.1) is outlined in the following box (82).
 
(a)  impede ENDS promotion to and uptake 
by non-smokers, pregnant women and 
youth;
(b)  minimize potential health risks to ENDS 
users and non-users;
(c)  prohibit unproven health claims from 
being made about ENDS; and
(d)  protect existing tobacco-control efforts 
from commercial and other vested 
interests of the tobacco industry.
ENDS regulation 
should:
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M
Governments are recommended to use their existing tobacco surveillance and 
monitoring systems to assess developments in ENDS use, disaggregated by important 
factors such as sex and age.
P
ENDS users should be legally banned from using ENDS indoors, especially where 
smoking is banned, until exhaled vapour is proven to be not harmful to bystanders and 
reasonable evidence exists that smoke-free policy enforcement is not undermined. This 
is because there is a reasonable expectation on the part of bystanders that there is not 
a “diminished risk” in comparison to exposure to second-hand smoke, but rather “no 
risk increase” from any product in the air they breathe. 
O
The evidence on the use of ENDS as a potential cessation aid is still being debated. 
Some evidence has suggested ENDS may work as a cessation aid for some people. 
However, the evidence required to support the role of ENDS as an intervention at 
population scale is limited. ENDS should therefore not be promoted as a cessation aid 
until adequate evidence is compiled on specific types of ENDS products and the public 
health community can agree upon the effectiveness of those specific products.
W
ENDS health warnings should be commensurate with proven health risks. In this regard, 
the following risk warnings could be considered: potential nicotine addiction; potential 
respiratory, eyes, nose and throat irritant effect; potential cardiovascular risk; potential 
adverse effect on pregnancy (due to nicotine exposure).
E
Given that the same promotional elements that make ENDS attractive to adult smokers 
could make them attractive to children and non-smokers, contemplate putting in place 
an effective restriction on ENDS advertising, promotion and sponsorship. Any forms 
of ENDS advertising, promotion and sponsorship must be regulated by an appropriate 
governmental body. If this is not possible, an outright ban on ENDS advertising, 
promotion and sponsorship is preferable. Further recommendations on the regulation 
of advertising, promotion and sponsorship of ENDS can be found in FCTC/COP/6/10 
Rev.1(82).
R
While they are generally less toxic than tobacco cigarettes, ENDS still carry health 
risks. The existing evidence shows that ENDS aerosol is not merely “water vapour” as 
is often claimed in the marketing for these products. ENDS use poses serious threats 
to adolescents and fetuses. In addition, it increases exposure of non-smokers and 
bystanders to nicotine and a number of toxicants. Taxes should therefore be applied to 
these products in line with national standards to prevent uptake, particularly by young 
people.  
EnDS have the potential to 
undermine tobacco control 
efforts
There are a number of challenges 
associated with regulating ENDS, which 
are often cited as “reduced harm”, 
“reduced risk”, or “clean alternatives” 
compared to conventional tobacco 
products. Because of these claims there 
are a number of consequences to public 
health and tobacco control. For instance, 
public health officials are concerned by 
the possibility that these devices serve 
as a “gateway” to conventional smoking 
among young people. ENDS are heavily 
marketed towards youth through the use 
of flavouring and promotional strategies. 
apart from the known harmful effects of 
nicotine on the developing brain, nicotine 
is addictive and could lead people, 
particularly young people, to take up 
more harmful forms of nicotine or tobacco 
consumption. Further, by using flavourings 
and branding strategies that appeal to 
young people, the industries involved 
in the manufacture and marketing of 
ENDS are employing tactics to expand 
their consumer base under the guise of 
contributing to public health work.  
ENDS products also have the potential 
to undermine existing tobacco control 
measures by, for instance, exempting 
these products from taxation or by 
allowing their use in smoke-free places.  
There is already significant confusion 
about (and conflation of) product 
categories. It can be very difficult to 
differentiate, for example, an ENDS 
product from an HTP.  This can be used to 
the advantage of the industry as is further 
discussed in the next chapter. Further, as 
ENDS and other novel products continue 
to evolve there is also the risk that they 
will fall through regulatory gaps and 
loopholes.
Since WHO’s initial evaluation of the 
evidence on the health risks of ENDS, 
their effectiveness in helping people quit 
smoking, and their impact on tobacco 
control, many additional articles have 
been published. However, given the 
diverse nature of ENDS and the many 
advances in product development since 
research began, more evidence is still 
needed to inform a conclusive statement 
on their health impacts and potential as 
a cessation tool. until then, there are a 
number of unknown factors which mean 
they cannot be safely recommended for 
consumption.
n	 ENDS should be carefully and clearly defined in the legislation in order that countries can regulate ENDS effectively.
n	 Countries often have the option of classifying ENDS as tobacco products. If this is possible then countries should ensure 
that existing tobacco control laws adequately protect people from the potential harms of ENDS.
n	 ENDS products may serve as a gateway to conventional smoking among young people or the renormalization of smoking 
in society. 
n	 Countries should apply bans on advertising and flavouring of products to deter use by young people.
n	 Countries should consider introducing policies to force manufacturers to make products unattractive to young people in 
order to discourage uptake, such as plain packaging.
Key information and recommendations for countries
Nicotine is addictive and ENDS use could lead 
people, particularly young people, to take up 
more harmful forms of tobacco consumption.
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Tobacco industry interference: 
the greatest obstacle to reducing 
tobacco use
The tobacco industry has a long history 
of systematic, aggressive, sustained and 
well-resourced opposition to tobacco 
control measures (84), including efforts 
to subvert life-saving tobacco control 
measures. It does this by deploying a wide 
variety of tactics to obstruct, delay, weaken 
or undermine political commitments 
and tobacco control measures taken 
by countries at international, regional, 
national and subnational levels. While 
some strategies are public and others 
more covert (be they directed at 
governments, the public, or the media), 
all have the goal of weakening tobacco 
control.  
Blocking tobacco industry interference 
is critical to successfully addressing the 
global tobacco epidemic and decreasing 
the public health consequences of 
tobacco use. In 2011, the united 
Nations General assembly recognized 
“the fundamental conflict of interest 
between the tobacco industry and public 
health”(85). recognizing this clear, 
irreconcilable conflict of interest, and 
despite ongoing attempts by the industry 
to position itself as a legitimate partner 
and stakeholder in tobacco control, Parties 
to the Convention must comply with their 
obligations under article 5.3 of the WHO 
FCTC, which requires that:  “In setting and 
implementing their public health policies 
with respect to tobacco control, Parties 
shall act to protect these policies from 
commercial and other vested interests of 
the tobacco industry in accordance with 
national law”(1).
 
  n intimidating governments with 
litigation or the threat of litigation; 
  n manipulating public opinion to gain 
the appearance of respectability. 
new industry players 
continue to subvert tobacco 
control 
Just over a decade ago, ENDS and ENNDS 
entered the market, with the most 
common prototype being e-cigarettes. at 
first these products were predominantly 
developed and marketed by non-
tobacco companies such as Pax Labs, 
which introduced JuuL (a popular ENDS 
product among young people in the uSa) 
Philip Morris International-funded Foundation for a 
Smoke-Free World
The Foundation for a Smoke Free World is funded solely by tobacco giant Philip morris International (PmI) with a 
commitment of uS$ 80 million annually over 12 years (approximately uS$ 1 billion) (86). It is part of an ongoing industry 
strategy to influence the scientific and policy agendas. The Foundation funds research programmes and studies that 
are supportive of products marketed by PmI and other producers as “reduced risk”, and offers funding to governments, 
universities, uN agencies, other international bodies and the public health community to encourage smokers to use such 
products, presumably in place of traditional cigarettes.  
In September 2017 WHO issued an official statement indicating that it will not partner with the Foundation, and 
recommending that governments and the public health community follow this lead (87). The WHO FCTC Secretariat has 
been similarly forthright in its rejection of the Foundation, stating in its WHO Framework Convention on Tobacco Control 
Secretariat’s statement on the launch of the Foundation for a Smoke-Free World that it is a clear attempt to breach the 
WHO FCTC by interfering in public policy “aimed at damaging the treaty’s implementation, particularly through the 
foundation’s contentious research programmes” (88).  
In 2019, the Foundation subsequently wrote to members of the WHO Executive Board, urging WHO to amend its stance 
on the Foundation, and to “review and consider how best to work with the Foundation to facilitate a rapid reduction in 
the use of lethal cigarettes”. This proposal was rejected by the Director-General, who reiterated WHO’s position in its 
2017 statement (89).
Tobacco industry 
interference takes many 
forms 
Common general tactics employed by 
the tobacco industry in opposing tobacco 
control include (16):
  n interfering with political and 
legislative processes;
  n fabricating support through front 
groups;
  n influencing the scientific and policy 
agendas;
  n making unproven claims and 
discrediting proven science; 
  n exaggerating the economic 
importance of the industry; 
in 2015. Due to the success of these 
products, the tobacco industry has heavily 
invested in such markets and diversified 
into manufacturing them alongside 
new-generation tobacco products such 
as heated tobacco products (HTPs). In 
December 2018, tobacco company altria 
acquired a 35% stake in JuuL for uS$ 
13 billion. Other tobacco companies such 
as British american Tobacco and Japan 
Tobacco International also have significant 
investment in such products (90).
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Philip Morris’ “Unsmoke” campaign: a case of smoke and 
mirrors 
Stopping Tobacco Organizations and Products (STOP)
Philip morris International (PmI) is one of the world’s largest 
cigarette manufacturers and a persistent opponent of tobacco 
control. Despite this, PmI is attempting to position itself as a 
responsible public health partner, and to influence the tobacco 
control agenda. Part of this is PmI’s “unsmoke” campaign, 
which encourages people “who don’t quit cigarettes” to 
“change to a better alternative”, in line with PmI’s goal 
to “replace cigarettes with the smoke-free products we’re 
developing and selling”. The campaign undermines tobacco 
cessation initiatives by presenting an easy alternative to 
breaking a nicotine addiction, and by undermining successful 
tobacco control initiatives (which have denormalized smoking 
in many countries) by portraying this form of tobacco use as 
socially acceptable.
PmI refers to both its HTPs and ENDS as “smoke-free products”. 
This strategy creates confusion between the product categories 
and promotes the industry claim that emissions from HTPs and 
ENDS are not “smoke” (though emissions from HTPs contain 
many of the toxic chemicals found in cigarette smoke). The 
campaign also fails to acknowledge that the impact of short-
and long-term use is largely unknown, and that current science 
does not support claims of reduced risk of health harms from 
HTPs. PmI avoids saying the products are less harmful, but 
instead states that it “believes” these products “while not risk 
free … have the potential to present less risk of harm than 
continued smoking”.1
Through promotion and lobbying by PmI and its front groups 
such as the Foundation for a Smoke Free World, this campaign 
seeks to pressure governments to allow these products into 
domestic markets and exempt them from tobacco control 
regulation, in particular TaPS bans, taxes and smoke free laws, 
thereby undermining tobacco control initiatives and weakening 
WHO FCTC implementation.  
The tobacco industry is the single greatest barrier to reducing 
deaths caused by tobacco use. To perpetuate sales of its 
products, the industry needs the weakest possible regulatory 
environment. In other words, it needs to make sure tobacco 
control policies do not come into effect or are rendered 
ineffective. The industry uses many strategies to accomplish 
this goal.
In 2018, Bloomberg Philanthropies established STOP (Stopping 
Tobacco Organizations and Products) – the first global tobacco 
industry watchdog. STOP’s mission is to expose the industry’s 
behaviour that undermines public health and to support 
efforts to counter industry interference in policy. STOP works 
around the world, with a special focus on low- and middle-
income countries where the industry is aggressively targeting 
communities and where the biggest populations are at risk 
of tobacco-related disease. STOP provides a platform for 
advocates, policy-makers and journalists to access the latest 
information on the tobacco industry – including exposés on 
abuses and tactics, analyses on industry behaviour and new 
tools to fight industry interference. 
 
STOP’s work consists of:
n collecting data and investing in comprehensive research;
n responding to policy-makers’ requests for help through a 
rapid response service;
n exposing and challenging the industry’s strategies by 
engaging with local and international media;
n collaborating across the tobacco control network and other 
sectors to ensure a comprehensive approach to countering 
industry tactics.
In its first 6 months, STOP galvanized support for WHO from 
more than 279 organizations and individuals in 50 countries 
to publicly reject an approach for collaboration from a Philip 
morris International-funded foundation. STOP also exposed 
dozens of organizations from more than 20 countries as 
industry allies that have worked to support tobacco-friendly 
policies. Policy-makers, advocates and journalists can search 
a public database for those groups in their countries and read 
the evidence that links them to the industry.
STOP is comprised of a partnership between The Tobacco 
Control research Group at the university of Bath, The Global 
Center for Good Governance in Tobacco Control, The union’s 
Department of Tobacco Control, and vital Strategies. To learn 
more, visit: exposetobacco.org.
Countering tobacco industry 
tactics
Commitment to countering industry 
interference is fundamental to successful 
implementation of effective tobacco 
control measures in accordance with 
the WHO FCTC – article 5.3 of which 
obliges Parties to act to protect public 
health policies from commercial and other 
vested interests of the tobacco industry in 
accordance with national law. 
In 2008, the Conference of Parties (COP) 
to the WHO FCTC adopted guidelines for 
the implementation of article 5.3. The 
Guidelines were developed based on both 
scientific evidence and the experiences 
of Parties (91). The purpose of the 
Guidelines is “to ensure that efforts to 
protect tobacco control from commercial 
and other vested interests of the tobacco 
industry are comprehensive and effective”. 
They state clearly that governments 
should limit interactions with the tobacco 
industry and avoid partnerships with it, 
and that governments should not accept 
financial or other contributions from 
the tobacco industry, or those working 
to further its interests. The Guidelines 
continue to be instrumental in combatting 
tobacco industry interference and should 
be applied to both conventional and 
emerging tobacco markets where, as 
already described, the tobacco industry 
attempts to present itself as a partner in 
tobacco control and harm reduction, while 
simultaneously blocking regulatory efforts. 
Effective government action to counter 
tobacco industry interference in cessation 
includes the following: 
  n requiring disclosure of, and clearly 
communicating, funding sources for 
research institutions, academics, and 
scientific studies to prevent unseen 
biases in science on which policy 
may be based, as well as to clarify 
the motivations of nongovernmental 
organizations, business and trade 
associations, consumer groups, think 
tanks, professional associations and 
others seeking involvement or input 
in tobacco control policies.
  n rejecting partnerships and non-
binding or non-enforceable 
agreements with the tobacco industry 
and those working in its interests, 
including financial support and 
endorsement of tobacco industry 
activities related to tobacco control.
  n raising awareness about the known 
addictive and harmful properties 
of tobacco and nicotine-containing 
products, and about tobacco industry 
interference with tobacco control 
policies.
  n Denormalizing and, to the extent 
possible, regulating and banning 
publicity around activities described 
as “socially responsible” by the 
tobacco industry.
  n requiring that the tobacco industry is 
held accountable for misinformation 
presented in marketing campaigns.
  n regulating HTPs as tobacco products 
in accordance with the WHO FCTC 
and regulating ENDS in accordance 
with the relevant COP decisions 
(Decision FCTC/COP6 and Decision 
FCTC/COP7).
  n requiring that information 
provided by the tobacco industry 
be transparent and accurate, with 
regular, truthful, complete and precise 
information on tobacco industry 
activities. 
  n Effective conflict of interest policies in 
place and enforced for policy-makers 
and officials engaged in developing, 
implementing and enforcing tobacco 
control policy. 
Blocking tobacco industry interference is critical 
to successfully addressing the global tobacco 
epidemic and decreasing the public health 
consequences of tobacco use.
1  See: https://www.pmi.com/glossary-section/glossary/smoke-free-products (accessed 04/06/2019)
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Industry tactics that interfere with tobacco cessation
The tobacco industry has in recent years become increasingly vocal in the promotion of products it claims can help people quit 
conventional smoking. These products, which include HTPs, ENDS and ENNDS are often promoted by the industry as “reduced risk” 
(relative to cigarettes) and/or cessation products that can help tobacco users or smokers of conventional products to quit conventional 
smoking. Such activities have ramifications for genuine initiatives to assist tobacco cessation, as they have the potential to misinform 
and mislead consumers and confuse governments. In this respect, the Guidelines for Implementation of article 14 of the WHO FCTC 
define the phrase “tobacco cessation” as “the process of stopping the use of any tobacco product, with or without assistance”.
 
Making unproven claims and influencing research
at the time of writing, the evidence is insufficient to recommend the use of ENDS as cessation devices at the population level. Existing 
studies have significant limitations, including selection bias, inadequate measures of exposure, and poor controls. moreover, a 
substantial amount of the available literature is funded by product manufacturers including in the tobacco industry, whose commercial 
interests pose an unavoidable conflict of interest (60).  
In the case of HTPs, because they are tobacco products, switching from conventional tobacco products such as cigarettes to HTPs is not 
considered tobacco cessation. In this context, there is a risk that industry marketing strategies focused around “quitting” or “switching” 
will lead consumers, regulators and decision-makers to conflate the two concepts.
 
Conflation of product categories
The tobacco industry has exploited the division in the public health community (resulting from the inconclusive evidence on the merits 
of these products as cessation aids) on the potential benefit of ENDS as a cessation aid. Consequently, some countries have lenient 
regulations for ENDS relative to conventional tobacco products, and where this is the case, the tobacco industry often leverages this by 
pitching HTPs as electronic products similar to ENDS to negotiate regulatory treatments similar to ENDS. 
This creates confusion between these product categories, which can result in the limited evidence that may support some forms of 
ENDS as a cessation aid under certain conditions being falsely attributed to HTPs too. For example, the name of the Philip morris 
International HTP product “iQOS” (which is an acronym for “I quit ordinary smoking” (72)) can contribute to this erroneous impression. 
Some countries and regions, including the uK, France and the Eu have left the option open to have new and novel products licensed as 
pharmaceutical products by including provisions in their relevant laws or directives, pending the evidence to support this and approval 
by relevant bodies. However, according to the information we currently have, none of these products is available commercially as a 
cessation aid.
HTPs are often promoted, especially to regulators, as “conventional smoking cessation” aids. However, there is limited evidence on the 
impact of HTP use on conventional smoking or on the relative harm of HTP use as compared to conventional cigarette smoking. 
 
Manipulating public opinion to gain the appearance of respectability
The recent positioning of big tobacco companies as proponents of “harm reduction” is a good example of a manipulative tobacco 
industry strategy. Extensive, high-profile messaging, misinformation based on unsubstantiated claims and lobbying by companies 
presenting themselves as part of the solution to reduce tobacco use prevalence may influence public opinion. 
Such lobbying promotes a new portfolio of products claimed to be “reduced risk”, “odour free” or “smoke-free”, and to offer “cleaner 
alternatives” to conventional cigarettes. This portrays the tobacco industry as responsible partners in the fight to end adult smoking, 
while downplaying established facts that cigarettes still comprise 97% of the worth of the global tobacco market which is dominated by 
the same companies. 
  
Strategic advertising to sustain nicotine or tobacco use
ENDS/ENNDS and HTPs are openly advertised as a way to circumvent smoking bans. Industry promotions aim to distance these products 
from cigarettes, claiming that they “do not involve combustion” and produce “vapour” rather than smoke, which is used as a basis 
for arguing that the products should be exempt from smoke-free and other laws. representatives of flagship stores are highly trained 
and skilled in luring potential consumers into their stores, and quick to offer these products as more pleasurable than smoking or 
using traditional tobacco products, sometimes arguing that they are more socially acceptable and can be used in smoke-free places. 
Such interference could deter quit attempts by would-be quitters as these products are aggressively marketed to sustain nicotine or 
tobacco use. This may also have implications for tried and tested nicotine and non-nicotine pharmacotherapies (which are proven to 
help smokers to quit tobacco use), as instead of those being chosen by smokers wanting to quit, smokers may opt for ENDS/ENNDS and 
HTPs instead. Now that ENDS/ENNDS regulation is becoming more common, the tobacco industry is actively countering attempts to 
incorporate ENDS/ENNDS into existing tobacco legislation. 
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Brazil marks singular achievement in 
tobacco control
■ Brazil’s efforts and commitment to tobacco control began in 
1981 when the ministry of Health created the Commission for 
the Study of the Consequences of Tobacco.
■ In 1988, the Constitution determined that tobacco advertising 
would be subject to legal restrictions and would contain 
warnings. 
■ In 1999, a National Commission on Tobacco Control was 
created to support the country’s role in negotiating the first 
global health treaty (under the auspices of WHO) that would 
later become WHO FCTC. Brazil was also elected to chair 
the treaty’s Intergovernmental Negotiating Body during the 
negotiations. 
■ In 2003 Brazil was among the first countries to sign the 
treaty, and ratified it in November 2005 despite being a 
developing country and a major tobacco producer. 
■ In 2003 the country’s National Commission for FCTC 
Implementation (CONICQ) was established, with the minister 
of Health serving as the chair. 
■ In 2018, Brazil ratified the Protocol to Eliminate Illicit Trade 
in Tobacco Products which will contribute to protecting the 
gains and maximize the impact of these very cost-effective 
tobacco control tools, such as raising tobacco taxes.
History of tobacco control in Brazil 
Tobacco use in Brazil is declining
Protect people from tobacco smoke
■ Brazil prohibited smoking in enclosed public and enclosed work 
places with an exception for designated smoking rooms (DSrs) in 
1996. In 2011 the law was strengthened to become a complete 
ban on smoking in enclosed public places, workplaces and public 
transport, thus fully aligning with article 8 of the WHO FCTC. 
■ Brazil was the first country with a population above 100 million 
to designate all public and work places as smoke free.
Offering help to quit tobacco
■ Since the 1990s the National Cancer Institute of Brazil (INCa) 
has been training health professionals to carry out cessation 
treatment. In 2001 the ministry of Health also began offering a 
national toll-free quit line, and currently the quit line number is 
displayed on the front of smoked tobacco packages.
■ In 2002 tobacco cessation treatment was formally included as 
part of the Brazilian Public Health System (SuS) making Brazil 
fully compliant with article 14 of the WHO FCTC in 2002. at first, 
tobacco cessation treatment was restricted to specialized health 
care services, but in 2004 the service was expanded to primary 
health care services.
■ Between 2005 and 2014 more than 800 000 smokers had access 
to smoking cessation treatment through SuS.
Warning about the dangers of tobacco
■ The first warnings, which stated “Health ministry warns: Smoking 
is harmful to health”, were printed on cigarette packages in 
Brazil in 1988. This warning was updated during the 1990s to 
eventually warn consumers that smoking causes lung cancer, 
heart disease and other health conditions.
■ In 2001, Brazil approved the first series of graphic health 
warnings using images that covered 100% of the back of 
cigarette packs. On each side of the package the number of 
the quit line appeared alongside the message: “There are no 
safe levels for the consumption of these substances.” This law 
also prohibited the use of wrappers or other features that could 
obscure the graphic health warnings.
■ Brazil was fully compliant with article 11 of the WHO FCTC in 
2003, before the treaty even came into force.
■ In 2004 Brazil launched the second series of graphic health 
warnings, with images and messages of greater impact that 
had to be included in the tobacco advertising at point of sale. 
This law included the following messages: “Sale prohibited 
to minors under 18 years according to Laws 8.069/1990 and 
10.702/2003”, and “This product contains more than 4700 
toxins and nicotine that cause physical and psychological 
dependency. There are no safe levels for the consumption of 
these substances.”
■ By the time the first WHO report on the global tobacco epidemic 
was published in 2008, not only was Brazil compliant with article 
11 of the FCTC, it was one of only three countries in the world 
that mandated graphic health warning images to cover 100% of 
the back of cigarette packs. 
■ The third series of warnings was launched in 2008. The images 
from this series were chosen as most impactful by an INCa 
(National Cancer Institute) study – the findings of which have 
been used by several countries in the americas to inform their 
policy on graphic health warnings.
■ In 2011, warning labels were expanded to include 30% of the 
front of the package, in addition to 100% of the back of the 
package. a new series of graphic health warnings was launched 
in may 2018.
Enforcing of bans on tobacco advertising, promotion 
and sponsorship
■ In 2000, a federal law banned tobacco advertising in mass media 
such as television, radio, magazines, newspapers, and billboards, 
while also banning some forms of indirect advertising and 
promotion. 
■ In 2011, the  federal law was amended to include the complete 
ban on advertising at point of sale, as well as the bans on 
promotional discounts and  brand sharing, allowing Brazil to 
become fully compliant with article 13 of the WHO FCTC. The 
law however still permits product display at point of sale, with a 
requirement to display graphic health warnings on display racks.
Raising taxes on tobacco
■ Brazilian cigarettes were once the sixth cheapest cigarettes in 
the world, but tobacco taxes have increased significantly since 
2007. By 2011 a minimum price policy was established and 
tobacco taxes were raised, thereby increasing the tax share as a 
proportion of the retail price of cigarettes.
■ as of 2018, tobacco taxes represent 82.97% of the retail price of 
the most sold brand, establishing Brazil as the country with the 
highest tobacco tax rate of all member States in the region of 
the americas.
■ Brazil has benefited from subregional forums designed to enable 
countries to exchange experiences and technical cooperation on 
tobacco tax. The four countries in the region of the americas 
that are implementing tobacco taxes at the highest level are all 
located in South america, making this subregion a leader on 
using tobacco taxes as a tool to reduce affordability. 
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MPOWER measures in Brazil
Tobacco use in Brazil is declining
■ adult smoking prevalence declined from 35% in 1989 to 
18.5% in 2008 (92).  according to the National Health 
Survey, smoking prevalence was 14.7% in 2013. Based on the 
telephone survey on NCDs, adult cigarette smoking decreased 
in capital cities from 15.6% in 2007 to 10.1% in 2017.
■ Despite declining smoking rates among adults, smoking 
prevalence among youth remains stable at around 5%, 
with 19% of boys and 17% of girls experimenting with 
smoking during their school years, according to PeNSE 
2015. Anti-tobacco Campaign by 
Ministry of Health, Brazil, 2019.
68 69WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC, 2019 WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC, 2019
Effective tobacco control 
measures 
Monitor tobacco use and prevention policies
Offer help to quit tobacco use
Enforce bans on tobacco advertising, promotion and sponsorship
Protect people from tobacco smoke
Warn about the dangers of tobacco
Raise taxes on tobacco
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Monitoring is the 
foundation of 
understanding and 
measuring tobacco control 
efforts
monitoring tobacco use and tobacco 
control programmes is critical to effectively 
combat the tobacco epidemic and assess 
the effects in each country of WHO FCTC 
Monitor tobacco use and 
prevention policies
mONITOrINGmONITOrING THE PrEvaLENCE OF TOBaCCO uSE – HIGHEST aCHIEvING COuNTrIES, 2018
0 1,750 3,500875 Kilometers
Monitoring the prevalence of tobacco use – Best practice countries, 2018
Best practice countries
Other countries
Not applicable
Countries with the highest level of achievement: armenia, australia, austria, azerbaijan, *Bahamas, Bangladesh, Belgium, Bhutan, Brazil, Brunei Darussalam, Bulgaria, 
Cambodia, Canada, Chile, Cook Islands, Costa rica, Croatia, Czechia, Denmark, Ecuador, Egypt, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, 
Indonesia, Iran (Islamic republic of), Ireland, Italy, Japan, Kazakhstan, Kuwait, Lao People’s Democratic republic, Latvia, Lebanon, Lithuania, Luxembourg, malaysia, malta, 
mongolia, myanmar, Netherlands, New Zealand, Norway, Pakistan, Palau, Panama, Peru, Philippines, Poland, Portugal, Qatar, republic of Korea, republic of moldova, 
romania, russian Federation, Serbia, Singapore, Slovakia, Slovenia, Spain, *Suriname, Sweden, Switzerland, Thailand, Turkey, ukraine, united Kingdom, united States of 
america, uruguay, and viet Nam.
 
* Country newly at the highest level since 31 December 2016.
article 20 of the WHO Framework Convention on Tobacco Control states: “…Parties shall establish …surveillance of the magnitude, 
patterns, determinants and consequences of tobacco consumption and exposure to tobacco smoke… Parties should integrate tobacco 
surveillance programmes into national, regional and global health surveillance programmes so that data are comparable and can be 
analysed at the regional and international levels…”(1) .
Almost 40% of the world’s 
population is covered by 
strong systems that monitor 
tobacco use 
There are 2.8 billion people in 74 
countries, or 38% of the world’s 
population, protected by strong monitoring 
systems that include recent, representative 
and periodic surveys for both adults and 
youth. most of these countries (44) are 
high-income countries. But despite having 
adequate resources, 25% of high-income 
countries still do not complete 5-yearly 
monitoring of tobacco use within their 
populations. and while some level of 
monitoring is happening in all but 27 of 
the world’s countries, there are still no 
low-income countries monitoring at best-
practice level, even though monitoring can 
be made more affordable if thoughtfully 
integrated with health systems 
strengthening activities. 
Sustained monitoring of 
tobacco use is a challenge 
for low- and middle-income 
countries
There are 35 countries (with a combined 
population of 2 billion) with recent and 
representative data on both adults and 
youth that only need to ensure both 
surveys are repeated within a 5-year time 
span to achieve best-practice monitoring 
level. most of these countries (23) are 
middle-income, six are high-income and 
six are low-income. If all 35 closed the 
gap to meet best-practice level, there 
would be 4.8 billion people (63% of the 
world’s population) living in countries that 
ensure effective monitoring of the tobacco 
epidemic.
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and mPOWEr measures. monitoring 
systems should track tobacco use 
indicators, including cigarette smoking and 
other forms of smoked tobacco (e.g. cigar, 
pipe, bidis, water pipe), smokeless tobacco 
products  (e.g. snus), and other tobacco 
products such as tobacco vaporizers 
and heated tobacco products, as well as 
non-tobacco forms of nicotine use (e.g. 
e-cigarettes). 
monitoring should also cover the impact 
of tobacco control policy interventions 
(38) and tobacco industry activities (93), 
as data such as these that are accurate 
and up-to-date enable appropriate policy 
implementation, precise measurement of 
policy impact and adjustment of strategies 
as needed, all of which greatly increase 
the likelihood of success (94).
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More countries need to 
monitor all forms of tobacco 
use as well as electronic 
nicotine delivery systems
Historical data show that after the 
WHO FCTC came into force in 2005 and 
monitoring began in 2007, no obvious 
progress was made until the countries new 
to monitoring the tobacco epidemic began 
completing their second round of surveys 
in 2011–2012. While progress appears to 
have stagnated since 2014, it is expected 
that as more recently completed surveys 
are published, coverage levels in 2016 and 
2018 will be revised upwards.
numbers of tobacco users 
remain stubbornly high
In total, there are 1.4 billion tobacco 
users aged 15 years and above worldwide 
– 1.07 billion smokers and 367 million 
smokeless tobacco users – a small number 
of whom use both smoked and smokeless 
tobacco. This number has declined slightly 
since 2007 when there were 1.46 billion 
tobacco  users.  There are 1.12 billion men 
currently using tobacco (5 million fewer 
than in 2007) and 279 million women (58 
million fewer than in 2007).
Despite three out of four countries having 
banned sales to minors under the age 
of 18 years – and another 10 countries 
having set an even higher age limit for 
tobacco purchases – an estimated 24 
million children aged 13–15 around 
the world smoke, and 13 million use 
smokeless tobacco.
Smoking rates are declining 
in all country income groups
Between 2007 and 2017, smoking rates 
decreased from a global average of 22.5% 
to 19.2%, showing a relative reduction of 
15% over 10 years. People in low-income 
countries smoke at about half the rate of 
people in high-income countries, and this 
ratio has changed little over the period.  
The relative reduction of the smoking 
rate in high-income countries was 20%, 
and in low-income countries was 19%. 
In middle-income countries, the relative 
reduction was only 12%. Smoking rates 
in middle-income countries, where three 
quarters of the world’s population live, 
reflect the global average. While smoking 
rates are declining fastest on average in 
high-income countries, they collectively 
still have the highest average smoking rate 
of all income groups in 2017 (21.6%). 
During this same decade, smoking among 
men decreased from 37.1% to 32.7%, 
and smoking among women decreased 
from 8.0% to 5.8%. In 2017, smoking 
rates among women in high-income 
countries are still the highest of all country 
income groups (16.4%) – over four times 
the average rate in low- and middle-
income countries for women (3.5%). In 
contrast, the highest rates among men are 
seen in middle-income countries (35.3%), 
which is almost double the average rate in 
low-income countries for men (20.2%).
Tobacco control must be 
accelerated to avoid future 
growth in the number of 
smokers
By 2030, when the ultimate success of 
the Sustainable Development Goals will 
be measured, the global average smoking 
rate is expected to have declined to about 
16%. In order to see smoking rates fall 
below 16%, countries need to accelerate 
their efforts. In high- and middle-income 
countries, smoking rates are expected 
to reach around 17% if they remain on 
their current trajectories. In low-income 
countries smoking rates are projected 
to decline to under 10% by 2030, but 
only if countries with low rates today are 
vigilant about not getting caught up in the 
tobacco epidemic. 
Global projections of smoking among 
men and women show a stark contrast, 
with women’s rates projected to decline 
to around 4% by 2030 while men’s rates 
are expected to remain high, at 28%. 
This scenario would mean a future rise 
in the number of men smoking due to 
population growth – up from 908 million 
in 2017 to 913 million in 2030. To prevent 
this disastrous outcome, urgent action 
needs to be taken, particularly among 
men in middle-income countries where 
the number of smokers could reach 750 
million by 2030.
PrOGrESS IN mONITOrING (2007–2018) CurrENT TOBaCCO SmOKING PrEvaLENCE amONG aDuLTS, 2007–2017
Note: While the average time between survey data collection and report release is unknown, the experience of this report is that it takes around 
4 years to obtain a complete list of national surveys run in a particular year. Therefore, the data for 2016 and 2018 are incomplete.
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The solid line represents the trend as 
indicated by survey data, the dotted 
line indicates the projected trend.
WHO-ESTImaTED TrEND IN CurrENT SmOKING PrEvaLENCE, aGES 15+
Over the past 2 years several countries in the WHO Eastern 
mediterranean region have achieved excellent outcomes in 
monitoring tobacco use. Lebanon and Sudan in particular 
have overcome significant challenges to complete landmark 
surveys on the burden of tobacco use among their populations, 
reversing long-standing deficits in the collection of tobacco use 
data.
In 2017 Lebanon implemented a WHO Stepwise approach to 
surveillance (STEPS) survey, incorporating Tobacco Questions 
for Surveys (TQS) to monitor the effects of tobacco policies and 
the use of tobacco products such as shisha and narghile. The 
survey included Syrian asylum seekers – a population hard to 
reach given their unstable and mobile living conditions. It was 
the first national survey to provide comparable indicators for 
migrants and the local population, and the results have helped 
the country evaluate existing policies and recommend changes. 
meanwhile, Sudan also undertook its first-ever TQS as part of 
a STEPS survey, planned and conducted in collaboration with 
the Federal ministry of Health, the Central Bureau of Statistics 
and WHO. Capturing populations such as those in remote 
and conflict-affected areas presented a major challenge. To 
overcome this, data collectors coordinated with the country’s 
military in order to travel safely. Data derived from the TQS 
have helped identify specific geographical areas and at-risk 
populations at which more targeted interventions can be 
directed.
Overcoming challenges to conduct surveys in the Eastern 
Mediterranean Region
Successful noncommunicable disease risk factor surveillance, 
Indonesia
Between 2007 and 2017, smoking rates 
decreased from a global average of 
22.5% to 19.2%, showing a relative 
reduction of 15% over 10 years.
The RISKESDAS team conducting field work in 
Jakarta, Indonesia, 2018.
The STEPS survey team conducting an 
interview, Sudan, 2018.
Tobacco use is the leading cause of preventable death and 
morbidity in Indonesia, whose National Institute of Health and 
research and Development (NIHrD) has been monitoring tobacco 
use and other NCD risk factors since 2004 using the national 
health survey. In 2007, riset Kesehatan Dasar (rISKESDaS, 
or “Basic Health research”) was created – an integrated and 
nationwide population-based survey which complements and is 
informed by global standards such as WHO’s STEPwise approach 
and the Global Tobacco Surveillance System, including the Global 
adult Tobacco Survey.
The success of rISKESDaS lies in its comprehensive coverage of 
all key NCD risk factors, along with its ability to provide reliable 
estimates at district, provincial and national levels – an important 
factor given the decentralized nature of health care delivery in 
Indonesia. Emphasis is placed on completing the survey and 
releasing the results within a few months, maximizing their 
timeliness and usefulness. Since the first rISKESDaS in 2007, 
NIHrD has conducted the survey every 5 years, completing the 
most recent round in 2018.  With 100% domestic funding, its 
integration with other key health indicators and its value to 
policy-makers have sustained the initiative over time.
rISKESDaS tobacco module collects information on the age of 
onset tobacco use, tobacco consumption patterns, cessation 
attempts, exposure to second-hand smoke, and the use of 
e-cigarettes. The data can be sorted by key socio- and age-
demographic characteristics and show that smoking prevalence 
among those aged 15 years and above has increased from 27% 
in 1995 to 33.8% in 2018. Knowing how the use of tobacco is 
changing within the population is essential for planning policies 
that will most effectively halt the tobacco epidemic. rISKESDaS 
results have helped central and district governments in evidence-
based planning, as well as in monitoring and evaluation.
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Protect people from tobacco smoke
article 8 of the WHO FCTC states: “… [S]cientific evidence has unequivocally established that exposure to tobacco smoke causes death, 
disease and disability … [Parties] shall adopt and implement … measures providing for protection from exposure to tobacco smoke in 
indoor workplaces, public transport, indoor public places and, as appropriate, other public places”(1).  WHO FCTC article 8 guidelines 
are intended to assist Parties in meeting their obligations under article 8 of the WHO FCTC and provide a clear timeline for Parties to 
adopt appropriate measures (within 5 years after entry into force of the WHO FCTC for a given Party) (95).
SmOKE-FrEE LEGISLaTIONSmOKE-FrEE ENvIrONmENTS – HIGHEST aCHIEvING COuNTrIES, 2018
Second-hand smoke kills
Exposure to second-hand smoke can lead 
to severe and fatal diseases including 
cardiovascular disease, respiratory disease, 
and cancer (96–99). Children and infants 
are particularly susceptible to second-hand 
smoke, and at increased risk for respiratory 
disease, middle ear disease, and sudden 
infant death syndrome (100–105). 
Fetuses and pregnant women exposed to 
second-hand smoke are more at risk of 
stillbirth, congenital malformations, and 
lower birth weights (105). There is no safe 
level of exposure to second-hand smoke 
and even brief exposure can cause harm 
(106). almost all non-smokers living with 
smokers are exposed and are at greater 
risk of premature deaths and diseases 
(107). The only way to adequately protect 
both smokers and non-smokers from 
second-hand smoke is to fully eliminate 
indoor smoking (107). 
To work, smoke-free laws 
must be comprehensive
Smoke-free laws are highly effective 
in decreasing exposure and enhancing 
indoor air quality for both smokers and 
non-smokers (108–110). However, to be 
sufficient, they must be comprehensive. 
It is a misconception that smoke-free 
places with designated smoking rooms 
protect non-smokers from second-hand 
smoke. The only intervention shown to 
fully protect from second-hand smoke is 
a smoke-free environment that permits 
no exceptions (111–113). It is important 
to remind countries that no safe level of 
exposure to second-hand smoke exists. 
accommodations for smoking including 
separate rooms, designated smoking –  
areas, ventilation systems, air exchanges, 
and filtration devices – are not protective, 
and cannot eliminate all second-hand 
smoke (98, 110, 111). Exceptions dilute 
the impact of smoke-free laws.
Smoke-free laws save lives
There is robust evidence that jurisdictions 
with legislative smoking bans enjoy 
reduced hospital admissions for acute 
coronary syndrome and reduced mortality 
from smoking-related illnesses (111). 
Smoke-free laws also denormalize 
smoking, encouraging healthier behaviours 
such as maintaining smoke-free homes 
and automobiles (114–116). Establishing 
smoke-free environments may also 
encourage smokers to reduce their tobacco 
use, make a quit attempt, and remain 
tobacco-free in the long-term (117, 118).  
Smoke-free laws are 
popular and do not hurt 
business
Smoke-free laws are not only life-
saving but relatively easy to pass and 
economically and politically feasible to 
enforce. an increasing number of countries 
continue to adopt comprehensive 
smoke-free legislation at national and 
subnational levels. In spite of the tobacco 
industry’s assertions to the contrary, the 
best-designed studies report that smoke-
free laws do not have adverse economic 
consequences for businesses, including 
the hospitality industry (119–121). When 
applied, invariably smoke-free laws 
achieve overwhelming support from the 
public (122, 123). 
Only 22% of the world’s 
population are protected 
by complete smoking bans 
in public places, workplaces 
and public transport
Comprehensive smoke-free legislation is 
in place for over 1.6 billion people in 62 
countries (covering 22% of the world’s 
population). There is remarkably little 
difference among income groups, with 
around one in three countries in each 
income group having a comprehensive ban 
in place. Two in three countries continue to 
leave their populations vulnerable to the 
dangers of second-hand smoke through 
weak or absent smoke-free laws, with 41 
high-income, 68 middle-income and 24 
low-income countries poorly or completely 
unprotected. among them, 24 countries 
(with 372 million people) have no bans at 
all – 21 of them low- and middle-income 
countries. The other 109 countries have 
partial bans that fall short of a complete 
ban on smoking in public places and 
workplaces.
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Countries, territories and areas with the highest level of achievement: afghanistan, albania, *antigua and Barbuda, argentina, australia, Barbados, *Benin, Brazil, Brunei 
Darussalam, Bulgaria, Burkina Faso, *Burundi, Cambodia, Canada, Chad, Chile, Colombia, Congo, Costa rica, Ecuador, Egypt, El Salvador, *Gambia, Greece, Guatemala, 
*Guyana, Honduras, Iran (Islamic republic of), Ireland, Jamaica, Lao People’s Democratic republic, Lebanon, Libya, madagascar, malta, marshall Islands, Namibia, Nauru, 
Nepal, New Zealand, North macedonia, *Niue, Norway, occupied Palestinian territory, including east Jerusalem, Pakistan, Panama, Papua New Guinea, Peru, romania, 
russian Federation, Seychelles, Spain, Suriname, *Tajikistan, Thailand, Trinidad and Tobago, Turkey, Turkmenistan, uganda, united Kingdom, uruguay, and venezuela 
(Bolivarian republic of).
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PrOGrESS IN SmOKE-FrEE LEGISLaTION (2007–2018)
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It is time for completely 
smoke-free environments to 
become the social norm 
In the past 2 years, seven countries have 
joined the group of countries providing 
protection at best-practice level, with all 
public places completely smoke-free. Five 
of these countries went from either no 
law (Burundi, Niue) or a very minimal law 
covering up to two public places (antigua 
and Barbuda, Gambia, Tajikistan) to a 
complete ban covering all public places 
and workplaces. The other two countries 
(Benin and Guyana) strengthened 
moderate laws already in place to reach 
best-practice level. Four of these seven 
countries are low-income countries. an 
additional eight countries upgraded their 
smoke-free laws but did not reach full 
coverage.
While there has been sustained progress 
in implementation of smoke-free laws 
since 2007 when only 10 countries had 
a complete law, progress among low- 
and middle-income countries has been 
particularly dramatic. In those 11 years, 40 
low- and middle-income countries (more 
than one in four) have adopted a complete 
smoke-free law, while only 12 high-income 
countries (one in five) have done the 
same. The population protected globally 
by smoke-free legislation at best-practice 
level has increased from 232 million to 1.6 
billion since 2007.
Comprehensive smoke-free 
legislation is a popular 
policy measure
There are 11 countries, representing 120 
million people, that only need to cover one 
more place with a smoking ban to join the 
62 other countries with a complete smoke-
free law: Tonga (universities); Democratic 
People’s republic of Korea (government 
facilities); Cook Islands, mauritius, ukraine 
and Zambia (indoor offices); Senegal 
(restaurants); Bhutan (cafes, pubs, bars); 
and Cyprus, Georgia and Hungary (public 
transport). Fifteen countries, with a 
combined 1.7 billion people, need only 
remove the possibility of designated 
smoking rooms in their laws to achieve 
best-practice level. Fifteen countries with 
1.6 billion people only need to cover two 
more places with a smoke-free ban to 
reach best-practice adoption. 
Of the 505 million people (6.6% of the 
world’s population) who live in one of 
the world’s 100 largest cities, only 284 
million (in 47 cities) are protected by a 
comprehensive smoke-free law. Five of 
these cities (Bandung, Jakarta, medan, 
Beijing and Hong Kong Sar) are covered 
by city-level smoke-free laws, ten are 
covered by state- or province-level 
smoke-free laws and the remaining 32 
are covered by national laws. Instead of 
waiting for a national policy to be put in 
place, the remaining 53 of the world’s 
largest cities not currently protected by a 
national best-practice policy could move 
ahead with a city, state or provincial level 
policy to protect their large populations 
sooner.
Comprehensive smoke-free legislation is in 
place for over 1.6 billion people 
in 62 countries (covering 22% of 
the world’s population).
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Xi’an city launches its smoke-free regulations at Daming 
Palace, 2018. A community engagement session to inform 
people about the harms of tobacco and second-
hand smoke using WHO visual resources in the 
Gambia.
Another city goes smoke free in China Public places go smoke-free in Gambia
Xi’an has long been one of the most popular tourist 
destinations in the world, with more than 200 million people 
visiting the city (population 10 million) each year. In august 
2018, with leadership from the municipal Legislative Office 
and strong support from the Xi’an municipal Government, 
the city adopted a regulation to ban indoor smoking in all 
workplaces, on public transport, and in indoor public spaces. 
Strong support from the health commission, international 
community, and domestic NGOs helped pass the regulation 
and protect the millions of citizens and visitors to the city from 
the harms of second-hand smoke. Extensive public education 
and awareness campaigns were 
initiated to promote the new smoke-free 
regulation and strong enforcement efforts 
were implemented. 
The municipal government started 
a competition among the various 
government agencies responsible for 
enforcement to encourage participation 
in the new regulations and asked them 
to submit on a monthly basis their 
enforcement numbers, fines, penalties, 
training events and communication 
campaigns. as of april 2019, more than 
155 000 venues were inspected, and more than 240 000 yuan 
in fines and penalties have been collected. 
 
For more than a 1000 years – and as the starting point of 
the Silk road – Xi’an has played a critically important role 
in the trade and economy of the region. Now its leadership 
will serve to inspire other cities to focus on the health of their 
citizens and visitors. The world looks forward to the continued 
leadership of Xi’an, and a tobacco-free Silk road in the near 
future.  
In 2015 Gambia took steps to draft a Tobacco Control act and 
protect the health of its citizens. Enacted in December 2016 
and officially launched in July 2017, the strong leadership of 
the ministry of Health (supported by WHO) and an effective, 
multisectoral platform helped facilitate the country’s substantial 
progress. While previous smoke-free legislation required people 
not to smoke in public indoor areas, these bans were incomplete, 
allowing smoking areas or designated smoking rooms in almost all 
venue types. The new act took a major step forward by removing 
these exemptions, making the ban complete across all venues. 
In 2018 a national tobacco control committee was established 
to facilitate the implementation of the act, which entered into 
force on 18 July 2018. at the same time civil society was mobilized 
to increase public and community awareness about the dangers 
of smoking, particularly in public places. WHO provided technical 
support and guidance to the ministry of Health, and involved the 
ministries, finance, justice, basic and secondary education, higher 
education, information and communication, tourism, trade, industry 
and employment, foreign affairs,  youth and sports, as well as the 
medical research council and the media.
With smoke-free legislation in place it is now important to monitor 
compliance in all venues and to ensure that the law is enforced to 
achieve the greatest impact on the health of Gambia’s population.
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Offer help to quit tobacco use
countries that reduced services, five were 
high-income (Brunei Darussalam, Estonia, 
Israel, malta and Panama) and one was 
middle-income (Islamic republic of Iran). 
Three of the countries (Brunei Darussalam, 
Israel and Panama) discontinued their 
toll-free quit line, and the other three 
discontinued cost-coverage of nicotine 
replacement therapy (NrT).
While progress has been slower in “O” 
than other mPOWEr measures since 
2007, best-practice adoption of cessation 
services nonetheless increased from 10 
countries (5% of the world’s population) 
in 2007 to 23 countries (32% of the 
world’s population) in 2018 – meaning 
2 billion more people are now protected 
by this measure. The population offered 
best-practice cessation services in 2018 is 
six times what it was in 2007 (when it was 
only 401 million people).
There are 67 countries – home to 
2.1 billion people – whose package 
of cessation support is missing only 
one element to achieve best-practice 
implementation: (i) a national toll-free 
quit line; (ii) cost-coverage of NrT; or 
(iii) cost-coverage of cessation services 
in clinical settings or in the community. 
Of these 67 countries, 28 need to add a 
national toll-free quit line in order to bring 
comprehensive tobacco cessation support 
to an additional 805 million people, 
while 38 need to offer cost-covered 
TOBaCCO DEPENDENCE TrEaTmENT
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Just over 30% of the world’s 
population are covered by 
comprehensive cessation 
services
as of 2018, comprehensive tobacco 
cessation services are in place for 2.4 
billion people in 23 countries – 32% 
of the world’s population. The number 
of countries adopting comprehensive 
tobacco cessation measures lags behind 
the other mPOWEr measures, with only 
16 high-income countries, six middle-
income countries and one low-income 
country (Senegal) offering comprehensive 
cessation support. 
Globally, almost all high-income countries 
make cessation services available and 
90% also offer at least partial cost 
coverage of these services. The majority 
of middle-income countries (72%) do 
the same, while only 24% of low-income 
countries offer any cost-coverage for 
services. There are 24 countries that 
provide no cessation support at all. These 
numbers show that while great work has 
begun, there is still much more to be done. 
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Tobacco dependence treatments – Best practice countries, 2018
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TOBaCCO DEPENDENCE TrEaTmENT – HIGHEST aCHIEvING COuNTrIES, 2018
Demand is building for 
cessation services – it is time 
to deliver
The proportion of the world’s population 
covered by comprehensive cessation 
services decreased by 1% between 
2016 and 2018. On a positive note, four 
countries with a combined population of 
60 million (Czechia, Saudi arabia, Slovakia, 
Sweden) began offering comprehensive 
cessation services in the past 2 years. 
Disappointingly, however, the number of 
people protected by these countries newly 
adopting best practice is offset by six 
countries – representing 97 million people 
– that dropped out of the best-practice 
group in the same period. Of these 
Countries with the highest level of achievement: australia, Brazil, Canada, *Czechia, Denmark, El Salvador, India, Ireland, Jamaica, Kuwait, Luxembourg, mexico, 
Netherlands, New Zealand, republic of Korea, *Saudi arabia, Senegal, Singapore, *Slovakia, *Sweden, Turkey, united arab Emirates, and united States of america.
 
* Country newly at the highest level since 31 December 2016.
Comprehensive tobacco cessation services are in 
place for 2.4 billion people in 23 countries – 32% of 
the world’s population.
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NrTs to cover an additional 1.3 billion 
people and one (Côte d’Ivoire) needs to 
begin cost-covering one or more of its 
cessation services in clinical settings or 
the community so that an additional 25 
million people will be covered. 
Of the 505 million people (6.6% of the 
world’s population) who live in one of 
the world’s 100 largest cities, only half 
(255 million in 49 cities) have access to 
appropriate cessation support. Of these 
cities, two have city-level policies in place 
(Hong Kong Sar and London), and the 
other 47 have national-level policies. 
Instead of waiting for a national policy to 
provide cessation support, the remaining 
51 could move ahead with a city, state or 
provincial level policy to more immediately 
protect their large populations.
Prioritize three key tobacco 
cessation interventions 
at a minimum, three cessation 
interventions should be included in 
a comprehensive tobacco control 
programme: brief cessation advice in 
primary care settings, national toll-free 
quit lines, and pharmacological therapy 
that at the very least includes NrT. 
Tobacco cessation support in 
primary care facilities 
middle-income countries have made 
notable progress in providing tobacco 
cessation support in at least some primary 
care settings since 2007. The population 
covered with cost-covered cessation 
support in at least some primary care 
facilities has increased from 23% to 
75%, with most of this increase occurring 
in middle-income countries. There has 
been little to no progress in high-income 
countries since 2012 and very little 
progress in low-income countries at all 
since to 2007. Currently, only 18 countries 
are providing fully cost-covered tobacco 
cessation support in most of their primary 
care facilities. 
national toll-free quit line
Only a third of countries have a national 
toll-free quit line in place – a situation 
that has changed very little since 2016.   
middle-income countries have made the 
most progress in establishing national 
toll-free quit lines, with the proportion of 
middle-income countries covered rising 
from 10% in 2007 to 33% in 2017.
National toll-free quit lines were the 
only cessation intervention that saw an 
increase in adoption since 2016. 
TOBaCCO CESSaTION SuPPOrT IN aT LEaST SOmE PrImary CarE FaCILITIES (2007–2018)
NaTIONaL TOLL-FrEE QuIT LINE (2007–2018)PrOGrESS IN TOBaCCO DEPENDENCE TrEaTmENT (2007–2018)
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Ten countries introduced a quit line in the 
last 2 years: Belarus, Bulgaria, Czechia, 
Latvia, republic of moldova, Saudi arabia, 
Slovakia, Timor-Leste, Turkmenistan, 
and ukraine. Five countries (Brunei 
Darussalam, Cambodia, Israel, Norway 
and Panama) discontinued their quit lines 
after 2016, leaving a net increase of five 
countries.
nicotine replacement therapy 
must be affordable
Globally, while more than two thirds of the 
world’s countries make NrTs available, less 
than one third either partially or fully cover 
the costs. Disappointingly, the number of 
countries providing NrTs has decreased 
since 2016 and only 45 countries have 
placed NrT on their essential drugs list.  
affordability of NrT is a key issue. 
Countries that do not (or only partially) 
cover NrT costs rely on tobacco users 
to finance this cessation tool out-of-
pocket. an analysis of prices from 56 
countries shows that (on average) the 
least expensive NrT option, adjusted for 
purchasing power parity, costs 40% less 
than the cost of smoking one pack a day 
of the cheapest cigarette brand over the 
same period of time. This means that, 
at least for heavy smokers, even paying 
for NrT out-of-pocket (no costs covered) 
while attempting to quit is likely to be less 
expensive than continuing to smoke.
The price difference between NrTs 
and the cheapest brand of cigarettes is 
greatest in high-income countries, where 
it is significantly cheaper to purchase an 
8-week course of nicotine replacement 
therapy compared to 56 packs of the 
cheapest cigarettes. Even in middle-income 
countries included in the analysis, where 
the cost of NrT is significantly higher, 
overall cost comparisons show the prices 
are similar over the same period of time. 
In countries that have some form of 
cost-coverage for NrTs, the cost of 
the cheapest NrT is almost 20% less, 
suggesting the presumably larger demand 
for these products helps reduce out-
of-pocket costs. It should be noted this 
same situation may not be the case in 
low- and lower-middle-income countries, 
where NrTs are likely to be relatively more 
expensive and cigarettes much cheaper. 
While far from being universally 
accessible, using NrT as a cessation tool 
is relatively affordable compared to the 
cost of smoking. Cost-coverage of NrTs 
is an important factor for governments 
to consider, particularly when trying to 
expand access to proven and effective 
cessation tools. 
NrT has the best balance of effectiveness, 
cost and safety.  as a result, two forms 
of NrT (nicotine gum and nicotine 
patch) have been added to WHO model 
List of Essential medicines since 2009 
(see: https://www.who.int/medicines/
publications/essentialmedicines/en/). The 
model list presents a list of drugs that 
are essential to health systems. Countries 
should consider adding NrT to their 
national essential drug lists.
Policies and capacity for 
tobacco cessation must 
improve 
WHO FCTC article 14 guidelines 
recommend the implementation of four 
specific infrastructure elements in order to 
promote tobacco cessation and provide 
effective tobacco dependence treatment: 
  n A national cessation strategy: 
among the countries for which there 
are data, almost 40% (73 out of 187) 
have national cessation strategies, 
ranging from 60% of high-income 
countries to 18% of low-income 
countries. 
  n national tobacco cessation 
guidelines: an assessment was 
made of countries’ national tobacco 
cessation guidelines and clinical 
guidelines for treating tuberculosis, 
cancer, cardiovascular disease, 
diabetes, chronic obstructive 
pulmonary disease, reproductive 
health, mental health and oral 
health problems. This revealed that 
82 countries (42% globally) have 
national tobacco cessation guidelines; 
and 136 countries (73% of those 
that submitted a questionnaire) have 
at least one disease-specific clinical 
guideline which includes cessation. 
Two thirds of these countries are low- 
and middle-income countries. 
  n Training capacity: a total of 50 
countries reported regularly training 
primary care providers in brief advice 
(which should be integrated into 
primary care disease prevention and 
control programmes) and/or providing 
at least one form of cessation training 
as part of medical, nursing or dental 
curricula. 
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  n All medical notes include 
information about tobacco 
use: Including tobacco use status 
in medical records helps to routinely 
identify tobacco users and advise 
them to quit. Of all the infrastructure 
and systems components examined, 
this was the least implemented. 
Tobacco use was reported in routine 
medical records in only 35 countries.  
 
While it is recommended that tobacco 
cessation measures are implemented 
synergistically with other tobacco control 
initiatives, only 45 countries reported 
integrating quit line information into mass 
media campaigns or placing quit line numbers 
on the graphic health warnings on tobacco 
products.  Of the countries that have a 
national toll-free quit line, no low-income 
countries had incorporated quit line numbers 
on graphic health warnings or in mass media 
campaigns.
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India is the second largest consumer of tobacco products, with 
more than 200 million users of smokeless forms of tobacco (SLT) 
and 276 million consumers of tobacco overall. In 2017 a Global 
adult Tobacco Survey (GaTS2) found 38.5% of adult smokers 
and 33.2% of adult SLT users in India had attempted to quit. The 
government recognized the demand for cost-effective and accessible 
cessation services and adopted a multi-pronged strategy to reach 
out to tobacco users across rural and urban India. In addition to 
the integration of brief advice in primary care, a toll-free quit line 
and a national framework for joint TB-Tobacco activities, India has 
leveraged technological solutions to increase access.
The National Tobacco Control Programme and the ministry of Health 
and Family Welfare, with support from WHO and the International 
Telecommunication union’s “Be He@lthy, Be mobile” initiative, 
implemented the mCessation programme. Part of the “Digital India” 
initiative, it uses two-way messaging between the individual seeking 
to quit and programme specialists, providing dynamic support for 
those who wish to quit. a unique feature of the programme allows 
users who want to quit to register by giving a missed call to a 
dedicated national number, or by registering at http://www.nhp.gov.
in/quit-tobacco. The government has recently released version 2 of 
the mTobaccoCessation platform, which is capable of delivering the 
content through SmS or interactive voice response in 12 languages. 
The programme’s progress is monitored in real time through 
an online dashboard that details the number of registrations, 
disaggregated by factors such as gender, geography, and tobacco 
use type.
To date, the programme has over 2.1 million self-registered users. an 
evaluation conducted by the ministry of Health and Family Welfare 
found an average quit rate of 7% for both smokers and smokeless 
tobacco users 6 months after enrollment. When 12 000 participants 
in the programme were asked about their tobacco use, more than 
19% said they had abstained over the past 30 days. 
India has also launched a second national mHealth programme, 
mDiabetes, for the prevention and management of diabetes. Both 
programmes have been integrated into the national NCD screening 
initiative under the national health protection scheme, “ayushman 
Bharat.”
Since 2005, the republic of Korea has promoted cessation services 
in all public health centres across the country. From June 2017 to 
June 2018 alone, 357 936 smokers were given brief advice to quit, 
and 70 833 (19.8%) of them had not smoked for 6 months after 
their quit date.   
In 2006 a national toll-free quit line was launched to strengthen and 
support the national cessation programme. The quit line is available 
13 hours a day on weekdays, and 9 hours a day on weekends, and 
provides registered users with free counseling sessions for 1 year. Of 
the 17 752 tobacco smokers who received at least one telephone 
counseling session between 2017 and 2018, 3368 (19%) had not 
smoked for 6 months after their quit date. 
In 2015 the National Health Insurance Service started to cover the 
cost of tobacco cessation consultation and cessation drug fees in 
hospitals and clinics across the country. an outreach service, known 
as “Quit Bus” was introduced to help and encourage socially 
marginalized smokers, such as women and out-of-school youth, 
to quit.  regional smoking cessation centres were established to 
provide free intensive treatment to heavy smokers. The expansion of 
services led to an increase in the number of people registering with 
national smoking cessation services from 439 971 in 2014 to 
861 086 in 2017. 
The comprehensive national smoking cessation services contributed 
to a significant decline in the smoking rate among adult males, from 
66.3% in 1998 to an historic low of 38.1% in 2017. The earmarking 
of tobacco tax revenue for quit services and providing cessation 
services in conjunction with other tobacco control initiatives are key 
factors that contributed to this success.
When Senegal adopted its Tobacco Control act in 2014, the Health 
Commission of the country’s National assembly affirmed that 
tobacco cessation was a national priority and that comprehensive 
smoking cessation support would be established to help smokers 
quit. at the time, the Chair of the Health Commission, awa Dia 
Thiam, told members of Parliament: “measures must be taken to 
support smokers who want to quit smoking and help them through 
the very difficult preliminary phase.”
Since then the ministry of Health and Social action has created a 
national toll-free quit line offering trained counselors who are able 
to give advice on smoking cessation and advise callers about the 
various treatments available in Senegal to help them quit. During 
the first 4 months, 4068 calls were received by the quit line.
more recently, the National Tobacco Control Program, which is 
responsible for coordinating tobacco control policy, has developed a 
National Tobacco Control Strategic Plan 2018–2022, which details 
the cessation services available.
India successfully implements mCessation The Republic of Korea offers comprehensive help to quit smoking
Smoking cessation counselling in a mobile 
clinic known as the Quit Bus, Republic of 
Korea.
Quit line featured on cigarette packs, 
Senegal. 
Ecuador ratified the WHO FCTC in 2006, and despite advances in 
tobacco control, according to the Institute of Health metrics and 
Evaluation (see https://vizhub.healthdata.org/gbd-compare/), an 
Ecuadorian citizen dies from tobacco every 2 hours1. Providing 
tobacco cessation support via the country’s health system is still a 
challenge – and one that can be met by encouraging collaboration 
with other sectors. In this context, in 2018 Ecuador took steps to 
integrate brief tobacco interventions into primary care, aligning with 
their “médico del Barrio” strategy (Neighborhood Doctor strategy)2.
as part of this intervention, the Ecuadorian ministry of Health has 
established a national training network, linking together training 
institutions responsible for on-the-job training of primary care 
providers and asking WHO to strengthen the capacity of their 
national training network on tobacco cessation. In response, WHO, 
PaHO and the European respiratory Society (which provided 
financial support) conducted a joint train-the-trainer tobacco 
cessation workshop for 55 national trainers in January 2018. In 
march 2018, integration of brief tobacco interventions into primary 
care began in Pichincha, Guayas, azuay and Cañar provinces. 
about 120 primary care providers were trained on brief tobacco 
interventions and have since been routinely identifying tobacco 
users and advising them to quit.
The results of the project have been very encouraging. From 
mid-march to mid-November 2018, 3916 tobacco users were 
identified and given advice on quitting. among the 2069 patients 
who completed a follow-up at 4 months, the 7-day self-reported 
abstinence rate was 57.2%, and of the 968 who completed a 
6-month follow-up 
assessment, the self-
reported abstinence 
rate was 48.9%. 
Based on these 
results, Ecuador plans 
to expand tobacco 
cessation integration 
to more provinces.
Integrating brief tobacco interventions into primary care, 
Ecuador
1  The data result displays a mean estimate expressed in the raw number of 5372 deaths and a 95% range of uncertainty interval from 4669 to 6143 deaths.
2  “medico del Barrio” is an advanced primary health care strategy developed and implemented by the Government of Ecuador, whose purpose is to provide health care services to vulnerable and priority populations via 
patient recruitment and screening. This is done through home visits by health teams consisting of a general practitioner, a nurse, a primary health care worker, and the support of a community and family physician and/or a 
general comprehensive physician working at the first level of care.
A man receives brief advice 
about quitting tobacco, 
Ecuador.
mCessation messages received in 
English and Hindi in India.
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Warn about the dangers of tobacco
high-income countries, 45% of middle-
income countries and 15% of low-income 
countries. Only 10% of countries (five 
high-income, nine middle-income and 
seven low-income) have not adopted any 
warning labels, and 22 others (11%) have 
issued warnings that cover less than 30% 
of the principal package display areas 
(below the minimum required by the WHO 
FCTC). One in three low-income countries 
has no warning, or a warning that is 
smaller than required.
article 11 of the WHO FCTC states: “Each Party shall … adopt and implement … effective measures to ensure that … tobacco product 
packaging and labelling do not promote a tobacco product by any means that are false, misleading, deceptive or likely to create an 
erroneous impression about its characteristics, health effects, hazards or emissions”(1). WHO FCTC article 11 guidelines are intended 
to assist Parties in meeting their obligations under article 11 of the WHO FCTC, which provides a clear timeline for Parties to adopt 
appropriate measures (within 3 years after entry into force of the WHO FCTC for a given Party) (95).
HEaLTH WarNING LaBELS – HIGHEST aCHIEvING COuNTrIES, 2018
Health warning labels
Health warnings provide 
critical information about 
the harms of tobacco use 
Despite the overwhelming evidence-
base on the harms of tobacco, many 
tobacco users still do not fully appreciate 
the dangers they expose themselves 
and others to by consuming tobacco  
(124). Consumers have a right to be 
warned about the health impacts of the 
products they purchase and consume, 
and this includes sufficient and accurate 
information regarding the risks of tobacco 
use (124–126). Graphic health warnings 
providing accurate information about the 
risks associated with tobacco use can help 
stimulate tobacco users to reduce their 
consumption and quit (127, 128).
Effective health warnings communicate the 
risks of consuming tobacco as well as the 
risk to others of exposure to second-hand 
smoke (129). There is significant evidence 
that accurate, prominent warnings prompt 
tobacco users to think about quitting, and 
can result in decreased tobacco use (130, 
131). 
Health warnings on tobacco 
packaging are effective 
Graphic health warnings on tobacco 
product packages reliably reach tobacco 
users each time they use the products 
(132). at the same time, applying warning 
labels to packaging is at relatively low 
expense to governments (132). Graphic 
health warnings are well-supported by the 
public – more so than most other tobacco 
control measures (129, 133).
Warnings should refer to specific health 
effects related to tobacco use. They are 
most effective when they are pictorial, 
graphic, comprehensive, and strongly 
worded (134, 135). It is important that 
the warning is large, covering at least half 
of a tobacco package’s surface (front and 
back) (132). To sustain their impact, labels 
should be rotated on a regular basis (136). 
Companies use packaging to manipulate 
users’ perceptions of a tobacco product’s 
taste, strength, and health impacts, in 
essence turning packaging into a product 
characteristic (137). Terms suggesting 
reduced health risks including “light”, 
“ultra-light”, and “low tar” are deceptive 
and should be prohibited (130). However, 
removing misleading descriptors 
may not be sufficient to decrease the 
misperceptions of reduced risk associated 
with these cigarette types (138, 139).
Over half of the world’s 
population are exposed to 
large and effective graphic 
health warnings 
Strong graphic pack warnings are in 
place for almost 3.9 billion people in 
91 countries – over half of the global 
population (52%). more people are 
protected by this mPOWEr measure 
than any other, with 47% of countries 
implementing graphic pack warning 
requirements at the highest level: 65% of 
0 1,750 3,500875 Kilometers
Health warning labels – Best practice countries, 2018
Best practice countries
Other countries
Not applicable
Countries with the highest level of achievement: argentina, armenia, australia, austria, Bangladesh, *Barbados, Belarus, Belgium, Bolivia (Plurinational State of), Brazil, 
Brunei Darussalam, Bulgaria, Burkina Faso, Cambodia, *Cameroon, Canada, Chad, Chile, Costa rica, *Croatia, *Cyprus, Czechia, Denmark, Djibouti, Ecuador, Egypt, 
El Salvador, Estonia, Fiji, Finland, France, *Georgia, Germany, Greece, *Guyana, *Honduras, Hungary, India, Iran (Islamic republic of), Ireland, Italy, Jamaica, Kazakhstan, 
Kyrgyzstan, Lao People’s Democratic republic, Latvia, Lithuania, *Luxembourg, madagascar, malaysia, malta, mauritius, mexico, mongolia, Namibia, Nepal, Netherlands,  
New Zealand, *Pakistan, Panama, Peru, Philippines, Poland, Portugal, republic of moldova, romania, russian Federation, *Saint Lucia, Samoa, *Saudi arabia, Senegal, 
Seychelles, Singapore, Slovakia, *Slovenia, Solomon Islands, *Spain, Sri Lanka, Suriname, Sweden, Thailand, *Timor-Leste, Trinidad and Tobago, Turkey, Turkmenistan, 
ukraine, united Kingdom, uruguay, vanuatu, venezuela (Bolivarian republic of), and viet Nam.
 
* Country newly at the highest level since 31 December 2016.
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Four out of five low-income 
countries do not mandate 
sufficient warnings on packs
In the past 2 years, 14 additional 
countries, with 4% of the world’s 
population, have joined the 77 countries 
that required large graphic warning labels 
on tobacco products. Seven were high-
income countries and the other seven 
were middle-income. Of the 14 countries, 
two (Barbados and St Lucia) went from 
no required health warnings at all to a 
complete law covering at least 50% of the 
pack with a graphic health warning, and 
the other 12 strengthened existing laws to 
meet best-practice level. No low-income 
countries achieved complete adoption of 
graphic warning laws in the past 2 years, 
meaning four out of five low-income 
countries are still not mandating sufficient 
warnings on packs. 
Strong graphic health 
warnings are in place for 
almost half of all countries 
and more than half of the 
global population 
Compared to 2007, when only nine 
countries (5% of the world’s population) 
had large graphic pack warnings on 
cigarettes, there are now 91 countries 
(52% of the world’s population) with 
comprehensive graphic pack warning 
requirements. This means 82 countries 
have taken action to adopt laws that 
require strong graphic health warnings 
on tobacco products since 2007. The 
28 member States of the European 
union (Eu) are large contributors to 
this increase, since all of them have 
incorporated the requirements for large 
graphic health warnings required by the 
2014 Eu warning label directive into their 
national laws (23 countries had done so 
by 2016 and the remaining five by 2018). 
In addition, India reached best-practice 
level in 2016, adding 1.35 billion people 
to the total population coverage. Of all 
mPOWEr measures, this one has seen the 
most progress since 2007 both in terms of 
countries acting and population covered 
by a best-practice policy.
Eight countries, with 384 million people, 
need only raise the pack coverage by 20% 
or less to meet all best-practice criteria for 
large graphic pack warnings. 
an additional 15 countries have mandated 
large warnings (at least 50% of the pack) 
and need only add one criterion to achieve 
best practice. Eight of these 15 countries, 
representing 157 million people, need 
only mandate that strong graphic health 
warnings appear on each package and any 
outside packaging used in the retail sale, 
and six countries, with 360 million people, 
need only add a requirement for a graphic 
image (instead of text only) – albania, 
Cook Islands, Niger, Togo, Tonga and the 
united States of america. The remaining 
member of this group, Gabon, with 2 
million people, only needs to require a 
specification of font style, font size and 
colour for pack warning requirements to 
reach best-practice level.
Of the 505 million people (6.6% of the 
world’s population) who live in one of 
the world’s 100 largest cities, two thirds 
(339 million) live in one of the 62 cities 
protected by graphic pack warnings 
containing all appropriate characteristics. 
These cities are all covered by a law 
passed at the national level, apart from 
Hong Kong Sar, which has a city-level law 
in place. 
HEaLTH WarNING LaBELS PrOGrESS IN HEaLTH WarNING LaBELS (2007–2018)
Low-incomeMiddle-incomeHigh-income
Data not reported
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Strong graphic health warnings are in place for 
almost 3.9 billion people in 91 countries – over half 
of the global population (52%).
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Plain packaging is 
effective and increases 
the effectiveness of health 
warnings
Plain packaging (also called standardized 
packaging) is packaging which restricts 
or prohibits “the use of logos, colours, 
brand images or promotional information 
on packaging other than brand names 
and product names displayed in a 
standard colour and font style” (95). 
Plain packaging simultaneously reduces 
the attractiveness of tobacco products, 
eliminates the effects of tobacco 
packaging as a form of advertising and 
promotion, minimizes misleading product 
descriptor language, and enhances 
the noticeability and effectiveness of 
health warnings (140–143). There is 
evidence that plain packaging reduces 
misperceptions that some cigarettes are 
less harmful than others, and decreases 
both smoking prevalence and smoking 
behaviours (144).
First implemented by australia in 2012, 
plain packaging has been challenged 
by the tobacco industry on the basis 
of protection of trademarks, freedom 
of commercial expression, protections 
for trade, and protections for the free 
movement of goods (145). These 
challenges have been rejected in the 
domestic courts of australia, England 
and Wales, France, and Norway (145). 
In addition, in June 2018, a World 
Trade Organization panel ruled against 
complaints brought by four countries 
regarding australia’s tobacco packaging 
law (146).
More and more countries 
require plain packaging of 
tobacco products
In spite of tobacco industry lobbying, 
several countries are now moving forward 
with plain packaging. By the end of 2018, 
10 countries had adopted legislation 
mandating plain packaging of tobacco 
products and had issued regulations 
with implementation dates (australia, 
France, Hungary, Ireland, New Zealand, 
Norway, Saudi arabia, Thailand, united 
Kingdom and uruguay). In addition, 
Belgium, Canada, Singapore and Turkey 
have passed plain packaging regulations 
in 2019. Burkina Faso, Georgia, Israel, 
romania and Slovenia have passed laws 
but not regulations and do not yet have 
implementation dates.
Georgia has one of the highest rates of tobacco use in the 
world. about 33% of the adult population are current smokers 
(including 57% of men), in addition to 12.6% of 13–15-year-
olds.  about 11 400 Georgians die every year as a result of 
tobacco use, and the country loses 2.4% of its annual GDP to 
tobacco-related deaths and disability. While the first tobacco 
control law in the country was adopted in 2003, strong 
interference from the tobacco industry prevented the law from 
being comprehensive. For more than a decade Georgia’s laws 
have remained stagnant. However, in 2015 a plan for change 
began to take shape. The Tobacco Control alliance, with 
support from several NGOs and funding and strong technical 
backing from the Campaign for Tobacco Free Kids, began an 
advocacy campaign, mobilizing and consolidating all local 
and international players working in tobacco control, health, 
and human rights. On 17 
may 2017 the new law was 
adopted. 
The law requires that pictorial 
health warnings cover at 
least 65% of the two biggest 
sides of the packaging of all 
smoking tobacco products 
(including cigarettes, cigars, water pipes, heated tobacco etc.). 
Georgia’s government decreed that the nine most effective 
pictorial warnings (selected by the ministry of Health based on 
focus group results) developed in australia and Canada must 
be used. Packages of smokeless tobacco products must provide 
written health warnings on 30% of the two biggest sides. 
Three general graphic health warnings and three additional 
ones with relevant pictograms are subject to rotation during a 
year and should be equally distributed on each type of tobacco 
package.
There is no place for complacency however, as ongoing tobacco 
industry interference continues to undermine tobacco control 
efforts in Georgia, with the industry successfully delaying the 
implementation of plain packaging to December 2021.
as the success of plain packaging requirements becomes 
ever-more apparent, more countries, including middle-income 
countries, are starting to adopt the measure.  The following 
three countries are the first in their respective regions to do so.
uruguay continues to lead the Americas 
In 2018 uruguay continued its role as a leader for the 
americas, becoming the first country in the region to enact 
plain packaging requirements for tobacco products. uruguay’s 
president, Tabaré vàsquez, signed an executive decree 
mandating plain packaging on 6 august 2018. Only a month 
later, however, the decree was suspended due to a lawsuit 
filed by British american Tobacco (BaT). The administrative 
First Instance Court ruled in favour of BaT because the plain 
packaging measure had been enacted by an executive decree 
instead of a law adopted by Parliament. The uruguayan 
government appealed this decision and on 11 October 2018 
the Court of appeal ruled in the government’s favour, although 
a law would still be necessary to establish plain packaging. 
a legislative effort was immediately launched that month, 
leading to the adoption of Law 19.723 on 12 
December 2018 and a detailed decree on 29 
april 2019, with the law to be implemented for 
all tobacco products from 22 December 2019.
Saudi Arabia introduces plain 
packaging 
In late 2018, the Saudi Food and Drug 
authority (SFDa) issued regulations requiring 
plain packaging on tobacco products, 
making Saudi arabia the first country in the 
Eastern mediterranean region to do so. In 
preparation for the legislation (which will be 
fully implemented on 1 January 2020), the 
SFDa issued a model plain package to all 
tobacco product manufacturers and importers, 
specifying the required standard colour and font style, and 
sample graphic health warnings that must be carried, selected 
from both the WHO and Eastern mediterranean regional 
Office’s Graphic Health Warnings database. In alignment with 
Saudi arabia’s 2030 vision for the promotion of public health, 
it is expected that this step will contribute to Saudi arabia’s 
overall tobacco control agenda.
Thailand is the first upper-middle-income country 
to introduce plain packaging 
In December 2018, Thailand made history when it became 
the first country anywhere in asia (and the first upper-middle-
income country in the world) to require plain packaging – a 
law that will be fully implemented by 9 September 2019. “Plain 
packaging is a landmark measure for tobacco control that will 
help reduce the use of these deadly products in Thailand,” 
said Dr Daniel a Kertesz, WHO representative to Thailand. The 
new measure complements earlier legislation requiring 85% of 
the surface of tobacco packs to show graphic warnings of the 
adverse effects of smoking on health. 
Georgia adopts new law on health warnings
Plain packaging spreads across the globe
Plain packaging guidelines, Uruguay.
The Georgian parliament votes for a tobacco control bill, 2017.
96 97WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC, 2019 WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC, 2019
Anti-tobacco mass media campaigns
article 12 of the WHO FCTC states: “Each Party shall promote and strengthen public awareness of tobacco control issues, using all 
available communication tools, as appropriate. … each Party shall … promote … broad access to effective and comprehensive 
educational and public awareness programmes on the health risks including the addictive characteristic of tobacco consumption and 
exposure to tobacco smoke; … [Each party shall promote] public awareness about the risks of tobacco consumption and exposure 
to tobacco smoke, and about the benefits of the cessation of tobacco use and tobacco-free lifestyles;… [each party shall promote] 
public awareness of and access to information regarding the adverse health, economic, and environmental consequences of tobacco 
production and consumption”(1). WHO FCTC article 12 guidelines are intended to assist Parties in meeting their obligations under 
article 12 of the WHO FCTC (95).
Well-designed anti-tobacco 
mass media campaigns can 
reduce tobacco use
Well designed, hard hitting anti-tobacco 
mass media campaigns can reduce 
tobacco use. There is strong evidence 
that mass media campaigns increase quit 
attempts, lower youth initiation rates and 
reduce second-hand smoke exposure 
(147–152). mass media anti-tobacco 
campaigns are commonly used in high-
income countries but have been shown 
to be effective in low-and middle-income 
countries as well (153). 
Sustained campaigns are more likely to 
have a longer-term impact on tobacco 
use behaviour, but campaigns running 
for as little as 3 weeks can still have a 
positive impact (148, 154, 155). Television 
campaigns using graphic imagery are 
known to be especially effective in 
motivating tobacco users to attempt to 
quit (151, 156).
mass media campaigns can be expensive, 
but they have the potential to quickly and 
efficiently reach very large populations 
(151). Including information about what 
tobacco users can do to quit, such as 
providing a toll-free quit line number on 
the products of the mass media campaign, 
e.g. on the bottom of posters or at the end 
of television advertisements.
Comprehensive tobacco 
control strategies must 
include mass media 
campaigns
anti-tobacco mass media campaigns not 
only create awareness and inform people 
about the harms of tobacco use and 
second-hand smoke, they also encourage 
maSS mEDIa CamPaIGNSaNTI-TOBaCCO maSS mEDIa CamPaIGNS – HIGHEST aCHIEvING COuNTrIES, 2018
Low-incomeMiddle-incomeHigh-income
Data not reported
No national campaign conducted 
between July 2016 and June 2018 
with a duration of at least 3 
weeks
National campaign implemented 
with 1–4 appropriate 
characteristics
National campaign implemented with 5–6 
appropriate characteristics, or with 7 
characteristics excluding airing on TV and/or 
National campaign implemented with at least 7 
appropriate characteristics including airing on 
television and/or radio
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quitting. as such it is imperative that these 
campaigns form an important part of any 
comprehensive tobacco control strategy 
or programme (156). Governments should 
develop and deliver messages designed 
to educate current and potential tobacco 
users about the dangers of tobacco 
influence attitudes and beliefs about 
tobacco use (149).
Mass media efforts continue 
to fall behind
Less than a quarter of the world’s 
population (1.7 billion people) live in 
a country that has aired at least one 
national comprehensive anti-tobacco mass 
media campaign in the past 2 years. Of 
the 39 countries that ran an anti-tobacco 
campaign during that time, 19 were high-
income, 18 were middle-income and two 
were low-income countries. almost half of 
the countries in the world (91) have not 
run any kind of sustained campaign in the 
past 2 years, leaving about 19% of the 
world’s population, and an estimated 220 
million tobacco users, unreached by any 
mass media campaign.  
 
People in low-income countries are the 
least exposed to anti-tobacco mass media:  
over 60% of the population of low-income 
countries, living in 24 countries, have not 
been exposed to any kind of campaign in 
the past 2 years.
The first year for which mass media 
campaigns were monitored was 2010. 
Since then, the proportion of the world’s 
population exposed to a best-practice mass 
media campaign rose until 2014, when 
4.2 billion people lived in countries airing 
such campaigns. regrettably, by 2018 this 
number had dropped by more than half, 
to 1.7 billion people. In 2015–2016, 42 
countries ran campaigns, a higher number 
of countries than during any other period. 
most countries that execute campaigns 
do not repeat the effort every 2 years. Of 
the 42 countries that ran a best-practice 
campaign in the period 2014-2016, 33 ran 
another campaign in the recent period, but 
only 22 of these were also best-practice 
campaigns. 
Of the 91 countries that ran no campaign 
at all in the last two years, 20 had 
previous experience running a best-
practice campaign.
Of the 14 countries that consistently 
ran campaigns in all of the five periods 
assessed (2009–2010, 2011–2012, 
2013–2014, 2015–2016 and 2017–2018) 
only four (australia, Turkey, united 
Kingdom and viet Nam) maintained 
best-practice implementation for each 
campaign. 
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Anti-tobacco mass media campaigns – Best practice countries, 2018
Best practice countries
Other countries
Not applicable
Countries with the highest level of achievement: australia, austria, *Belarus, *Brazil, *Brunei Darussalam, Costa rica, *Cyprus, El Salvador, Estonia, Fiji, *France, *Georgia, 
*Germany, Indonesia, *Iraq, Ireland, Italy, Jordan, *Luxembourg, *myanmar, New Zealand, Norway, Pakistan, *Panama, *Qatar, republic of Korea, republic of moldova, 
*Saint Lucia, *Senegal, Seychelles, Switzerland, *Timor-Leste, *Togo, Tonga, Turkey, *Turkmenistan, united Kingdom, united States of america, and viet Nam.
 
* Country newly at the highest level since 31 December 2016.
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PrOGrESS IN aNTI-TOBaCCO maSS mEDIa CamPaIGNS (2010–2018)
Note: Data reporting for anti-tobacco mass media campaigns started in 2010.
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a 2014 STEPS survey in myanmar showed 43.2% of the 
population (62.2% male and 24.1% female) used smokeless 
tobacco, with 94% reporting the use of smokeless tobaccos 
containing betel quid. To combat the health risks associated 
with tobacco use, myanmar implemented its first mass media 
campaign to increase awareness of the health harms of 
tobacco use (including betel quid) in September 2017. The 
national NGO People’s Health Foundation, in collaboration 
with civil authorities and creative, media and research agencies 
across myanmar, designed and implemented the campaign. 
The support of the ministry of Health and Sports and the 
ministry of Information through free and reduced-cost radio 
and Tv air time, as well as technical and financial support 
from vital Strategies (a non-governmental organization), was 
also instrumental. The 6-week campaign was the first to ever 
feature stories about actual people harmed by smokeless 
tobacco in myanmar on Tv, radio and posters. Development 
followed an evidence-based strategic communication approach 
that included target audience identification; refinement, pre-
testing and production of Public Service annoucements; the 
use of public and private media (Tv, radio); and post-campaign 
assessment of the reach and impact. mass media campaigns 
for tobacco control have been recognized as a WHO “best-
buy” approach (28). The significant reach of the campaign, 
covering 48% of the population in 2017 and over 80% during 
2018, is encouraging, and an excellent example of how 
multistakeholder collaboration can create maximum impact at 
the country level. 
China is the biggest consumer of tobacco products. Even 
though progress has been made in advancing tobacco control 
initiatives, China’s addiction to tobacco remains strong. 
The tobacco industry continues to unleash large marketing 
campaigns and is still able to expand its consumer base and 
successfully acquire a new generation of smokers. Tobacco-
related diseases kill 1 million people in China every year and 
100 000 non-smokers die from exposure to second-hand 
smoke.
In may 2017, a campaign for a smoke-free next generation 
harnessed the power of the entertainment industry by 
teaming up with celebrities and a fashion magazine (based 
on their appeal to youth and women in particular) to spread 
the message that choosing a healthy, smoke-free lifestyle is 
empowering.  
 
The campaign was launched during World No Tobacco Day 
2017 and exploded on social media, earning 34 million views 
in just 3 days. It was ranked as the number one social-good 
hashtag and within its first week had reached more than 120 
million social media users, 70% of them under the age of 40. 
more than 80 million users participated in campaign discussion 
threads during the week. Within the first 30 days, 184 media 
outlets covered the campaign in China and the video was 
displayed on more than 100 LED screens in landmark buildings 
and sites throughout China. Even Xiamen airlines aired the 
video in its lounges around China, and in its aircraft.
Myanmar launches first-ever mass media anti-tobacco 
campaign
Entertainment industry helps create a smoke-free next 
generation in China
The #stopbetelmyanmar campaign, Myanmar.
Less than a quarter of the world’s 
population live in a country that 
has aired a national comprehensive 
anti-tobacco mass media campaign 
in the past 2 years.
The Smoke-Free Next Generation campaign, 
China.
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Enforce bans on tobacco advertising, 
promotion and sponsorship
Bans on tobacco advertising, 
promotion and sponsorship 
must be comprehensive
more than 10 years after the adoption 
of the Guidelines for implementation of 
article 13 of the WHO FCTC, the following 
principle stipulated at its beginning is still 
relevant today: “It is well documented 
that tobacco advertising, promotion and 
sponsorship increase tobacco use and 
that comprehensive bans on tobacco 
advertising, promotion and sponsorship 
decrease tobacco use” (95).
Every year the tobacco industry spends 
billions of dollars on advertising, 
article 13 of the WHO FCTC states: “... [a] comprehensive ban on advertising, promotion and sponsorship would reduce the 
consumption of tobacco products. Each Party shall ... undertake a comprehensive ban of all tobacco advertising, promotion and 
sponsorship. … [W]ithin the period of 5 years after entry into force of this Convention for that Party, each Party shall undertake 
appropriate legislative, executive, administrative and/or other measures and report accordingly in conformity with article 21”(1). WHO 
FCTC article 13 guidelines are intended to assist Parties in meeting their obligations under article 13 of the WHO-FCTC (95).
Bans are effective at 
reducing tobacco use
Evidence from across the world indicates 
that comprehensive bans are effective 
in reducing tobacco sales and tobacco 
consumption (164–167). The impact of 
TaPS bans may be even more dramatic 
in low- and middle-income countries 
than in high-income countries (167). 
TaPS bans are recognized as a key policy 
measure as they comprise one of only two 
provisions in the WHO FCTC that impose a 
mandatory timeframe for implementation 
(the other one being article 11 of the 
Convention). 
Bans must be comprehensive 
and well-enforced
TaPS bans should cover all TaPS activities 
including both direct and indirect varieties 
of promotion. Direct forms of advertising 
include among others television, radio, 
print publications and billboards, while 
indirect forms of advertising include 
among others brand stretching, free 
distribution, price discounts, point of 
sale product displays, and sponsorships 
including corporate social responsibility 
programmes (168). Point of sale displays 
“normalize” the products, act as a prompt 
to smoke, encourage impulse purchases, 
interfere with quitting, and increase the 
susceptibility of children and young people 
to try the product (169–174). When bans 
are not comprehensive, tobacco companies 
exploit legal loopholes or simply shift their 
investments to forms of promotion that 
are not banned (164, 175, 176).
When tobacco companies make financial 
or in-kind contributions to any other 
entity for deserving or socially responsible 
causes such contributions fall within the 
definition of tobacco sponsorship under 
article 1(g) of the Convention and should 
therefore be banned (168). Corporate 
social responsibility activities are typically 
employed to convince governments to 
delay and refrain from implementing 
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Enforce bans on tobacco advertising – Best practice countries, 2018
Best practice countries
Other countries
Not applicable
ENFOrCE BaNS ON TOBaCCO aDvErTISING, PrOmOTION aND SPONSOrSHIP – HIGHEST 
aCHIEvING COuNTrIES, 2018
Countries with the highest level of achievement: afghanistan, albania, *antigua and Barbuda, *azerbaijan, Bahrain, *Benin, Brazil, Chad, Colombia, 
*Congo, *Democratic republic of the Congo, Djibouti, Eritrea, *Gambia, Ghana, Guinea, *Guyana, Iran (Islamic republic of), Kenya, Kiribati, Kuwait, 
Libya, madagascar, maldives, mauritius, mongolia, Nepal, Niger, Nigeria, *Niue, Panama, Qatar, republic of moldova, russian Federation, *Saudi arabia, Senegal, Seychelles, *Slove-
nia, Spain, Suriname, Togo, Turkey, Tuvalu, uganda, united arab Emirates, uruguay, vanuatu, and yemen.
 
* Country newly at the highest level since 31 December 2016.
promotion, and sponsorship (TaPS) 
activities to promote their tobacco 
products and increase tobacco sales (157). 
Despite tobacco companies’ insistence that 
advertising only increases their market 
share at the expense of competitors, there 
is longstanding and consistent evidence 
of a causal relationship between TaPS 
activities and increased or sustained 
tobacco use through both the effective 
recruitment of new tobacco users or by 
discouraging tobacco users from quitting 
(148, 158, 159).  
Tobacco companies employ a combination 
of marketing techniques to target different 
groups. TaPS activities are tailored to 
specific populations through new products 
that circumvent regulations and maintain 
social acceptability (160). youth and 
women are especially targeted in low- and 
middle-income countries (161). Exposure 
to tobacco advertising and promotion 
increases the likelihood that adolescents 
will start to use tobacco which may lead 
to a higher prevalence of adult tobacco 
users in the future (159, 162, 163). 
Promotional and sponsorship activities are 
also effective at influencing businesses 
that may benefit from the billions of 
dollars that the tobacco industry invests in 
TaPS. To counter this, comprehensive bans 
in all TaPS activities are needed as a key 
tobacco control strategy (164).
More low-income countries
have adopted a TAPS ban than
any other MPOWER measure.
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TAPS ban should apply to 
new media
Tobacco companies now frequently 
utilize novel media platforms for TaPS 
activities such as social media sites and 
mobile phone applications (178). On a 
wide variety of social media platforms, 
influencers, spokespeople, and brand-
sponsored contests are used to promote 
tobacco products (178, 179). The 
enormous growth in communications 
technology and use of Internet-based 
mobile phones has made it essential to 
keep a check on tobacco advertising and 
promotion on platforms such as Instagram, 
youTube, Facebook etc. Children and 
adolescents are particularly exposed to 
these platforms (180). Legislation banning 
TaPS may not necessarily include a ban 
on advertisements on the Internet and 
therefore ensuring that bans are inclusive 
of Internet-based media is crucial (181, 
182). In some cases enforcing TaPS 
bans on social media sites may require 
legislation to be implemented across 
borders and for this reason countries will 
need to cooperate and coordinate efforts 
(179).
More countries than ever 
are adopting complete bans 
on tobacco advertising, 
promotion and sponsorship 
Banning TaPS remains an under-adopted 
measure, with only 18% of the world’s 
population, in 48 countries, covered by 
a comprehensive ban. at the same time, 
there are 44 countries (11 high-income, 
21 middle-income, and 12 low-income 
countries) that have not adopted any TaPS 
bans to date.
Interestingly, more low-income countries 
have adopted a TaPS ban than any 
other mPOWEr measure, with 14 low-
income countries – or 40% – having 
comprehensive TaPS bans in place.  By 
contrast, under 20% of high-income 
countries (11) have achieved this best-
practice level.
More low-income countries 
than high-income countries 
completely ban TAPS
In the past 2 years, 10 more countries 
have banned all forms of direct and 
indirect advertising, raising the global 
population covered at best-practice level 
by 150 million, to 1.3 billion people. 
Three of these countries were low-income 
countries (Benin, Democratic republic 
of the Congo and Gambia); four were 
middle-income countries (azerbaijan, 
Congo, Guyana and Niue) and three 
were high-income countries (antigua and 
Barbuda, Saudi arabia and Slovenia).
adoption of complete TaPS bans has 
steadily increased over the years, from 
seven countries in 2007 to 48 countries 
(one in four) in 2018, an increase of 
tobacco control programmes and should 
be included in TaPS bans (174).
The tobacco industry attempts to avoid 
regulation by adopting weak voluntary 
advertising codes, discrediting the 
evidence base for restrictions, and using 
both lobbyists and litigation to avoid 
bans (148, 165). However, limited bans 
have little or no effect (148, 164, 177). 
For bans to be effective, they must be 
comprehensive. Legislation should use 
clear, uncomplicated language and 
unambiguous definitions, and should 
avoid providing lists of prohibited activities 
that are, or could be understood to be, 
exhaustive (167). moreover, legislation 
must be coupled with strong enforcement 
and monitoring, with high financial 
penalties for violations (95).
BaNS ON aDvErTISING, PrOmOTION aND SPONSOrSHIP
PrOGrESS IN BaNS ON TOBaCCO aDvErTISING, PrOmOTION aND SPONSOrSHIP 
(2007–2018)
41 countries. Low- and middle-income 
countries have been leaders in adopting 
strong TaPS bans throughout the years. 
In 2007, all seven best-practice countries 
were low- and middle-income countries 
(albania, Djibouti, Eritrea, Islamic republic 
of Iran, Kenya, madagascar and Niger). at 
any point in time there has always been 
more low-income countries than high-
income countries with a complete TaPS 
ban. 
There are only 44 countries 
that have not adopted any 
TAPS bans
Thirty countries, with 2.1 billion people, 
are only one provision away from a 
complete advertising ban. Nine need only 
to ban brand-stretching (Bhutan, Croatia, 
Finland, France, Georgia, Lithuania, Sri 
Lanka, Thailand and Turkmenistan). Seven 
need only to ban advertising of tobacco 
products at point of sale (argentina, 
Cook Islands, India, mali, montenegro, 
Netherlands and South africa). Seven need 
only to ban industry sponsorship (Egypt, 
Iceland, New Zealand, Sudan, Syrian 
arab republic, united Kingdom and viet 
Nam). Four need only ban promotional 
discounts (Cyprus, Ethiopia, Lebanon 
and Papua New Guinea). Norway need 
only ban brand-sharing, Tonga need 
only ban the appearance of tobacco 
products or brands in Tv and/or films, and 
occupied Palestinian territory, including 
east Jerusalem, need only ban the free 
distribution of tobacco products.
almost a quarter of the 505 million people 
(125 million) who live in 26 of the world’s 
100 largest cities are protected completely 
from exposure to TaPS by national 
legislation. In all 26 cities, bans on TaPS 
operate at national level. The other 74 
cities are not currently protected by a 
national TaPS ban, but could move ahead 
with city, state, or provincial level laws and 
thereby protect a combined 380 million 
more people. 
Low-incomeMiddle-incomeHigh-income
Data not reported
Complete absence of ban, or ban 
that does not cover national TV, 
radio and print media
Ban on national TV, radio 
and print media only
Ban on national TV, radio 
and print media as well as 
on some but not all other 
forms of direct and/or 
indirect advertising
Ban on all forms of direct 
and indirect advertising (or 
at least 90% of the 
population covered by 
complete subnational bans)
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The republic of the Congo, a Central african country straddling 
the Equator, ratified the WHO FCTC in February 2007. It 
entered into force in may 2007. as part of the implementation 
of article 13, the country banned some but not all forms of 
TaPS and its products. This initiative was reinforced on 4 July 
2012 by the adoption and promulgation of the law on tobacco 
control, but TaPS bans were still not completed. 
In June 2018, Congo adopted a decree that expanded the 
legislation to cover point-of-sale advertising as well as a ban 
on promotional discounts, brand-stretching and sponsorship, 
among other TaPS bans. Congo is now one of the 17 
countries in the african region that have complete TaPS bans. 
Compliance data collected in the country for this report show 
that most of the advertising bans that entered into force in 
2006 are well implemented in the country, which is a good 
omen for the bans recently adopted.
With globalization, Niue which is an island country in the South 
Pacific Ocean, is now far more connected to the rest of the 
world than ever before, and therefore became more susceptible 
to tobacco industry marketing. However, Niue, although a 
Party to the WHO FCTC, had no effective TaPS regulation until 
recently. Laws to prevent TaPS, particularly at point of sale, are 
an essential part of protecting the health of the country’s future 
generations. In 2016, Niue’s government started to work on 
aligning its tobacco control legislation with the requirements of 
the Convention.  The ministry of Health led public consultations 
with members of the public sector as well as representatives 
from civil society organizations and community groups, and 
in 2018 the Tobacco Control act was passed. The act includes 
complete TaPS bans. 
Since the passage of the law, stakeholders have become 
increasingly aware of the various forms of TaPS, and the new 
law even prohibits the display of tobacco products at point of 
sale. In addition to this, the act also bans smoking in public 
places, workplaces and public transport; bans the import and 
manufacture of smokeless tobacco, and requires the display of 
health warnings on packages of smoking tobacco products. In 
recognition of their outstanding work in tobacco control, Niue’s 
ministry of Social Services is one of five institutions to receive a 
WHO World No Tobacco Day 2019 award.
The Republic of the Congo tightens TAPS ban
Niue passes Tobacco Control Act introducing TAPS ban
In 2017 Guyana became only the second country in the 
English-speaking Caribbean (CarICOm) and WHO region 
of the americas to enact comprehensive tobacco legislation 
that adopted complete TaPS bans, alongside a mandate for 
complete smoke-free environments and a requirement for 
health warnings on tobacco products. This action propelled 
Guyana from having zero tobacco control measures to having 
three “WHO best-buys” (28) adopted at best-practice level. 
TaPS bans, relative to measures for smoke free environments 
and graphic health warnings, have not been as widely adopted 
across the americas region or globally. In the absence of 
TaPS bans,  the tobacco industry has an avenue through 
which they can continue to recruit tobacco users, making 
this achievement particularly notable. Guyana’s Tobacco 
Control act was developed by the ministry of Health, which 
understood the need to prevent industry influence when 
enacting new legislation and committed itself to push through 
a comprehensive initiative that complied with article 13 (E), 
as well as article 8 (P) and 11 (W). although compliance with 
the ban has been moderate and compliance at point of sale 
has been described as low, the ministry of Health has held 
meetings with stakeholders from the business community, 
transport services, workers’ unions, and consumer associations, 
as well as the general public, to strengthen buy-in and 
compliance. 
Guyana enacts comprehensive tobacco legislation
Awareness raising campaign to introduce 
bans on tobacco advertising at point of sale, 
Congo.
President of Guyana and the Minister of Health of Guyana receiving the World No Tobacco 
Day 2018 Award for efforts in tobacco control, including TAPS bans.
Government and community representatives 
provide input into the draft Tobacco Control 
Bill in Niue, 2017.
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Raise taxes on tobacco
Tobacco taxation is also inexpensive to 
implement, costing low- and middle-
income countries as little as uS$ 0.05 
per capita each year to administer (186). 
Having the potential for massive impact 
combined with a low implementation cost, 
tobacco taxation is rightly considered as 
a highly cost-effective “WHO best-buy” 
intervention, meaning that the returns and 
economic benefits from this measure are 
several times higher than its cost (187, 
188).
Increasing taxes increases 
government revenues and 
can help expand health 
sector funding
Tax increases not only reduce tobacco use 
and improve health, they also generate 
more government revenues (121). This 
additional funding can be used for tobacco 
control programmes as well as other 
important health and social initiatives, 
which have now been successfully 
demonstrated in some countries (189, 
190). using tax revenues in this manner 
will further increase public support for 
higher taxes.
Taxes should be raised 
significantly and periodically 
to reduce the affordability 
of tobacco products
Tobacco products have become 
increasingly affordable in many countries 
where income and purchasing power are 
growing rapidly (191). Despite some of 
these countries raising tobacco tax rates, 
these have not been enough to offset 
inflation and income growth, causing an 
article 6 of the WHO Framework Convention on Tobacco Control states: “…  [P]rice and tax measures are an effective and important 
means of reducing tobacco consumption … [Parties should adopt] … measures which may include: … tax policies and … price policies 
on tobacco products so as to contribute to the health objectives aimed at reducing tobacco consumption” (1).
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Raise taxes on tobacco – Best practice countries, 2018
Best practice countries
Sale of cigarettes is banned
Other countries
Not applicable
raISE TaXES ON TOBaCCO – HIGHEST aCHIEvING COuNTrIES, 2018
TOTaL TaX ON CIGarETTES
Countries, territories and areas with the highest level of achievement: *andorra, argentina, *australia, austria, Belgium, Bosnia and Herzegovina, *Brazil, Bulgaria, Chile, 
*Colombia, Croatia, Czechia, *Egypt, Estonia, Finland, France, Greece, Ireland, Israel, Italy, Jordan, Latvia, madagascar, malta, *mauritius, *montenegro, *New Zealand, 
Niue, *North macedonia, occupied Palestinian territory, including east Jerusalem, Poland, Serbia, Slovakia, Slovenia, Spain, *Thailand, Turkey, and united Kingdom.
 
* Country newly at the highest level since 31 December 2016.
Increasing taxes is a highly 
cost-effective measure to 
decrease tobacco use
many studies have established that raising 
taxes to increase the price of tobacco 
products is the single most effective 
tobacco control measure (23, 121, 183). 
On average, a 10% price increase will 
reduce consumption by 5% in low- and 
middle-income countries (up to 8% in 
some instances), and by about 4% in high-
income countries (121). approximately half 
of this reduction is due to tobacco users 
quitting, and half due to existing users 
smoking less (184). To put these figures 
into perspective, a recent study estimated 
that a 50% price increase in 13 selected 
countries would cause 67 million people 
to quit (185).
erosion of the tax’s value and effectiveness 
in reducing consumption (192). Nominal 
tax increases that fail to make tobacco 
products less affordable are unlikely 
to reduce consumption and encourage 
cessation. Governments need to monitor 
tobacco tax rates and prices relative to real 
income and significantly raise tax rates at 
regular intervals as required to ensure that 
tobacco products do not become more 
affordable.
Tobacco tax policies 
work better when tax 
administration is improved
Strengthening tax and customs 
administration as well as improving 
enforcement capacity amplifies the 
impacts of raising tobacco taxes (193). 
Experiences from numerous countries 
show that illicit trade of tobacco products 
can be successfully addressed even when 
taxes and prices are increased, hence the 
threat of tax evasion should not be used 
as a reason to forgo tax increases. With 
the WHO FCTC Protocol to Eliminate Illicit 
Trade in Tobacco Products entering into 
force, governments now have more tools 
at their disposal to control the supply 
chain and ensure that the right amount of 
taxes are being paid.
On the other hand, tax administration can 
become easier with the right tax policy. 
among the different types of tax levied 
on tobacco products, excise taxes are 
the most effective at raising prices and 
triggering significant health impacts (194). 
Simpler tax structures are likewise easier 
to administer – complex structures and 
tiered excise taxes should be avoided to 
diminish scenarios that can undermine 
the health and revenue impact of tobacco 
taxes (193).
The world’s population 
covered by high tobacco 
taxes doubled between 2016 
and 2018
raising the price of tobacco through 
tobacco taxes – the most effective and 
efficient way to reduce tobacco use – is 
the least-achieved mPOWEr measure, 
with only 14% of the world’s population 
living in the 38 countries with sufficiently 
high taxes in 2018.
most of the countries that have already 
adopted high taxes are high-income 
countries. There is still only a very small 
number of low- and middle-income 
countries (15 countries, or 11%) that have 
adopted high taxes on tobacco. 
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Since 2016, 10 countries have raised taxes 
to a level at or above 75% of the price 
of the most sold brand of cigarettes. The 
population living in these 10 countries, 
462 million people, are now protected by 
higher taxes. Seven of the countries were 
middle-income countries: Brazil, Colombia, 
Egypt, mauritius, montenegro, North 
macedonia and Thailand. The other three 
were high-income countries: andorra, 
australia, and New Zealand. The most 
significant tax share increase in the 10 
countries was made by Colombia, whose 
2016 rate of 49.5% was raised to 78.4% 
by 2018. No low-income countries have 
raised taxes to 75% or above since 2016. 
Indeed, only one low-income country 
(Liberia) increased taxes enough since 
2016 to move one category closer to 
best practice level. and since 2016, three 
countries (Cyprus, Lithuania and ukraine) 
dropped out of the best practice group as 
they were unable to keep their tax share at 
or above the 75% level.
In 2018 the global 
population protected by 
high taxes crossed the 
1 billion mark
Since 2008, progress in raising taxes has 
been remarkably slow. The population 
protected by high tobacco taxes remained 
at around the half-billion mark for 8 years, 
and only in the past 2 years has the global 
population protected exceeded 1 billion. 
However, while in 2008 only one country 
in 9 imposed taxes comprising 75% or 
more of the retail price, in 2018 this 
number has almost doubled: close to one 
country in five is now protected.  
There are nine high-income countries that 
have raised taxes sufficiently to reach 
the highest level of implementation since 
2008, while three high-income countries 
(Germany, Portugal, and Seychelles) have 
dropped out of that group. Nine middle-
income countries have reached the highest 
level of taxation since 2008, and three 
middle-income countries (Cuba, Kenya, 
and Tunisia) dropped into a lower group. 
One low-income country began taxing 
at or above 75% in 2010 (madagascar) 
and currently remains the only low-
income country at the highest level of 
implementation.
In 2008, 82% of the half-million people 
protected by high tobacco taxes were 
people living in high-income countries. 
Today, middle-income countries now 
contribute more than half of the 
population (54%) protected by this 
measure. Only 3% of protected people live 
in low-income countries.
PrOGrESS IN TOTaL TaX ON CIGarETTES ≥75% OF rETaIL PrICE (2008–2018)
More countries are adopting 
recommended excise tax 
structures on tobacco
more countries are now adopting 
excise tax structures on cigarettes, as 
recommended in previous editions of 
the WHO report on the global tobacco 
epidemic. among the 181 countries 
tracked over seven reports, the number 
of countries imposing a specific excise 
tax structure increased from 57 to 62 
between 2008 and 2018, and the number 
of countries imposing a mixed excise tax 
structure that relies more on specific excise 
increased from 22 to 37 during the same 
period. The number of countries relying on 
ad valorem excise decreased from 55 in 
2008 to 41 in 2018. 
as of 2018, only 15 countries do not levy 
an excise tax on tobacco products. This is 
an important reduction from 2008 when 
23 countries had no excise on tobacco 
products. Notably, 11 of the 15 countries 
without a tobacco excise tax are low- and 
middle-income countries.
In 2018 half a billion people 
lived in countries with a tax 
level within 5 percentage 
points of the highest level of 
implementation
One in three countries (62) levies taxes 
that fall short of the 75% threshold but 
that are at or above 50% of the retail 
price. Twenty of these countries (with 
a combined population of half a billion 
people) have taxes comprising 70% 
or more of the price, so are within 5 
percentage points of best practice. an 
additional 12 countries (with a combined 
population of 352 million) are within 10 
percentage points of best practice.  If all 
62 countries in this category increased 
taxes to 75%, an additional 4.7 billion 
people would be protected, meaning a 
total of 5.7 billion people – an incredible 
75% of the world’s population – would be 
protected by high taxes. 
as of today, over a quarter of the 505 
million people who live in one of the 
world’s 100 largest cities (141 million 
people in 29 cities) are covered sufficiently 
by high taxes on cigarette products. For 
each of the 29 protected cities, the tax 
rates are implemented at the national 
level. No city has yet independently (of 
national government) introduced taxes 
on tobacco products that have resulted in 
raising the share of total taxes to 75% or 
more of the retail price of cigarettes.
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Note: Averages are weighted by WHO estimates of number of current cigarette smokers ages 15+ in each country in 2017. Prices are 
expressed in Purchasing Power Parity (PPP) adjusted dollars or international dollars to account for differences in the purchasing power across 
countries. Based on 53 high-income, 97 middle-income and 28 low-income countries with data on prices of most sold brand, excise and other 
taxes, and PPP conversion factors. Numbers may not add exactly due to rounding.
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CHaNGE IN aFFOrDaBILITy OF CIGarETTES, 2008–2018
Note: Change in affordabilty computed as the least squares rate of change in the per capita GDP required to purchase 2000 cigarettes of the most sold brand in 
local currency in any given year. Please refer to Technical Note III for details of computation. 
Cigarette prices and taxes 
continue to be higher in 
high-income countries, 
even after adjusting for 
purchasing power parity
Price and tax levels continue to be highest 
in high-income countries, even when 
adjusting for differences in purchasing 
power. Cigarette pack prices, total taxes 
and the tobacco excise component as 
a share of pack prices are all lower in 
low- and middle-income countries, with 
average total tax as a proportion of price 
varying between 38% and 58%. This 
proportion reaches almost 68% in high-
income countries, even though the non-tax 
portion of cigarette prices is fairly similar 
throughout the world. There is a strong 
case for all countries, particularly low- and 
middle-income countries, to increase their 
excise taxes further, which will have the 
effect of making cigarettes less affordable.
Tobacco use is not effectively discouraged 
if products become more affordable over 
time. When price increases do not keep 
pace with increases in per capita income, 
tobacco products become more affordable 
(117, 189).  Seeing trends in the 
affordability of cigarettes over a reference 
period helps policy-makers understand 
how cigarette prices have changed relative 
to the population’s ability to purchase 
them, and can guide recommended 
changes in tax policy to influence price 
levels and effectively reduce consumption.
affordability of cigarettes for each of the 
years 2008, 2010, 2012, 2014, 2016 and 
2018 was measured by the per capita 
GDP required to purchase 2000 cigarettes 
of the most sold brand reported in that 
year. The average change over the period 
2008–2018 was then calculated.
using this measure, cigarettes became 
less affordable in 83 countries and did 
not significantly change in 63 countries, 
while they became more affordable in 30 
countries. Of those 30 countries, 28 were 
low- and middle-income countries.
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In 2015, Colombia’s ministers of Health and Finance 
recommended a 200% increase in cigarette taxes during the 
period 2016 to 2017, followed by a 150% increase by 2020, 
as part of the country’s ongoing effort to reform tax laws. The 
recommendation aimed to raise the country’s historically very 
low level of tobacco taxation and revenue to be more in line 
with WHO recommendations and other countries in the region. 
The success of the tax hike that was ultimately approved 
relied on a multisectoral team of experts and health officials 
from national and international civil society working together 
to combat industry interference by using solid data and 
translating it into politically viable policy change. To counteract 
the argument on the part of the tobacco industry that tax 
increases would create an unmanageable surge in illicit trade, 
civil society groups implemented the first public study of 
the size of the illicit cigarette trade in Colombia and found 
it represented only a fraction (3.5% of all sales) in the five 
Colombian cities studied. In December 2016, the Colombian 
Congress approved a 100% excise tax increase on cigarettes 
and manufactured tobacco, an additional 50% increase in 
January 2018 and annual adjustments beginning in January 
2019 – equivalent to the annual change in the consumer 
price index plus 4% (195). This means that the specific tax 
on cigarettes doubled from 700 Colombian pesos (COP$) per 
20-cigarette pack to COP$ 1400 in January 2017 and was 
subsequently increased to COP$ 2100 in January 2018. as 
of 2018, the tax share for the most sold brand of cigarettes 
in Colombia stands at 78.4%, with excise taxes comprising 
62.5% (52.5% specific and 10% ad valorem). This places 
Colombia at the highest level of achievement under the raise 
taxes on tobacco mPOWEr measure. In terms of impact, in 
2017 excise revenues increased by 54% while cigarettes sales 
declined by 23% in comparison with 2016.
Colombia triples cigarette taxes in 2 years
rEaL PrICE aND TOTaL TaX SHarE EvOLuTION FOr a PaCK OF mOST SOLD 
BraND OF CIGarETTES, COLOmBIa 2008–2018
2008 2010 2012
Total tax share of most sold band
2014 2016 2018
1769 1837
2197
2407
2521
3864
Re
al
 p
ric
e 
pe
r p
ac
k 
of
 2
0,
 C
O
P 
 $
 (2
00
8 
ba
se
)
To
ta
l t
ax
 s
ha
re
, %
34.3%
50.6%49.9% 49.4%
49.5%
78.4%
Real price per pack of most sold brand, 2008 COP$
Source: (195)
112 113WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC, 2019 WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC, 2019
In 2016, countries in the Gulf Cooperation Council (GCC) 
agreed to introduce an excise tax on products harmful to 
humans and the environment, including tobacco. Before this 
agreement, GCC member States (Bahrain, Kuwait, Oman, 
Qatar, Saudi arabia and the united arab Emirates) had 
historically relied solely on import duties to tax tobacco, which 
collectively stood at around 20% of retail price. The new 
excise tax is an effort both to diversify sources of income and 
to recognize the danger of tobacco products. Saudi arabia 
was the first GCC country to implement the excise tax on 
manufactured tobacco products in June 2017, followed by 
the united arab Emirates in October 2017 and by Bahrain 
in December 2017. Qatar joined them in January 2019, and 
Oman’s excise tax increase is due in June 2019. The new excise 
tax is harmonized in the GCC at 100% of the retail price 
excluding taxes, and is already making a noticeable impact 
on the price of tobacco products. It is expected that the tax 
and subsequent price increases in these countries will lead to 
reductions in tobacco consumption and its consequent burden 
of disease.
Gulf Cooperation Council introduces excise tax on harmful 
products
rETaIL PrICE OF mOST SOLD BraND OF CIGarETTES, PPP1
TOTaL TaX aS % OF PrICE OF mOST SOLD BraND OF CIGarETTES
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Since 2008, the number of countries 
imposing high taxes has almost 
doubled: close to one country 
in five is now protected.
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National tobacco control programmes: 
vital for ending the tobacco epidemic 
integrated into countries’ broad health 
and development agendas (196).
In large countries or those with federal 
political systems where governing powers 
are divided between a central national 
authority and constituent regional or 
local political units, decentralizing NTCP 
authority to subnational level can allow 
more flexibility in policy development 
and programme implementation, and 
potentially enable those policies and 
programmes to reach a wider population 
(197).
as many tobacco control interventions 
are carried out at regional and community 
levels (even when planning occurs 
nationally), public health and government 
leaders at the appropriate subnational 
levels need adequate resources to build 
implementation capacity that can be 
sustained over time (94). NTCPs should 
also ensure that population subgroups 
with disproportionately high rates of 
tobacco use are reached by policies and 
programmes tailored to their needs (197).
Tobacco control requires 
active civil society 
participation
NTCPs require support not only from 
government partners but also from civil 
society; this specifically excludes the 
tobacco industry and its allies, which 
cannot be legitimate stakeholders 
in tobacco control efforts (94). 
Continued involvement by appropriate 
nongovernmental organizations and 
other civil society groups is essential 
to maintaining continued progress on 
national as well as global tobacco control 
efforts (197).  
Two thirds of world’s 
population covered by a 
national agency for tobacco 
control
One in four countries globally has a 
national agency with responsibility for 
tobacco control objectives staffed by at 
least five full-time equivalent people. 
Fortunately, because many of these 
countries are populous, two thirds of the 
world’s population is protected by such an 
agency. 
an additional 117 countries (with one 
third of the world’s population) are 
working on tobacco control objectives 
with fewer staff (84 countries), or with an 
unknown number of staff (33 countries). 
Only 17 countries (with 145 million 
people) do not have a national agency for 
tobacco control, 14 of which are low- and 
middle-income countries.
In the past 2 years, only three countries 
enhanced their national tobacco control 
programmes sufficiently to reach the 
highest level of adoption (Botswana, Iraq 
and Qatar), adding 44 million people to 
the population covered. at the same time, 
one country dropped below best-practice 
level: Suriname reduced the number 
of staff dedicated full-time to tobacco 
control.
Since 2008, an additional 15 countries, 
with 499 million people, have established 
a well-staffed national team working full-
time on tobacco control.
It is worth noting that this measure may 
underestimate the true extent of NTCPs in 
countries because information on tobacco 
control programme staffing at the national 
level is incomplete, with no formal 
mechanism for collecting this information 
from countries.
The WHO Framework Convention on Tobacco Control strongly suggests that countries to set up a national tobacco control programme 
(NTCP) to lead their tobacco control efforts. To this end, WHO FCTC article 5 states that: “Each Party shall develop, implement, 
periodically update and review comprehensive multisectoral national tobacco control strategies, plans and programmes … [and] 
establish or reinforce and finance a national coordinating mechanism or focal points for tobacco control.” In addition, WHO FCTC article 
26.2 sets out that: “Each Party shall provide financial support in respect of its national activities intended to achieve the objective of the 
Convention” (1).
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Decentralizing nTCP 
authority is important
adequately financed, clearly focused 
NTCPs or coordination mechanisms are 
critical for developing and maintaining the 
sustainable policies that can reverse the 
tobacco epidemic (1). ministries of health, 
or equivalent government agencies, 
should take the lead on strategic tobacco 
control planning and policy setting, with 
other ministries or agencies reporting to 
this centralized authority (175). Tobacco 
control programmes should also be 
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In 2003 Ireland became the first country in the world to 
implement smoke-free environments. Tobacco consumption, 
however, continues to have a huge impact on Ireland, with at 
least 5500 people dying from tobacco-related diseases each 
year. although the country has a strong tobacco control track 
record and use has gradually decreased over the past few 
decades, in 2013 Ireland decided to bring tobacco control to 
the “endgame”, or final stages of achieving a tobacco-free 
Ireland. 
 
In order to achieve this, the plan makes 60 recommendations 
to significantly reduce smoking to less than 5% of the adult 
population by 2025. It was estimated that more than 55 000 
current smokers would have to quit each year for the next 10 
years to reach this ambitious target.  
The Tobacco Free Ireland policy was developed by Ireland’s 
Department of Health and its Health Service Executive 
in 2013. This government strategy (2013–2025) works 
to coordinate and lead tobacco control activity across 
the health service and has several cross-governmental 
actions based on mPOWEr measures, with the goal of 
denormalizing tobacco use in Ireland, especially for the next 
generation.
Ireland’s 2017 status report on the progress of the Tobacco 
Free Ireland policy shows great progress, including legislation 
requiring standardized packaging of tobacco products and 
the development of the new QuIT campaign, which aims to 
enhance support for people who wish to quit smoking. 
In 2018 a Health Service Executive national implementation 
plan (2018–2021) was published, establishing the strategic 
direction and priority actions required to achieve the goals 
set out in the plan. Over the next 4 years the objectives 
of the Tobacco Free Ireland policy include prioritizing the 
protection of children in all initiatives and encouraging 
the denormalization of tobacco use for future generations; 
supporting people to quit and treating tobacco dependence 
as a health care issue; and monitoring, building, and 
maintaining compliance through tobacco legislation. 
The Tobacco Free Ireland Programme 
One in four countries globally has a national 
agency with responsibility for tobacco 
control objectives staffed by at least five 
full-time equivalent people.
Campaign for the Tobacco Free Ireland 
Programme.
madagascar has demonstrated huge commitment and 
progress towards tobacco control, and to date has adopted 
four of the mPOWEr measures at the highest level of 
achievement. 
In 2007, the Consultative Committee of anti-Tobacco 
Control (CCoLaT) was created to support coordination of 
WHO FCTC implementation activities across all sectors. 
This multisectoral committee meets every three months, 
comprising members from a wide range of ministries and 
civil society organizations working to combat tobacco use. 
The committee plays an intermediary role between the 
ministry of Health and their corresponding entities and 
provides an opportunity for effective collaboration.  For 
example, civil society organizations and certain ministerial 
departments (Sport, National Education, Population, 
Health) have worked together to develop and deliver 
public awareness-raising activities. The CCoLaT also plays 
a monitoring role and sounds the alarm in case of non-
compliance with regulations and industry interference. In 
addition, and with the support of the ministry of the Interior, 
the country is gradually setting up multi-sector committees in 
different regions of the country. 
Through these coordinating mechanisms, madagascar 
continues to demonstrate its dedication to the fight against 
tobacco epidemic to save lives and improve the well-being of 
the population. 
Multisectoral collaboration boosts tobacco control, 
Madagascar 
Awareness raising during World No Tobacco Day 2018, Madagascar.
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Conclusion
There has been substantial progress made 
globally since the 2003 adoption of the 
WHO FCTC. The successful scaling up of 
mPOWEr measures over the past 10 years 
to the best-practice level, adopted by 
countries of all sizes and income levels, is 
evidence of the successful implementation 
of the WHO FCTC demand reduction 
measures. as countries continue to work 
towards creating and implementing 
effective tobacco control strategies 
they can find encouragement in the 
examples set by other countries that have 
successfully adopted measures at best-
practice levels. 
In the years since mPOWEr was launched, 
the challenges faced have been great. 
There have been, and will continue to be, 
setbacks, unexpected barriers, interference 
from the tobacco industry and difficult 
political obstacles to overcome. Despite 
these challenges, there are now 5 billion 
people who are protected by at least one 
best-practice tobacco control measure 
– 3.9 billion more than were covered 
in 2007. On the other hand, 2.6 billion 
people remain unprotected by evidence-
based tobacco control best-practices, 
leaving them at risk from the health and 
economic harms caused by tobacco use.
millions of lives have been saved since 
the introduction of mPOWEr, and it 
has only been through the coordinated 
focus of a global community that tobacco 
control efforts have been so successful. 
unfortunately, however, the tobacco 
epidemic is far from over. although 
tobacco use has declined in most countries 
and regions, population growth means the 
total number of people using tobacco has 
remained stubbornly high. Tobacco control 
programmes are not always quick and 
easy to implement, and all countries can 
benefit from strengthened tobacco control 
policy development and enforcement. 
Since the last report, only one country – 
Brazil – has joined Turkey in putting all 
mPOWEr measures in place at their most 
comprehensive level, and there are only 
a handful of other countries that have 
more than two measures in place at best-
practice levels. Even in countries where 
best-practice measures exist, much can be 
done to strengthen compliance and ensure 
full impact. 
The focus of this report, Offer help to quit 
tobacco use, is the “O” of mPOWEr. Only 
23 countries provide cessation services at 
best-practice level, even though in many 
countries, many tobacco users report 
wanting to quit. Nevertheless, progress is 
being made – 2 billion more people have 
been covered by comprehensive tobacco 
cessation services since 2007, and there 
are 67 countries that are only one step
away from providing comprehensive
tobacco cessation services. middle-income 
countries have made most obvious 
progress in providing tobacco cessation 
support in primary care settings and 
operating national toll-free quit lines since 
2007. 
The evidence shows tobacco users’ 
chances of quitting successfully improve 
dramatically if they use effective cessation 
interventions. This report provides 
guidance for countries on effective 
cessation services and how those services 
can be provided to best meet the needs 
of tobacco users who want to quit, in 
line with article 14 of the WHO FCTC. 
Countries should, at the minimum, 
provide brief advice on quitting to all 
tobacco users whenever they consult 
a primary health care provider for any 
reason. Countries should also provide a 
national toll-free quit line and mCessation 
services to reach a larger population. 
Finally, providing cost-covered nicotine 
replacement therapy will help increase quit 
rates. Combining two or more of these 
approaches further increases tobacco 
cessation success. Even low-income 
countries with limited resources can start 
to integrate brief advice into existing 
primary health care systems as one of 
the first actions to develop their tobacco 
cessation support.
Brief advice in primary care should be 
included in universal health coverage to 
potentially benefit 80% of all tobacco 
users a year. Currently, only 18 countries 
are providing fully cost-covered tobacco 
cessation support in most of their primary 
care facilities and others should follow suit.
Every country has an obligation to protect 
the health of its people, and all Parties 
to the WHO FCTC have made a specific 
commitment to implement strong tobacco 
control policies, including effective 
cessation services, as an important means 
of fulfilling their obligation to protect the 
health of their people. There has been 
incredible progress in the 11 years since 
mPOWEr monitoring began, including 
millions of lives saved, but it is only the 
beginning. It is important that we all 
recommit to ensuring all the people of the 
world are protected fully from the great 
harms of the tobacco epidemic.
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TECHNICAL NOTE I
Evaluation of existing policies
and compliance
This report provides summary indicators of 
country achievements for each of the mPOWEr 
measures, and the methodology used to 
calculate each indicator is described in this 
Technical Note. To ensure consistency and 
comparability, the data collection and analysis 
methodology used in this report are largely 
based on previous editions of the report. 
Some details of the methodology employed 
in earlier reports, however, have been revised 
and strengthened for the present report. Where 
revisions have been made, data from previous 
reports have been re-analysed so that results are 
comparable across years.
Data sources
Data were collected using the following sources:
•	 For all areas: official reports from WHO FCTC 
Parties to the Conference of the Parties (COP) 
and their accompanying documentation.1
•	 For m (monitoring): tobacco prevalence 
surveys not reported under the COP reporting 
mechanism were collected mainly through 
WHO regional and WHO Country Offices. 
Technical Note II provides further details.
•	 For P (protect people from tobacco smoke), 
W (warn about the dangers of tobacco) 
and E (enforce bans on tobacco advertising, 
promotion and sponsorship): original tobacco 
control legislation (including regulations) 
adopted in all member States that relate to 
smoke-free environments, packaging and 
labelling measures and tobacco advertising, 
promotion and sponsorship. In cases where 
a law had been adopted by 31 December 
2018 but had not yet entered into force, 
the respective law was assessed and data 
were reported with an asterisk denoting 
“provision adopted but not implemented by 
31 December 2018”.
•	 For W (mass media): data on anti-tobacco 
mass media campaigns were obtained from 
member States. In order to avoid unnecessary 
data collection, WHO conducted a screening 
for anti-tobacco mass media campaigns in 
all WHO Country Offices. In countries where 
potentially eligible mass media campaigns 
were identified, focal points in each country 
were contacted for further information 
on these campaigns, and data on eligible 
campaigns were gathered and systematically 
recorded.
•	 For O (offer help to quit tobacco use): data 
not reported under the COP reporting 
mechanism were collected mainly through 
WHO regional and WHO Country Offices. 
•	 For r (raise taxes on tobacco): the prices 
of the most sold brand of cigarettes, the 
cheapest brand and a premium brand were 
collected through regional data collectors. 
Information on the taxation of cigarettes (and 
when possible, most commonly used other 
smoked and smokeless tobacco products) and 
revenues from tobacco taxation was collected 
from ministries of finance. Technical Note III 
provides the detailed methodology used.
Based on these sources of information, WHO 
assessed each indicator as of 31 December 
2018. Exceptions to this cut-off date were 
tobacco product prices and taxes (cut-off date 
31 July 2018) and anti-tobacco mass media 
campaigns (cut-off date 30 June 2018). 
Data validation
For each country, every data point for which 
legislation was the source was assessed by two 
expert staff from two different WHO offices, 
generally one from WHO headquarters and 
the other from the respective WHO regional 
Office. any inconsistencies were reviewed by 
the two WHO expert staff involved and a third 
expert staff member not yet involved in the 
appraisal of the legislation. Disagreements 
in the interpretation of the legislation were 
resolved by: (i) checking the original texts of 
the legislation; (ii) trying to obtain consensus 
from the two expert staff involved in the data 
collection; (iii) trying to obtain clarification from 
judges or lawyers in the concerned country; 
and (iv) the decision of the third expert in 
cases where differences remained. Data were 
also checked for completeness and logical 
consistency across variables.
Data sign-off
Final, validated data for each country were sent 
to the respective government for review and 
sign-off. To facilitate review by governments, a 
summary sheet was generated for each country 
and was sent for review prior to the close of 
the report database. In cases where national 
authorities requested data changes, the requests 
were assessed by WHO expert staff according 
to both the legislation/materials and the 
clarification shared by the national authorities, 
and data were updated or left unchanged. In 
cases where national authorities explicitly did 
not agree with the data assessment, this is 
specifically noted in the appendix tables. Further 
details about the data processing procedure are 
available from WHO.
Data analysis
It is important to note that data about laws 
reflect the status of legislation adopted by 31 
December 2018 which has a stated date of 
effect and is not undergoing a legal challenge 
that could impact the date of implementation. 
Data from laws not in effect by 31 December 
2018 have a footnote stating this. The summary 
measures developed for the WHO report on the 
global tobacco epidemic, 2019 are the same as 
those used for the 2017 report.
The report provides analysis of progress made 
between 2016 and 2018, and between 2007 
and 2018 using the latest assessment of the 
status of measures in each year so that the 
results are comparable across years. For r, the 
earliest comparable data are 2008 and for mass 
media, data are available only from 2010. To 
calculate the change in the percentage of the 
population covered by each policy or measure 
over time, population estimates for the year 
20182 were used. using a static year eliminates 
the effect of population growth when measuring 
change over time. Indicators from previous years 
have been recalculated, according to legislation/
materials received after the assessment period 
of the respective report or according to changes 
in the indicator methodology. all income groups 
used for this report derive from the World Bank 
income-group classification published on 1 July 
2018 by the World Bank.3 upper-middle and 
lower-middle income groups are combined into 
one group for this report.
When country or population totals for 
mPOWEr measures are referred to collectively 
in the analysis section of this report, only the 
implementation of tobacco control policies 
(smoke-free legislation, cessation services, 
warning labels, advertising, promotion and 
sponsorship bans, and tobacco taxes) is included 
in these totals. 
monitoring of tobacco use and anti-tobacco 
mass media campaigns are reported separately. 
Correction to previously 
published data
The 2016 data published in the last report were 
reviewed, and about 3% of data points were 
corrected. The full set of mPOWEr data revised 
for all years back to 2007 is available in an Excel 
file on the report website.
Monitoring of tobacco use 
and prevention policies
The strength of a national tobacco surveillance 
system is assessed by the frequency and 
periodicity of nationally representative youth and 
adult surveys in countries. Countries are grouped 
in the top monitoring category when all criteria 
listed below are met for both youth and adult 
surveys:
•	 whether a survey was carried out recently;
•	 whether the survey was representative of the 
country’s population;
•	 whether a similar survey was repeated within 
5 years (periodic); and
•	 whether the youth and adult populations 
were surveyed through school-based 
and household population-based surveys 
respectively.
Surveys were considered recent if conducted in 
the past 5 years. For this report, this means 2013 
or later. Surveys were considered representative 
only if a scientific random sampling method was 
used to ensure nationally representative results. 
(although they provide useful information, 
subnational surveys or national surveys of 
specific population groups provide insufficient 
information to enable tobacco control action for 
the total population.) Surveys were considered 
periodic if the same survey or a survey using the 
same or similar questions was repeated at least 
once every 5 years. The following definitions 
were applied for youth and adult surveys:
youth surveys: school-based surveys of 
students aged 13–15 years. The questions 
asked in the surveys should provide indicators 
that are consistent with those specified in the 
Global youth Tobacco Survey questionnaires and 
manuals.
Adult surveys: population-based surveys that 
can provide indicators for adults aged 15 years 
and over, consistent with those specified in the 
Global adult Tobacco Survey questionnaires and 
manuals.
The groupings for the monitoring indicator are 
listed below. 
No known data or no recent* data or 
data that are not both recent* and 
representative**
recent* and representative** data for 
either adults or youth
recent* and representative** data for 
both adults and youth
recent*, representative** and 
periodic*** data for both adults and 
youth
* Data from 2013 or later.
**  Survey sample representative of the national 
population.
*** Collected at least every 5 years.
Smoke-free legislation
There is a wide range of places and institutions 
that can be made smoke-free by law. Smoke-
free legislation can be in place at the national 
or subnational level. The report includes data 
based on national legislation, and legislation 
in subnational jurisdictions where available 
and where national laws are incomplete. The 
assessment of subnational smoke-free legislation 
includes first-level administrative subdivisions 
of a country, as listed in ISO3166. Subnational 
data reported in appendix vI only reflect the 
content of the subnational laws. Provisions 
covered by national legislation are indicated 
by an informative note next to the subnational 
data. In cases where the status of smoke-free 
legislation is not reported for some or all 
subnational jurisdictions, we assume the existing 
national law applies. Legislation was assessed 
to determine whether smoke-free laws provided 
for a complete4 indoor smoke-free environment 
at all times, in all the facilities of each of the 
following eight places:
•	 health care facilities;
•	 educational facilities other than universities;
•	 universities;
•	 governmental facilities;
•	 indoor offices and workplaces not considered 
in any other category;
•	 restaurants or facilities that serve mostly food;
•	 cafés, pubs and bars or facilities that serve 
mostly beverages;
•	 public transport.
Groupings for the smoke-free legislation 
indicator are based on the number of places 
where indoor smoking is completely prohibited. 
Countries with no complete smoking ban at 
national level but where at least 90% of the 
population is covered by complete subnational 
smoke-free laws are grouped in the top category.
The groupings for the smoke-free legislation 
indicator are listed below.
Not reported/not categorized
Complete absence of bans, or up to two 
public places completely smoke-free
Three to five public places completely 
smoke-free
Six to seven public places completely 
smoke-free
all public places completely smoke-
free (or at least 90% of the population 
covered by complete subnational smoke-
free legislation)
 
In addition to the data used for the above 
groupings of the smoke-free legislation indicator, 
other related data such as information on 
fines and enforcement were collected and are 
reported in appendix vI.
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In a few countries, in order to significantly 
expand the creation of smoke-free places, 
including restaurants and bars, it was politically 
necessary to include exceptions to the law that 
allowed for the provision of designated smoking 
rooms (DSrs) with requirements so technically 
complex and strict that, for practical purposes, 
few or no establishments are expected to 
implement them. In order to meet the criteria 
for “very strict technical requirements”, the 
legislation has to include at least three out of the 
six following characteristics (and must include at 
least criteria 5 or 6).
The designated smoking room must:
1. be a closed indoor environment;
2. be furnished with automatic doors, generally 
kept closed;
3. be non-transit premises for non-smokers;
4. be furnished with appropriate forced- 
ventilation mechanical devices;
5. have appropriate installations and functional 
openings installed, and air must be expelled 
from the premises;
6. be maintained, with reference to surrounding 
areas, in a depression not lower than 5 
Pascals. 
The few countries whose laws provide for DSrs 
with very strict technical requirements for five 
or more of the assessed public places have not 
been categorized in the analyses for this section 
because their smoke-free legislation substantially 
departs from the recommendations of WHO 
FCTC article 8 guidelines, and it has been 
difficult to obtain evidence indicating that the 
law resulted in the intended very low number 
of DSrs in these countries. The countries whose 
laws provide for DSrs with very strict technical 
requirements for fewer than five of the assessed 
public places have been grouped according to 
the number of completely smoke-free public 
places. 
Tobacco dependence 
treatment
The indicator of achievement in treatment for 
tobacco dependence is based on whether the 
country has available:
•	 nicotine replacement therapy (NrT);
•	 smoking cessation support; 
•	 reimbursement for any of the above; and
•	 a national toll-free quit line.
Despite the low cost of quit lines, few low- or 
middle-income countries have implemented 
such programmes. Thus, national toll-free quit 
lines are included as a qualification only for the 
highest category. reimbursement for tobacco 
dependence treatment is considered only for the 
top two categories to take restricted national 
budgets of many lower-income countries into 
consideration.
The top three categories reflect varying levels 
of government commitment to the provision 
of nicotine replacement therapy and cessation 
support.
The groupings for the tobacco dependence 
treatment indicator are listed below.
Data not reported
None
NrT* and/or some cessation services** 
(neither cost-covered) 
NrT* and/or some cessation services** 
(at least one of which is cost-covered)
National quit line, and both NrT* and 
some cessation services** (cost-covered)
* Nicotine replacement therapy.
**  Smoking cessation support available in any 
of the following places: health clinics or other 
primary care facilities, hospitals, office of a 
health professional, the community or other 
settings.
In addition to data used for the grouping of the 
tobacco dependence treatment indicator, other 
related data such as information on countries’ 
essential medicines lists, etc. were collected and 
are reported in appendix vI. 
For this edition of the WHO report on the 
global tobacco epidemic, countries were asked 
additional questions about their cessation 
services.  The questions included focused on 
policies and guidelines, structural capacity and 
the integration of cessation into other tobacco 
control approaches. Data collected are presented 
in appendix II. 
Policies and guidelines
National tobacco strategy: to be eligible a 
country’s national strategy had to be operational 
Clinical Guidelines: countries were asked about 
the presence of national clinical guidelines 
for tobacco cessation, as well as the inclusion 
of tobacco cessation in clinical or treatment 
guidelines for:
•	 Tuberculosis
•	 Cardiovascular diseases
•	 Hypertension
•	 respiratory diseases
•	 Diabetes
•	 Cancer
•	 Psychiatric disorders
•	 Oral diseases
•	 reproductive health
Survey responses were reviewed and verified 
using supporting documentation that was either 
(a) attached by survey respondents, or (b) where 
applicable, found in the WHO Noncommunicable 
Disease Document repository. For the sake of 
cross-country comparability, only national-level 
guidelines were deemed to be eligible.
To be considered eligible, clinical guidelines were 
required to meet the following two criteria:
•	 Be statements or recommendations regarding 
clinical practice that would assist clinicians 
and patients in optimizing patient care.
•	 Explicitly recommend tobacco cessation, or 
require clinicians to ask and record tobacco 
use status during the patient interview (e.g., 
using a standardized form or risk calculator).
PEN (package of essential noncommunicable 
disease interventions for primary health care in 
low-resource settings) protocols, regional (multi-
country) guidelines, and international guidelines 
were accepted in place of country-specific 
guidelines in cases where national adoption 
could be demonstrated. Integrated or primary 
care guidelines including practitioner handbooks 
were also considered eligible. 
Structural capacity
Countries were asked whether they routinely 
recorded tobacco use in medical records 
(supporting documentation required)  and 
whether cessation was part of a degree 
curriculum for primary care providers.
Integrating cessation into other tobacco 
control approaches
Countries were asked if information about a 
toll-free quit line had been included on cigarette 
packages or in mass media campaigns over the 
last 12 months.  Supporting documentation was 
required and verified.
Nicotine replacement therapy cost 
analysis
NrT price data was sourced from Euromonitor 
which included 56 countries  – 37 high-income 
and 19 middle-income, as grouped by World 
Bank country income classification.
Total costs were calculated assuming a simplified 
NrT regimen lasting 8 weeks. Based on expert 
recommendations, the commodity requirement 
for this period was set at either 56 patches (once 
daily), or 532 pieces of gum (12 pieces daily for 
4 weeks, 8 pieces daily the next 2 weeks, then 
6 pieces daily the last 2 weeks). The pack size(s) 
available in each country was also considered 
when the least expensive option was calculated.
It was also assumed that those more heavily 
dependent on nicotine will consume the same 
amount of gum/patches as those who are less 
dependent, although using an appropriate NrT 
option with higher nicotine concentrations. Since 
prices for different nicotine concentrations of the 
same brand did not vary significantly (<5%), the 
simulated costs were uniform regardless of the 
level of dependence.
To have comparability across countries, the 
total price for each NrT option was adjusted for 
purchasing power and converted to International 
Dollars using the ImF 2018 Implied PPP 
Conversion rate. This was compared to the cost 
of smoking the cheapest pack of cigarettes daily 
during the same period, using the price data 
submitted for this report. Lastly, simple averages 
were calculated for each grouping, either by 
country income or cost-coverage.
Warning labels on tobacco 
packaging
The section of the report that assesses each 
country’s legislation on health warnings includes 
the following information about cigarette 
package warnings:
•	 whether specific health warnings are 
mandated;
•	 the mandated size of the warnings, as a 
percentage of the front and back of the 
cigarette package;
•	 whether the warnings appear on individual 
packages as well as on any outside packaging 
and labelling used in retail sale;
•	 whether the warnings describe specific 
harmful effects of tobacco use on health;
•	 whether the warnings are large, clear, visible 
and legible (e.g. specific colours and font 
styles and sizes are mandated);
•	 whether the warnings rotate;
•	 whether the warnings are written in (all) the 
principal language(s) of the country;
•	 whether the warnings include pictures or 
pictograms.
The size of the warnings on both the front 
and back of the cigarette pack were averaged 
to calculate the percentage of the total 
pack surface area covered by warnings. This 
information was combined with the warning 
characteristics to construct the groupings for the 
health warnings indicator.
The groupings for the health warnings indicator 
are listed below.
Data not reported
No warnings or small warnings 1
medium size warnings 2 missing some3 
or many 4 appropriate characteristics5 
Or large warnings 6 missing many 4 
appropriate characteristics5
medium size warnings 2 with all 
appropriate characteristics5 Or large 
warnings6 missing some 3 appropriate 
characteristics 5
Large warnings 6 with all appropriate 
characteristics5
1  average of front and back of package is less than 30%.
2  average of front and back of package is between 30 
and 49%.
3 One to three.
4 Four or more.
5  appropriate characteristics:
•	specific health warnings mandated;
•	appearing on individual packages as well as on any 
outside packaging and labelling used in retail sale;
•	describing specific harmful effects of tobacco use 
on health;
•	are large, clear, visible and legible (e.g. specific 
colours and font style and sizes are mandated);
•	rotate;
•	include pictures or pictograms;
•	written in (all) the principal language(s) of the 
country.
6  average of front and back of the package is at least 
50%.
In addition to the data used for the grouping of 
the health warnings indicator, other related data 
such as the appearance of the quit line number, 
the requirement for plain packaging, etc. were 
collected and are reported in appendix vI. 
Plain packaging (also called standardized 
packaging) is defined by WHO FCTC article 
11 guidelines as a measure “to restrict or 
prohibit the use of logos, colours, brand images 
or promotional information on packaging 
other than brand names and product names 
displayed in a standard colour and font style”. 
In order for a country to appear in this report 
as having introduced plain packaging, the 
following criteria (established by WHO FCTC 
article 13 guidelines) are requested: 
•	 black and white or two other contrasting 
colours, as prescribed by national 
authorities;
•	 nothing other than a brand name, a product 
name and/or manufacturer’s name, contact 
details and the quantity of product in the 
packaging, without any logos or other 
features apart from health warnings, tax 
stamps and other government-mandated 
information or markings; 
•	 prescribed font style and size; 
•	 standardized shape, size and materials:
•	 there should be no advertising or promotion 
inside or attached to the package or on 
individual cigarettes or other tobacco 
products.
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The first four types of advertising listed are 
termed “direct” advertising, and the remaining 
six are termed “indirect” advertising. Complete 
bans on tobacco advertising, promotion and 
sponsorship usually start with bans on direct 
advertising in national media and progress to 
bans on indirect advertising as well as promotion 
and sponsorship.
The basic distinction for the two lowest groups 
is whether bans cover national television, radio 
and print media or not, and the remaining 
groups were constructed based on how 
comprehensively the law covers bans of other 
forms of direct and indirect advertising included 
in the questionnaire. In cases where the law did 
not explicitly address cross-border advertising, 
it was interpreted that advertising at both 
domestic and international levels was covered by 
the ban only if advertising was totally banned at 
national level.
The groupings for the bans on advertising, 
promotion and sponsorship indicator are 
listed below. Countries where at least 90% of 
the population were covered by subnational 
legislation completely banning tobacco 
advertising, promotion and sponsorship are 
grouped in the top category.  
Data not reported
Complete absence of ban, or ban that 
does not cover national television (Tv), 
radio and print media
Ban on national Tv, radio and print media 
only
Ban on national Tv, radio and print 
media as well as on some (but not all) 
other forms of direct* and/or indirect** 
advertising
Ban on all forms of direct* and 
indirect**advertising (or at least 90% of 
the population covered by subnational 
legislation completely banning tobacco 
advertising, promotion and sponsorship)
* Direct advertising bans:
•	 national television and radio;
•	 local magazines and newspapers;
•	 billboards and outdoor advertising;
•	 point of sale (indoor).
** Indirect advertising bans:
•	 free distribution of tobacco products in the mail or 
through other means;
•	 promotional discounts;
•	 non-tobacco goods and services identified with 
tobacco brand names (brand stretching);
•	 brand names of non-tobacco products used for 
tobacco products (brand sharing);
•	 appearance of tobacco brands (product placement) 
or tobacco products in television and/or films;
•	 sponsorship, (contributions and/or publicity of 
contributions).
In addition to the data used for the grouping 
of the bans on advertising, promotion and 
sponsorship indicator, other related data, such as 
bans on internet sales or on display of tobacco 
products at points of sale were collected and are 
reported in appendix vI.
Anti-tobacco mass media 
campaigns
Countries undertake communication activities 
for many reasons, including improving public 
relations, creating attention for an issue, building 
support for public policies, and prompting 
behaviour change. anti-tobacco communication 
campaigns, which are a core tobacco control 
intervention, must have specified features in 
order to be minimally effective: they must be 
of sufficient duration and must be designed to 
effectively support tobacco control priorities, 
including increasing knowledge, changing social 
norms, promoting cessation, preventing tobacco 
uptake, and increasing support for good tobacco 
control policies.
With this in mind, and consistent with the 
definition of “anti-tobacco mass media 
campaigns” in the last report, only mass media 
campaigns that were: (i) designed to support 
tobacco control; (ii) at least 3 weeks in duration 
and (iii) implemented between 1 July 2016 
and 30 June 2018 were considered eligible for 
analysis. For the sake of logistical feasibility and 
cross-country comparability, only national-level 
campaigns were considered eligible. Consistent 
with the last report and to enable greater 
accuracy, materials from campaigns had to be 
submitted and verified based on the eligibility 
criteria for all countries.
Eligible campaigns were assessed according 
to the following characteristics, which signify 
the use of a comprehensive communication 
approach:
1. The campaign was part of a comprehensive 
tobacco control programme.
2. Before the campaign, research was 
undertaken or reviewed to gain a thorough 
understanding of the target audience.
3. Campaign communication materials were 
pre-tested with the target audience and 
refined in line with campaign objectives. 
4. air time (radio, television) and/or placement 
(billboards, print advertising, etc.) were 
obtained by purchasing or securing it using 
either the organization’s own internal 
resources or an external media planner or 
agency (this information indicates whether 
the campaign adopted a thorough media 
planning and buying process to effectively 
and efficiently reach its target audience).
5. The implementing agency worked with 
journalists to gain publicity or news 
coverage for the campaign.
6. Process evaluation was undertaken to 
assess how effectively the campaign had 
been implemented.
7. an outcome evaluation process was 
implemented to assess campaign impact.
8. The campaign was aired on television and/
or radio.
The groupings for the mass media campaigns 
indicator are listed below. 
 
Data not reported
No national campaign conducted 
between July 2016 and June 2018 with a 
duration of at least 3 weeks
National campaign conducted with one 
to four appropriate characteristics
National campaign conducted with five 
to six appropriate characteristics, or with 
seven characteristics excluding airing on 
television and/or radio
National campaign conducted with at 
least seven appropriate characteristics 
including airing on television and/or radio
Bans on advertising, 
promotion and sponsorship
The report includes data on legislation in 
national as well as subnational jurisdictions. 
The assessment of subnational legislation on 
advertising, promotion and sponsorship bans 
includes first-level administrative subdivisions 
as listed in ISO3166. Subnational data reported 
in appendix vI only reflect the content of 
subnational laws. Provisions covered by national 
legislation are indicated by an informative note 
next to the subnational data. In cases where the 
status of advertising, promotion and sponsorship 
legislation is not reported for some or all 
subnational jurisdictions, we assume the existing 
national law applies.
Country-level achievements in banning tobacco 
advertising, promotion and sponsorship were 
assessed based on whether the bans covered the 
following types of advertising:
•	 national television and radio;
•	 local magazines and newspapers;
•	 billboards and outdoor advertising;
•	 point of sale (indoor);
•	 free distribution of tobacco products in the 
mail or through other means;
•	 promotional discounts;
•	 non-tobacco products identified with tobacco 
brand names (brand stretching);5
•	 brand names of non-tobacco products used 
for tobacco products (brand sharing);6
•	 appearance of tobacco brands (product 
placement) or tobacco products in television 
and/or films;
•	 sponsorship (contributions and/or publicity of 
contributions).
The compliance assessment was obtained 
for legislation adopted by 1 april 2018. 
For countries with more recent legislation, 
compliance data are reported as “not 
applicable”. Compliance with smoke-free 
legislation was not assessed in cases where the 
law provides for DSrs with very strict technical 
requirements. 
The compliance assessments are listed in 
appendix vI. appendix I summarizes this 
information. Compliance scores are represented 
separately from the grouping (i.e. compliance is 
not included in the calculation of the grouping 
categories). 
1. Parties report on the implementation of the WHO 
Framework Convention on Tobacco Control according to 
article 21. The objective of reporting is to enable Parties 
to learn from each other’s experience in implementing the 
WHO FCTC. Parties’ reports are also the basis for review 
by the COP of the implementation of the WHO FCTC. 
Parties submit their initial report 2 years after entry into 
force of the WHO FCTC for that Party, and then every 
subsequent 3 years, through the reporting instrument 
adopted by COP. Since 2012, all Parties report at the 
same time, once every 2 years. For more information 
please refer to https://www.who.int/fctc/reporting/en/.
2. united Nations Department of Economic and Social 
affairs, Population Division in World population prospects: 
the 2017 revision (median fertility projection for the 
year 2018). For more information please refer to https://
population.un.org/wpp/Download/Standard/Population/. 
3. The World Bank: World development indicators published 
July 1, 2018. For more information please refer to 
https://datahelpdesk.worldbank.org/knowledgebase/
articles/906519-world-bank-country-and-lending-groups.  
4. “Complete” is used in this report to mean that smoking 
is not permitted, with no exemptions allowed, except in 
residences and indoor places that serve as equivalents to 
long-term residential facilities, such as prisons and long-
term health and social care facilities such as psychiatric 
units and nursing homes. ventilation and any form of 
designated smoking rooms and/or areas do not protect 
from the harms of second-hand tobacco smoke, and the 
only laws that provide protection are those that result in 
the complete absence of smoking in all public places. 
5. When legislation did not explicitly ban the identification 
of non-tobacco products with tobacco brand names 
(brand stretching) and did not provide a definition of 
tobacco advertising and promotion, it was interpreted 
that brand stretching was covered by the existing ban of 
all forms of advertising and promotion when the country 
was a Party to the WHO FCTC, assuming that the WHO 
FCTC definitions apply. 
6. When legislation did not explicitly ban the use of brand 
names of non-tobacco products for tobacco products 
(brand sharing) and did not provide a definition of 
tobacco advertising and promotion, it was interpreted 
that brand sharing was covered by the existing ban of all 
forms of advertising and promotion when the country was 
a Party to the WHO FCTC, assuming that the WHO FCTC 
definitions apply.
Tobacco taxes
Countries are grouped according to the 
percentage contribution of all tobacco taxes 
to the retail price of a pack of 20 of the most 
popular brand of cigarettes. Taxes assessed 
include excise tax, value added tax (sometimes 
called “vaT”), import duty (when the cigarettes 
were imported) and any other taxes levied. 
In the case of countries where different levels 
of taxes applied to cigarettes are based on 
length, quantity produced, or type (e.g. filter vs. 
non-filter), only the rate that applied to the most 
popular brand is used in the calculation.
Given the lack of information on country and 
brand-specific profit margins of retailers and 
wholesalers, their profits were assumed to 
be zero (unless provided by the national data 
collector).
The groupings for the tobacco tax indicator are 
listed below. Please refer to Technical Note III for 
more details.
Data not reported
< 25% of retail price is tax 
≥ 25% and < 50% of retail price is tax 
≥ 50% and < 75% of retail price is tax 
≥ 75% of retail price is tax 
Trend in affordability of the 
most sold brand of cigarettes
The affordability of cigarettes was computed as 
the percentage of per capita GDP required to 
purchase 2000 cigarettes of the most popular 
brand in each year of this report from 2008 to 
present. The least-squares annual growth rate 
of affordability was computed by fitting a linear 
regression trend line to the logarithmic values of 
the affordability measure.
The groupings for the affordability indicator are 
listed at the top of the next column. Please refer 
to Technical Note III for more details. 
YES
Cigarettes less affordable – per 
capita GDP needed to buy 2000 
cigarettes of the most sold brand 
increased on average between 2008 
and 2018
NO
Cigarettes more affordable – per 
capita GDP needed to buy 2000 
cigarettes of the most sold brand 
declined on average between 2008 
and 2018
No trend change in affordability of 
cigarettes since 2008
…
Insufficient data to conduct a trend 
analysis
national tobacco control 
programmes
Classification of countries’ national tobacco 
control programmes is based on the existence of 
a national agency with responsibility for tobacco 
control objectives. Countries with at least five 
full-time equivalent staff members working 
at the national agency with responsibility for 
tobacco control meet the criteria for the highest 
group.
The groupings for the national tobacco control 
programme indicator are listed below.
Data not reported
No national agency for tobacco control
Existence of national agency with 
responsibility for tobacco control 
objectives with no or fewer than five 
full-time equivalent staff members
Existence of national agency with 
responsibility for tobacco control 
objectives and at least five full-time 
equivalent staff members
Compliance assessment
Compliance with national and comprehensive 
subnational smoke-free legislation as well as 
with advertising, promotion and sponsorship 
bans was assessed by up to five national experts, 
who scored the compliance in these two areas 
as “minimal”, “moderate” or “high”. These five 
experts were selected according to the following 
criteria:
•	 person in charge of tobacco prevention in the 
country’s ministry of health, or the most senior 
government official in charge of tobacco 
control or tobacco-related conditions;
•	 the head of a prominent nongovernmental 
organization dedicated to tobacco control;
•	 a health professional (e.g. physician, nurse, 
pharmacist or dentist) specializing in tobacco-
related conditions;
•	 a staff member of a public health university 
department;
•	 the tobacco control focal point of the WHO 
Country Office.
The experts performed their assessments 
independently. average scores were calculated 
by WHO from the five individual assessments by 
assigning two points for highly enforced policies, 
one point for moderately enforced policies and 
no points for minimally enforced policies, with 
a potential minimum of 0 and maximum of 10 
points in total from these five experts.
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TECHNICAL NOTE II
Tobacco use prevalence  
in WHO Member states
monitoring the prevalence of tobacco use is 
central to efforts to control the global tobacco 
epidemic. reliable prevalence data on the 
magnitude of the tobacco epidemic and its 
influencing factors provide the information 
needed to plan, adopt and evaluate the impact 
of tobacco control interventions. This report 
contains survey data for both smoking1 and 
smokeless tobacco use among young people 
and adults (appendix XI). It also presents 
WHO-modelled, age-standardized prevalence 
estimates for tobacco use for people aged 15 
years and over (appendix X). This technical note 
provides information on the method used to 
generate the WHO prevalence estimates. 
Sources of information 
For the analysis, the following sources of 
information were explored (where official survey 
reports explaining the sampling, methodology 
and detailed results were not publicly available, 
member States were asked to provide them):
•	 information on surveys provided by Parties to 
the WHO FCTC Secretariat;
•	 information collected through WHO tobacco-
focused surveys conducted under the aegis of 
the Global Tobacco Surveillance System – in 
particular, the Global adult Tobacco Survey 
(GaTS);
•	 tobacco information collected through other 
WHO surveys including WHO STEPwise 
surveys and World Health Surveys;
•	 other systems-based surveys undertaken by 
other organizations, including surveys such as 
the Demographic and Health Surveys (DHS) 
and the multiple Indicator Cluster Survey 
(mICS); and
•	 an extensive search through WHO 
regional offices and WHO country offices 
to identify country-specific surveys not 
part of international surveillance systems 
– such as the National Survey of risk 
Factors in argentina, or the mauritius Non 
Communicable Diseases Survey.
For the analysis, information from surveys 
conducted since 1990 was used if it:
•	 was officially recognized by the national 
health authority;
•	 included randomly selected participants who 
were representative of the general population;
•	 provided data for one or more of six tobacco 
use definitions: daily tobacco user, current 
tobacco user, daily tobacco smoker, current 
tobacco smoker, daily cigarette smoker or 
current cigarette smoker; and
•	 presented prevalence values by age and sex.
The above indicators provide for the most 
complete representation of tobacco use across 
countries and at the same time help minimize 
attrition of countries from further analysis 
because of lack of adequate data. although 
differences exist in the types of tobacco products 
used in different countries and grown or 
manufactured in different regions of the world, 
data on these six indicators are available in most 
countries, thereby permitting robust statistical 
analyses.2
The information identified above is stored in the 
WHO Tobacco Control Global DataBank and, 
along with the source code used for generating 
the WHO smoking prevalence estimates, is 
published alongside this report at http://www.
who.int/tobacco/.
Analysis and presentation 
of tobacco use prevalence 
indicators
Estimation method
a statistical model based on a Bayesian negative 
binomial meta-regression was used to model 
crude adjusted and age-standardized estimates 
for countries for each indicator (current and daily 
tobacco use, current and daily tobacco smoking, 
and current and daily cigarette smoking) 
separately for men and women.  a trend was 
considered to be statistically significant if the 
posterior probability of the increase or decrease 
was greater than 0.75. a full description of the 
method is available as a peer-reviewed article in 
the Lancet, volume 385, No. 9972, p966–976 
(2015).
Once the prevalence rates from national surveys 
were compiled into a dataset, the model was fit 
to calculate trend estimates for the six indicators 
specified above.
The model has two main components:
(a) adjusting for missing indicators and age 
groups, and (b) running the regression to 
generate an estimate of trends over time as well 
as the credible interval around the estimate.
Depending on the completeness of survey data 
from a particular country, the model at times 
makes use of data from other countries to fill 
information gaps. Countries with data gaps 
“borrow information” from “priors” calculated 
from their data pooled with data from countries 
in the same uN subregion3.
Differences in age groups covered by each survey
Survey results for any one country were 
sometimes reported for a variety of different 
age groups. Where data were missing for any 
age group in the range of 15 years and above, 
the model uses available data from a country’s 
other surveys to estimate the age pattern of 
tobacco use. For ages that the country has 
never surveyed, the average age pattern seen in 
countries in the same uN subregion is applied to 
the country’s data.
Differences in the indicators of tobacco use 
measured
Similarly, countries may report different 
indicators across surveys (e.g. current smoking 
in one survey and daily smoking in another, or 
tobacco smoking in one and cigarette smoking 
in another). Where data were missing for any 
indicator, the model uses available data from a 
country’s other surveys to estimate the missing 
information. For indicators on which the country 
has never reported, the average relationships 
seen in countries in the same uN subregion are 
applied to the country’s data.
modelled results 
The model was run for all countries with surveys 
that met the inclusion criteria. results for 
countries with insufficient survey data (e.g. only 
one survey with a detailed age breakdown for 
prevalence for either sex) were not reported.
The output of the model is a set of trend lines 
for each country that summarize its prevalence 
history from 2000 to the most recent survey, 
and project trends to 2030. Countries with few 
surveys will have more borrowed information 
blended into their trend line than countries with 
many surveys. 
For this report, country-level trends have been 
summarized into average trends for high-income 
countries, middle-income countries, low-income 
countries and a global average. Trends from 
2007 to 2017 are presented, with projections 
of the same lines to 2030. The projection 
assumes that the pace and level of adoption of 
new policies during the period covered by the 
country’s surveys will continue unchanged. In 
future, when countries adopt stronger tobacco 
control policies and complete new surveys, 
recalculated trend lines will reflect the changes.
In this report, comparable estimates of current 
tobacco smoking among people aged 15 years 
and over are presented for all countries in one 
year (2017). These rates are taken from the 
trend line for each country for the year 2017. 
The rates are comparable because the model 
has standardized the survey results as described 
above, and then age-standardized as described 
below.
When calculating global and World Bank income 
group average prevalence rates, countries 
without estimates were included in the averages 
by assuming their prevalence rates are the 
average rates seen in the uN subregion to which 
they belong.3
age-standardized prevalence rates
Comparison of crude rates between two or 
more countries at one point in time, or of 
one country at different points in time, can 
be misleading if the two populations being 
compared have significantly different age 
distributions or differences in tobacco use by sex. 
The method of age-standardization is commonly 
used to overcome this problem and allows for 
meaningful comparison of prevalence between 
countries, once all other comparison issues 
described have been addressed. The method 
involves applying the age-specific rates by sex 
in each population to one standard population 
(this report uses the WHO Standard Population, 
a fictitious population whose age distribution 
is largely reflective of the population age 
structure of low- and middle-income countries). 
The resulting age-standardized rates refer to 
the number of smokers per 100 WHO Standard 
Population. as a result, the rates generated using 
this process are only hypothetical numbers with 
no inherent meaning. They are only meaningful 
when comparing rates obtained from one 
country with those obtained in another country.
Comparison with smoking 
estimates in earlier editions 
of this report
The estimates in this report are consistent with 
each other but not with estimates produced for 
earlier editions of this report. While the method 
of estimation is the same, the updated data 
set for the period 1990–2018 is much more 
complete.
For example, since the WHO report on the global 
tobacco epidemic, 2017, 242 national surveys 
from 89 countries have been added to the data 
set, and 46 existing surveys have been updated 
with additional data points. Each round of 
WHO estimates is calculated using all available 
survey data back to 1990. The more data points 
available, the more robust the trend estimates 
are. Each estimation round therefore improves 
upon earlier published estimates, and only the 
latest round should be used. While country-level 
estimates in this report pertain only to 2017, 
the entire trend series from 2000 to 2025 is 
published in the biennial WHO global report on 
trends in tobacco smoking  2000–2025.
1  Tobacco smoking includes cigarette, cigar, pipe, 
hookah, shisha, water-pipe, heated tobacco products 
and any other form of smoked tobacco.
2  For countries where prevalence of smokeless tobacco 
use is reported, we have published these data.
3  For a complete list of countries by uN subregion, 
please refer to pages ix to xiii of World population 
prospects: the 2017 revision, published by the uN 
Department of Economic and Social affairs at https://
population.un.org/wpp/Publications/Files/WPP2017_
volume-I_Comprehensive-Tables.pdf (accessed april 
17, 2019). Please note that, for the purposes of 
tobacco use analysis, the following adjustments were 
made: (i) Eastern africa subregion was divided into 
two regions: Eastern african Islands and remainder 
of Eastern africa; (ii) armenia, azerbaijan, Estonia, 
Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, 
Tajikistan, uzbekistan and Turkmenistan were 
classified with Eastern Europe; (iii) Cyprus, Israel and 
Turkey were classified with Southern Europe; (iv) 
Central africa and Southern africa were combined 
into one subregion; (v) melanesia, micronesia and 
Polynesia subregions were combined into one 
subregion; and (vi) Ireland and the united Kingdom 
were classified with Northern america. 
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This report includes appendices containing 
information on the share of total and excise 
taxes in the price of the most widely sold brand 
of cigarettes, based on tax policy information 
collected from each country. This note contains 
information on the methodology used by WHO 
to estimate the share of total and tobacco excise 
taxes in the price of a pack of 20 cigarettes using 
country-reported data. It also provides information 
on additional data collected for this report in 
relation to tobacco taxation.
1. Data collection
all data were collected between June 2018 and 
January 2019 by WHO regional data collectors. The 
two main inputs into calculating the share of total 
and excise taxes were (1) prices and (2) tax rates 
and structure. Prices were collected for the most 
widely sold brand of cigarettes, the least-expensive 
brand and a premium brand for July 2018.
Data on tax structure were collected through 
contacts with ministries of finance. The validity 
of this information was checked against other 
sources. For many countries, this was done 
through the wealth of work and knowledge 
accumulated by WHO working directly with 
ministries of finance on tobacco taxation since 
2009. Other sources, including tax law documents, 
decrees and official schedules of tax rates and 
structures and trade information, when available, 
were either provided by data collectors or were 
downloaded from ministerial websites or from 
other databases such as the ImF or the World 
Bank. 
The tax data collected focus on indirect taxes 
levied on tobacco products (e.g. excise taxes of 
various types, import duties, value added taxes), 
which usually have the most significant impact 
on the price of tobacco products. Within indirect 
taxes, excise taxes are the most important 
because they are applied exclusively to tobacco 
TECHNICAL NOTE III
Tobacco taxes in WHO 
Member states
1. Specific excise taxes a specific excise tax is a tax on a selected good produced for sale within a country or imported and sold in that country. 
In general, the tax is collected from the manufacturer or at the point of entry into the country by the importer, in 
addition to import duties. These taxes come in the form of an amount per stick, pack, per 1000 sticks, or per kilogram. 
Example: uS$1.50 per pack of 20 cigarettes.
2.  ad valorem excise taxes an ad valorem excise tax is a tax on a selected good produced for sale within a country or imported and sold in that 
country. In general, the tax is collected from the manufacturer or at the point of entry into the country by the importer, 
in addition to import duties. These taxes come in the form of a percentage of the value of a transaction between two 
independent entities at some point of the production/distribution chain; ad valorem taxes are generally applied to the 
value of the transactions between the manufacturer and the retailer/wholesaler. Example: 60% of the manufacturer’s 
price.
3.  Import duties an import duty is a tax on a selected good imported into a country to be consumed in that country (i.e. the goods are 
not in transit to another country). In general, import duties are collected from the importer at the point of entry into the 
country. These taxes can be either amount-specific or ad valorem. amount-specific import duties are applied in the same 
way as amount-specific excise taxes. ad valorem import duties are generally applied to the CIF (cost, insurance, freight) 
value, (i.e. the value of the unloaded consignment that includes the cost of the product itself, insurance and transport 
and unloading). Example: 50% import duty levied on CIF.
4. value added taxes and sales          
taxes
The value added tax (vaT) is a “multi-stage” tax on all consumer goods and services applied proportionally to the price 
the consumer pays for a product. although manufacturers and wholesalers also participate in the administration and 
payment of the tax all along the manufacturing/distribution chain, they are all reimbursed through a tax credit system, 
so that the only entity who pays in the end is the final consumer. most countries that impose a vaT do so on a base 
that includes any excise tax and customs duty. Example: vaT representing 10% of the retail price.
Some countries, however, impose sales taxes instead. unlike vaT, sales taxes are levied at the point of retail on the total 
value of goods and services purchased. For the purposes of the report, care was taken to ensure the vaT and/or sales 
tax shares were computed in accordance with country-specific rules.
5. Other taxes Information was also collected on any other tax that is not called an excise tax, import duty, vaT or sales tax, but that 
applies to either the quantity of tobacco or to the value of a transaction of a tobacco product, with as much detail as 
possible regarding what is taxed and how the base is defined. 
and contribute the most to increasing the price 
of tobacco products and subsequently reducing 
consumption. Thus, rates, amounts and point of 
application of excise taxes are central components 
of the data collected.
Certain other taxes, in particular direct taxes such 
as corporate taxes, can potentially impact tobacco 
prices to the extent that producers pass them on 
to consumers. However, because of the practical 
difficulty of obtaining information on these taxes 
and the complexity in estimating their potential 
impact on price in a consistent manner across 
countries, they are not considered.
The table below describes the types of tax 
information collected.
2. Data analysis
The price of the most sold brand of cigarettes 
was considered in the calculation of the tax as a 
share of the retail price reported in appendix I and 
appendix Table 9.1. In the case of countries where 
different levels of taxes are applied on cigarettes 
based on length of cigarette, quantity produced, or 
type (e.g. filter vs. non-filter), only the relevant rate 
that applied to the most sold brand was used in 
the calculation.
In the case of Canada and the united States of 
america, national average estimates calculated for 
prices and taxes reflect the fact that different rates 
are applied by state/province over and above the 
applicable federal tax. In the case of Brazil, where 
state vaTs vary, the highest rate, which is applied 
in most states, was applied. In the Federated 
States of micronesia, which also has varying vaT 
rates across states, the vaT rate applicable to the 
state where price data was collected (Pohnpei) 
was used. a weighted average of retail price 
and tax was calculated for China given the very 
large array of brands sold in the market: the 
most sold brand changing almost every year and 
representing a very small share of the market was 
not representative.
The import duty was only used in the calculation of 
tax shares if the most sold brand of cigarettes was 
imported into the country. Import duty was not 
applied in the total tax calculation for countries 
reporting that the most sold brand, even if an 
international brand, was produced locally. In cases 
where the imported cigarettes originated from a 
country with which a bilateral or multilateral trade 
agreement waived the duty, care was taken to 
ensure that the import duty was not taken into 
account in calculating taxes levied.
“Other taxes” are all other indirect taxes not 
reported as excise taxes, import duties or vaT. 
These taxes were, however, treated as excises 
if they had a special rate applied to tobacco 
products. For example, Thailand reported the 
tax earmarked from tobacco and alcohol for the 
ThaiHealth Promotion Foundation as “other tax”.  
However, since this tax is applied only on tobacco 
and alcohol products, it acts like an excise tax and 
so was considered an excise in the calculations. 
3. Calculation 
Denote Sts as the share of taxes on the price of a 
widely consumed brand of cigarettes (20-cigarette 
pack or equivalent). Then,
Sts = Sas + Sav + Sid + SVAT     j
Where:
Sts =  Total share of taxes in the price of a pack of 
cigarettes;
Sas =  Share of amount-specific excise taxes 
(or equivalent) in the price of a pack of 
cigarettes;
Sav =  Share of ad valorem excise taxes (or 
equivalent) in the price of a pack of 
cigarettes;
Sid =  Share of import duties in the price of a pack 
of cigarettes (if the most popular brand is 
imported);
SVAT =  Share of the value added tax in the price of 
a pack of cigarettes.
Calculating Sas is fairly straightforward and involves 
dividing the specific tax amount for a 20-cigarette 
pack by the total price. unlike Sas, the share of 
ad valorem taxes, Sav is much more difficult to 
calculate and involves making some assumptions 
described below. Import duties are sometimes 
amount-specific, sometimes value-based. Sid is 
therefore calculated the same way as Sas if it is 
amount-specific and the same way as Sav if it is 
value-based. vaT rates reported for countries are 
usually applied on the vaT-exclusive retail sale price 
but are also sometimes reported on vaT-inclusive 
prices. SVAT is calculated to consistently reflect the 
share of the vaT in vaT-inclusive retail sale price. 
COUNTRy A (US$) COUNTRy B (US$)
[a] manufacturer’s price (same in both countries) 2.00 2.00
[B] Country a: ad valorem tax on manufacturer’s price (20%) = 20% 
x [a]
0.40 -
[C] Wholesalers’ and retailers’ profit margin (same in both countries) 0.20 0.20
[D] Country B: ad valorem tax on retailer’s price (20%) = 20% x [E] - 0.55
[E] Final price = P = [a]+[B]+[C]  or [a]+[C]+[D] 2.60 2.75
Total tax share (as % of P) 0.40/2.60 = 15.4% 0.55/2.75 =20%
The next step of the exercise was to convert all 
taxes to the same base – in our case, the tax- 
inclusive retail sale price (hereafter referred to as 
P). Standardizing bases is important in calculating 
tax share correctly, as the example in the table 
above shows. Country B apparently applies the 
same ad valorem tax rate (20%) as Country a, but 
in fact ends up with a higher tax rate and a higher 
final price because the tax is applied later in the 
distribution chain. Comparing reported statutory 
ad valorem tax rates without taking into account 
the stage at which the tax is applied could 
therefore lead to biased results.
a similar methodology was used to calculate the 
price and tax share of the most common type of 
smoked (other than cigarettes) and smokeless 
tobacco products, as reported by each country. The 
calculation was made for the price of a product for 
20 grams for any smoked or smokeless tobacco 
product except for cigars and cigarillos, for which 
the price and tax was reported per piece. Price and 
tax for smoked tobacco products (including bidis, 
cheroots, cigarillos, cigars, pipe tobacco, roll-your-
own or waterpipe tobacco) was calculated for 
70 countries, while the calculation for smokeless 
tobacco products (chewing tobacco, dry snuff, 
moist snuff nose tobacco or snus) was made for 
27 countries (see Table 9.5 in online appendix IX).
Price and tax for heated tobacco products (per 20 
sticks) was also calculated but only for a very small 
number of countries that reported them (nine 
countries).
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The price of a pack of cigarettes can be expressed 
as the following:
P =  [(M + M×ID) + (M + M×ID) ×  
Tav% + Tas + π] × (1 + VAT%)
or
P = [M × (1×ID) × (1+Tav%) +
       Tas + π] × (1 + vaT%)     k
Where: 
P =  Price per pack of 20 cigarettes of the most 
popular brand consumed locally;
M =  manufacturer’s/distributor’s price, or import 
price if the brand is imported;
ID =  Import duty rate (where applicable) on a pack 
of 20 cigarettes;1
Tav =  Statutory rate of ad valorem tax;
Tas =  amount-specific excise tax on a pack of 20 
cigarettes;
π =  retailers’, wholesalers’ and importers’ 
profits per pack of 20 cigarettes (sometimes 
expressed as a mark-up);
VAT =  Statutory rate of value added tax on vaT-
exclusive price.
Changes to this formula were made based on 
country-specific considerations such as the 
base for the ad valorem tax and excise tax, the 
existence – or not – of ad valorem and specific 
excise taxes, and whether the most popular 
brand was locally produced or imported. In many 
cases (particularly in low- and middle-income 
countries) the base for ad valorem excise tax was 
the manufacturer’s price or CIF value. But in fact, 
the base of the ad valorem varies a lot around the 
world and can include other bases, such as retail 
price, retail price net of some taxes (and/or some 
predefined margins), retail price net of all taxes, 
etc.  
Given knowledge of price (P) and amount-specific 
excise tax (T
as), the share Sas is easy to recover 
(=Tas/P). The case of ad valorem taxes (and, where 
applicable, Sid) is fairly straightforward when, 
by law, the base is retail price (as is the case in 
several European union countries). The calculation 
is more complicated when retail price is not the 
base, because the base (m) needs to be recovered 
to calculate the amount of ad valorem tax. In most 
of the cases, m was not known (unless specifically 
reported by the country), and therefore had to be 
estimated.
using equation (2), it is possible to recover m: 
 P 
 1 + VAT% 
M = (1 + Tav%) x (1 + ID)    
l
 
π, or wholesalers’ and retailers’ profit margins, 
are rarely publicly disclosed and will vary from 
country to country. For domestically produced 
most popular brands, we considered π to be nil 
(i.e. = 0) in the calculation of m because the 
retailers’ and wholesalers’ profit margins are 
assumed to be small. Setting the margin to 0, 
however, would result in an overestimation of m 
and therefore of the base for the ad valorem tax. 
This will in turn result in an overestimation of 
the amount of ad valorem tax. Since the goal of 
this exercise is to measure how high the share of 
tobacco taxes is in the price of a typical pack of 
cigarettes, assuming that the retailer’s/wholesaler’s 
profit (π) is nil, therefore, does not penalize 
countries by underestimating their ad valorem 
taxes. Considering this, it was decided that unless 
country-specific information was made available to 
WHO, the retailer’s or wholesaler’s margin would 
be assumed to be nil for domestically produced 
brands. 
For countries where the most popular brand is 
imported, the import duty is applied on
 CIF values, 
and the consequent excise taxes are typically 
applied on a base that includes the CIF value and 
the import duty, but not the importer’s profit. For 
domestically produced cigarettes, the producer’s 
price includes its own profit, so it is automatically 
included in m. In practice, however, the importer’s 
profit can be relatively significant and setting it to 
zero (as in the case of domestically manufactured 
cigarettes) would substantially overestimate m, 
and thereby substantially overestimate the share 
of ad valorem tax in final price. For this reason, 
m had to be estimated differently for imported 
products: m* (or the CIF value) was calculated 
either based on information reported by countries 
or using secondary sources (data from the united 
Nations Comtrade database2). m* was normally 
calculated as the import price of cigarettes in a 
country (value of cigarette imports divided by the 
quantity of cigarette imports for the importing 
country). However, in exceptional cases where no 
such data were available (Democratic republic 
of the Congo, Equatorial Guinea, and Libya), the 
export price was considered instead (where the 
export price was considered too low – i.e. below 
uS$ 0.2 per pack – the value was approximated 
as the export price plus uS 10 cents). The ad 
valorem and other taxes were then calculated in 
the same way as for local cigarettes, using m* 
rather than m as the base, where applicable. 
In the case of vaT, in most of the cases the 
base was P excluding the vaT (or, similarly, the 
manufacturer’s/distributor’s price plus all excise 
taxes). In other words:
SVAT  = vaT% × (1 - SVAT), equivalent to     m 
SVAT  = vaT% ÷ (1+ vaT%)
In some cases, however, we were informed that 
the vaT was not effectively collected at all levels 
of the supply chain and was mainly levied at the 
import or manufacturing point. In this case, the 
vaT was calculated on the basis of m (or m*) 
and the different taxes collected at this stage, 
mainly import duties and excise taxes (angola, 
Benin, Cabo verde, Cameroon, Cook Islands, 
Côte d’Ivoire, Equatorial Guinea, Ethiopia, 
Gabon, Gambia, Guinea-Bissau, Iran, Kiribati, 
mali, mauritania, Suriname, Tonga, Tuvalu, 
uganda, vanuatu and viet Nam).
In sum, the tax rates are calculated this way:
Sts  = Sid + Sas + Sav + SVAT            n
Sas = Tas ÷ P
Sav =  (Tav % × M) ÷ P  
or  
(Tav % × M*× (1+ Sid)) ÷ P 
3 
if the most popular brand was imported
Sid =  (TID % × M*) ÷ P  
(if the import duty is value-based)  
or  
ID ÷ P  
(if import duty is a specific amount per 
pack)
SVAT = vaT% ÷ (1+ vaT%) 
4. Prices 
Primary collection of price data in this and 
previous reports involved surveying retail outlets. 
Price data were collected in the following manner:
•	 In addition to the most sold brand reported in 
previous years, there was a space provided for 
data collectors to report a new most sold brand 
- π -Tas
in case the one collected in past years was not 
the most sold brand anymore.
•	 For each brand, prices were required from two 
different types of retail outlets.
Questionnaires sent to data collectors were 
pre-populated with the names of the highest 
selling brand in each country. The popular 
brand was identified using data collected 
from the 2016 questionnaires, from secondary 
data (Euromonitor4) and through WHO’s close 
collaboration with ministries of finance. For the 
countries where such data were not available, 
data collectors were asked to indicate the names 
of the popular brands and provide their prices. 
The two types of retail outlets were defined as 
follows:
1. Supermarket/hypermarket: chain or 
independent retail outlets with a selling space 
of over 2500 square metres and a primary 
focus on selling food/beverages/tobacco and 
other groceries. Hypermarkets also sell a range 
of non-grocery merchandise.
2. Kiosk/newsagent/tobacconist/independent 
food store: small convenience stores, retail 
outlets selling predominantly food, beverages 
and tobacco or a combination of these (e.g. 
kiosk, newsagent or tobacconist) or a wide 
range of predominantly grocery products 
(independent food stores or independent small 
grocers).
most sold brands have been used consistently over 
time to gain a better reflection of the change in 
prices. However, in some cases where the market 
share of the brand initially used was considered 
to have changed substantially, a change was 
made to the new, more prevalent brand. In 2018, 
changes in the brand were made for antigua and 
Barbuda, australia, Benin, Cuba, Cyprus, Gabon, 
Gambia, Kazakhstan, Niger, Saint vincent and 
the Grenadines, Serbia, viet Nam (different brand 
but same price category), azerbaijan, Barbados, 
Belize, Brazil, Grenada, Nicaragua, Pakistan, Papua 
New Guinea, Peru, Thailand (cheaper brand), El 
Salvador, Bosnia and Herzegovina, mozambique 
(more expensive brand) and Turkmenistan (not 
possible to determine how the new brand 
compared to the previous one).
In 11 other countries (austria, Bolivia 
(Plurinational State of),, Denmark, Hungary, Nauru, 
Panama, Poland, romania, Slovakia, Spain and 
Sweden) the brand reported in 2018 was a variant 
of the brand reported in 2016, and these were 
treated as identical in both years for purposes of 
price comparisons.
as in 2012, 2014 and 2016, the price used for 
each of the 28 countries of the European union 
(Eu)5 was the most sold brand collected by WHO. 
Prior to 2012, price and tax information were 
taken entirely from the Eu’s Taxation and Customs 
union website. The price used by the Eu in the 
past to calculate tax rates was the most popular 
price category (mPPC), which was assumed to 
be similar to the most sold brand price category 
collected in this report. However, since 2011, the 
Eu calculates and reports tax rates based on the 
Weighted average Price (WaP) and therefore 
information on the mPPC is no longer readily 
available for Eu countries. Consequently, in order 
to be consistent with past years’ estimates and to 
ensure comparability with other countries, WHO 
decided in 2012 to collect first-hand prices of the 
most sold brand (the brand was determined based 
on brand market shares reported from secondary 
sources) to calculate tax rates. Excise and vaT 
rates are still collected from the Eu published 
tables. This means, however, that tax shares as 
computed and reported in this report will not 
necessarily be similar to the rates published by 
the Eu. This is mainly due to the calculation of the 
specific excise tax rates as a percentage of the 
retail price, which will vary depending on the price 
used. See details of the difference in price and tax 
share for the Eu countries in the table (left).
Total tax share (% of retail price) Retail price (20 cigarettes)
Country WHO estimates EU reported 
rates
WHO reported 
MSB
EU reported 
WAP
Currency
austria 75.3% 78.53% 5.50 4.76 Eur
Belgium 77.0% 79.37% 6.60 5.88 Eur
Bulgaria 83.6% 85.09% 5.20 5.02 BGN
Croatia 78.8% 79.91% 25.00 23.93 HrK
Cyprus 74.4% 75.67% 4.50 4.28 Eur
Czechia 75.4% 78.31% 94.00 86.00 CZK
Denmark 74.1% 79.89% 44.50 40.16 DKK
Estonia 79.4% 85.82% 4.25 3.55 Eur
Finland 87.4% 88.67% 7.22 6.70 Eur
France 82.4% 85.07% 8.00 6.81 Eur
Germany 68.3% 72.49% 6.40 5.64 Eur
Greece 81.2% 85.64% 4.60 4.10 Eur
Hungary 72.3% 75.22% 1,245.00 1,118.72 HuF
Ireland 78.4% 89.12% 12.20 10.07 Eur
Italy 76.0% 77.13% 5.50 4.76 Eur
Latvia 80.0% 83.99% 3.50 3.20 Eur
Lithuania 73.8% 79.46% 3.75 3.18 Eur
Luxembourg 68.3% 69.40% 5.30 4.60 Eur
malta 77.6% 79.40% 5.50 5.25 Eur
Netherlands 71.8% 78.29% 7.00 6.19 Eur
Poland 76.8% 80.04% 15.50 13.82 PLN
Portugal 71.7% 76.16% 5.00 4.47 Eur
romania 68.6% 72.56% 17.50 15.86 rON
Slovakia 77.1% 77.88% 3.30 3.23 Eur
Slovenia 79.2% 81.28% 3.70 3.51 Eur
Spain 78.2% 79.28% 5.00 4.52 Eur
Sweden 68.4% 74.16% 65.00 57.94 SEK
united Kingdom of 
Great Britain and 
Northern Ireland
79.4% 88.80% 9.40 7.81 GBP
Comparisons of prices and total tax shares are computed from WHO’s most sold brand 
(MSB) survey and EU weighted average price (WAP).
Note: WHO estimates pertain to most sold brand prices collected in July 2018. Eu reported rates and weighted average prices 
pertain to data collected by the Eu and are also reported for July 2018. as indicated earlier, the most sold brand was used for all 
Eu countries except for Finland, which reported directly to WHO its weighted average price (WaP) for 2008, 2010, 2012, 2014, 
2016 and 2018. The 2018 data shows a different WaP for WHO compared to the Eu reported WaP for Finland. This is because the 
price reported to WHO was an estimate updated in 2019, while the Eu reported WaP was collected in 2018.
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5. Considerations in 
interpreting tax share 
changes
Changes in tax as a share of price are not only 
dependent on tax changes but also on price 
changes. Therefore, despite an increase in tax, 
the tax share could remain the same or go down; 
similarly, sometimes a tax share can increase even 
if there is no change/increase in the tax. 
In the current database, there are cases where 
taxes increased between 2016 and 2018 but 
the share of tax as a percentage of the price 
went down. This is mainly due to the fact that, in 
absolute terms, the price increase was larger than 
the tax increase (particularly in the case of specific 
excise tax increases). For example, in mongolia, 
the specific excise tax increased from 3480 mNT 
per 100 cigarettes in 2016 to 3830 mNT per 100 
cigarettes in 2016 (a 10% increase) while the 
price of the most sold brand increased from 1700 
to 2000 mNT per pack (an 18% increase). In 
terms of tax share, the excise represented 52.9% 
of the price in 2016 and went down to 47.4% of 
the price in 2018. This is because prices rose more 
than taxes. 
In the same way there are cases where increases 
(decreases) in tax as a share of price were 
mitigated by factors not directly related to tax 
rates. In the current database, this was attributable 
to one or more of the following reasons:
•	 In some instances, the price increased without 
a tax change, leading to a decrease in the tax 
share for a specific or mixed excise structure 
(e.g. China, Cyprus, Denmark, Dominica, 
Ecuador, Germany, Israel, mexico, Palau, Poland, 
Saint vincent and the Grenadines, Switzerland, 
Timor-Leste, Tunisia, and yemen).
•	 In other cases, prices increased above tax 
increases, leading to a decrease in tax share for 
a specific or mixed excise structure (e.g. algeria, 
austria, Canada, Chile, Cook Islands, Costa 
rica, Czechia, Dominican republic, Gambia, 
Grenada, Honduras, Hungary, Iceland, Iran 
(Islamic republic of), Jamaica, Jordan, Lithuania, 
Luxembourg, malta, mongolia, Norway,  
Portugal, republic of moldova, romania, 
Samoa, Serbia, Seychelles, Slovakia, Spain, 
Suriname, Sweden, Tonga, Trinidad and Tobago, 
Turkey, uganda, ukraine, united Kingdom of 
Great Britain and Northern Ireland, united 
republic of Tanzania, united States of america).
•	 In the case of imported products, the CIF value 
is an external variable that also influences the 
calculation of tax share. This has implications 
in countries where ad valorem is based on the 
CIF value, when import duties are applicable 
on the CIF value or when the vaT is calculated 
on the base of CIF value and excise rather than 
vaT-exclusive retail price. For example, if the 
CIF value increases, the base for the application 
of the tax is higher, leading to a higher tax 
percentage if nothing else changes. Countries 
that have seen changes in their tax share mainly 
due to changes in CIF value include Togo, Libya 
and micronesia (Federated States of).  
•	 Care should also be taken in relation to 
countries where the most sold brand changed 
between 2016 and 2018. This also has had an 
impact on the tax proportion of the affected 
countries that had a specific or mixed excise 
structure. In some cases, because the new brand 
reported was more expensive and despite tax 
increases, the total tax share decreased (Bosnia 
and Herzegovina, mozambique and Peru). 
In the case of El Salvador, the tax proportion 
decreased despite no tax change, because of 
the apparent increase in prices due to the new, 
more expensive brand reported as the most 
sold brand. In one other case (Belize), the new 
brand reported was cheaper, so the tax share 
increased despite no tax increase.  
Finally, when new and improved information 
was provided in terms of taxation and prices for 
some countries, corrections were made in the 
calculations of tax rates for 2008, 2010, 2012, 
2014 and 2016 estimates, as needed.
6. Supplementary tax 
information (see Table 9.3, 
online Appendix IX)
an important consideration highlighted in this 
report is that many aspects of tobacco taxation 
need to be taken into account in order to assess if 
a tax policy is well designed. Tax as a proportion 
of price does not tell the whole story about the 
effectiveness of a tax policy. To explore other 
dimensions of tax policy, the report has been 
collecting since 2015 additional information in 
relation to tobacco taxation and presents it as 
data that can inform researchers and policy-
makers further on tax policy in different countries.
The information is compiled and classified in 
this report according to two main themes: tax 
structure/level and tax administration. Information 
was also collected in relation to countries that 
earmark tobacco taxes to fund health programmes 
and/or tobacco control activities. The different 
sets of data/indicators reported under each of the 
themes were developed and are justified based on 
evidence provided in past reports.
I. Tax structure/level
a. Excise tax proportion of price: higher tax 
rates and greater reliance on excise is better. 
b. Type of excise applied: if excise tax is 
specific, ad valorem, a mix of the two, or if no 
excise is applied.
c. Uniform vs. tiered excise tax system: a 
uniform excise is easier to administer than a 
tiered system where variable rates apply based 
on selected criteria within one tobacco product 
(not applicable in countries where no excise 
tax is implemented).
d. Whether a country applies a specific excise or a 
mixed system relying more on the specific 
tax component (> 50% of total excise 
is specific): specific excises typically lead to 
higher prices and a smaller price gap between 
different brands, and so are more effective (not 
applicable in countries where only ad valorem 
excise is applicable or where no excise tax is 
implemented).
e. If the excise applied is ad valorem or if it is 
mixed, and whether there is a minimum 
specific tax. a minimum tax provides 
protection against products being undervalued. 
It also forces prices up since the price will not 
be lower than the tax paid (this category does 
not apply to countries where only specific 
excise tax is applicable or where no excise tax 
is implemented). 
f. Base of the ad valorem tax in countries that 
apply an ad valorem or a mixed excise system. 
Ad valorem taxes applied to the retail 
price or the retail price excluding vaT are 
administratively simpler. The retail price is 
easier to determine than producer price or 
CIF value, and therefore there is less risk of 
undervaluation (not applicable in countries 
where only specific excise is applicable, or 
where no excise tax is implemented).
g. If the excise tax applied is specific or if it 
is mixed, and whether the specific tax 
component is automatically adjusted 
for inflation (or other). If the specific tax is not 
adjusted for inflation (or another indicator such 
as income) over time, its impact will be eroded. 
It is good to have it adjusted automatically 
(this category does not apply to countries 
where only ad valorem excise tax is applicable 
or where no excise tax is implemented).
h. minimum price policy: while this is not 
reported as a best practice, it was considered 
important to report the countries that did 
impose minimum prices as part of their excise 
tax policy. 
i. Price dispersion: share of cheapest brand 
price in premium brand price (cheapest brand 
price ÷ premium brand price × 100). The 
higher the proportion, the smaller the gap and 
the fewer the opportunities for substitution to 
cheaper brands.
II. Tax administration
a. requirement of tax stamps (or fiscal 
marks) on tobacco products: tax stamps 
help administrators ensure that producers 
and importers comply with tax payment 
requirements and help detect illicit tobacco 
products. a note was made of countries 
requiring tax stamps to bear special features 
beyond those found on traditional paper 
stamps. Specifically, these are encrypted tax 
stamps that include unique identifiers used to 
detect the presence of illicit products. Data was 
collected to identify which countries had an 
additional feature on those marks which was 
used for tracking and tracing purposes. 
b. Sales of duty free cigarettes: In most countries 
tobacco products are found to be sold without 
excise (and other indirect taxes such as vaT 
and import duties) in duty-free shops in 
airports, on international transport vehicles 
and/or other tax-free shops. Duty-free tobacco 
products are usually made available to 
travellers going out of the country, but they 
are now also made available for travellers 
entering a country. Banning the sale of 
duty-free cigarettes for personal consumption 
reduces the chance that these products end 
up in the illicit market. additionally, there is 
no justification for selling a deadly product 
duty-free; those foregone taxes are a revenue 
loss for the government. Some countries have 
already acted and have banned the sale of 
duty-free tobacco products. Those products 
may still be found in airport and other tax-free 
shops, but they are sold with (excise) taxes 
included.
III. Earmarking (portion of taxes or revenues from 
taxes dedicated to health and/or tobacco 
control). Taxes can generate substantial 
revenues. One way of correcting the negative 
externality of tobacco use would be to increase 
taxes to reduce consumption and fund health 
care, which is often underfunded and put 
under strain because of tobacco use (see Table 
9.4 in online appendix IX).
7. Estimates of the 
affordability of cigarettes 
(see Table 9.5, online 
Appendix IX)
The affordability of cigarettes for each of the 
years 2008, 2010, 2012, 2014, 2016 and 2018 
was measured by the per capita GDP required to 
purchase 2000 cigarettes of the most sold brand 
reported in that year. analysis of affordability in 
this report informs the following:
•	 affordability index (% of GDP per capita to 
buy 2000 cigarettes): across countries, a higher 
value indicates cigarettes are relatively more 
expensive in relation to income.
•	 Whether cigarettes have become relatively 
more affordable between 2008 and 2018 
(change in the affordability index as measured 
above): as affordability decreases, consumption 
is discouraged.
Estimates of GDP per capita in local currency units 
were sourced from the ImF’s World Economic 
Outlook (WEO) database which provides a 
complete series of estimates for most of the 195 
countries reported on. Where GDP per capita data 
were not available in the WEO database, (andorra, 
Cuba, occupied Palestinian territory, including 
east Jerusalem, and Somalia), the World Bank’s 
GDP per capita data series was used. In the case 
of the Cook Islands, government data was used.
For each country–year pair, the currency reported 
for the most sold brand was tallied with the 
corresponding currency for the GDP series, and 
exchange rate conversions and adjustments were 
performed as needed (Belarus, Cambodia, Estonia, 
Latvia, Liberia Lithuania, Turkmenistan, Zambia) to 
align the two data series. 
To assess whether affordability changed on 
average since 2008, the average annual 
percentage change in affordability was calculated 
as the least squares growth rate for all countries 
with four or more years of data, including data 
for 2018. This criterion automatically excluded 
countries where World Bank GDP per capita 
estimates were used, given that the series ended 
with the year 2017 at the time the analysis was 
performed. 
The affordability of cigarettes was judged to have 
been unchanged if the least squares trend in 
the per capita GDP required to purchase 2000 
cigarettes (that is, 100 packs of 20 cigarettes) was 
not significant at the 5% level. Cigarettes were 
judged to have become less (more) affordable on 
average if the least squares trend in the per capita 
GDP required to purchase 2000 cigarettes was 
positive (negative) and significantly different from 
zero at the 5% level. 
1 Import duties may vary depending on the country of origin 
in cases of preferential trade agreements. WHO tried to 
determine the origin of the pack and relevance of using 
such rates where possible.
 2 https://comtrade.un.org/ 
 3 Or Sav = (Tav % × m*) ÷ P, if the ad valorem tax was 
applied only on the CIF value, not the CIF value + the 
import duty.
4 Euromonitor International’s Passport, 2018.
5 Except for Finland where the weighted average price of 
cigarettes was used for years 2008, 2010, 2012, 2014, 
2016 and 2018.
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Appendix I provides an overview of 
selected tobacco control policies. For 
each WHO region an overview table is 
presented that includes information on 
monitoring and prevalence, smoke-free 
environments, treatment of tobacco 
dependence, health warnings and 
packaging, anti-tobacco mass media 
campaigns, advertising, promotion 
and sponsorship bans, taxation levels, 
and affordability of tobacco products, 
based on the methodology outlined in 
Technical Note I.
Country-level data were generally but 
not always provided with supporting 
documents such as laws, regulations, 
policy documents, etc. Available 
documents were assessed by WHO 
and this appendix provides summary 
measures or indicators of country 
achievements for each of the MPOWER 
measures. Detailed information, 
including detailed footnotes on 
each of the indicators, is available in 
Appendix II for tobacco dependence 
treatment, in Appendix VI for smoke-
free environments, health warnings and 
packaging, anti-tobacco mass media 
campaigns, advertising, promotion and 
sponsorship bans, and in Appendix IX 
for tobacco taxation and affordability. 
It is important to note that data about 
laws reflect the status of legislation 
adopted by 31 December 2018 which 
has a stated date of effect and is not 
undergoing a legal challenge that could 
impact the date of implementation. 
REGIONAl SUMMARy OF MPOWER 
MEASURES
Appendix i:
The summary measures developed for 
the WHO report on the global tobacco 
epidemic, 2019 are the same as those 
used for the 2017 report. 
The methodology used to calculate each
indicator is described in Technical 
Note I. This review, however, does not 
constitute a thorough and complete 
legal analysis of each country’s 
legislation. Except for smoke-free 
environments and bans on tobacco 
advertising, promotion and sponsorship, 
data were collected at the national/
federal level only and therefore provide 
incomplete policy coverage for Member 
States where subnational governments 
play an active role in tobacco control.
Daily smoking prevalence for the 
population aged 15 years and over in 
2017 is an indicator modelled by WHO 
from tobacco use surveys published by
Member States. Tobacco smoking is one 
of the most widely reported indicators
in country surveys. The calculation of 
WHO estimates to allow international 
comparison is described in Technical 
Note II.
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Africa
Table 1.1 
Summary of 
MPOWER measures
. . . Data not reported/not available.
— Data not required/not applicable.
2018 INDICATOR AND COMPLIANCE  CHANGE SINCE 2016
COUNTRy
ADULT DAILy 
SMOKING 
PREvALENCE 
(2017)
M
MONITORING
P 
SMOKE-FREE 
POLICIES
O 
CESSATION
W
WARNINGS
E 
ADvERTISING 
BANS
R P 
SMOKE-FREE 
POLICIES
O 
CESSATION 
PROGRAMMES
W 
HEALTH
WARNINGS
E 
ADvERTISING 
BANS
R 
TAxATION
LINES REPRESENT 
LEVEL OF 
COMPLIANCE
HEALTH
WARNINGS
MASS  
MEDIA
LINES REPRESENT 
LEVEL OF 
COMPLIANCE
TAXATION
CIGARETTES LESS 
AFFORDABLE 
SINCE 2008
CHANGE IN POWER INDICATOR GROUP, UP OR DOWN, SINCE 2016
Algeria 12% IIIII IIIII 34.2% YES
Angola . . . . . . — 23.7% YES p
Benin 5% IIIII IIIIIIII 4.9% NO p q p
Botswana 15% — . . . 49.9% ↔ p
Burkina Faso 11% IIII IIIIII 41.6% ↔
Burundi 7% — — 42.8% ↔ p p p
Cabo Verde . . . IIIII IIIIIII 11.2% NO
Cameroon 6% . . . 8 . . . 21.3% NO p
Central African Republic . . . — — 41.5% ↔ q
Chad 7% III IIIIIII 34.1% YES
Comoros 11% III IIIIII 37.3% ↔ p
Congo 9% I IIIIIIII 37.1% ↔ p
Côte d'Ivoire 9% — — 33.3% NO
Democratic Republic of the 
Congo . . . 8 — 8 38.7% NO p p
Equatorial Guinea . . . — — 25.3% ↔
Eritrea 5% — . . . 55.4% ↔
Eswatini 6% — IIIIIIIIII 52.7% NO p
Ethiopia 2% IIIII I IIIII 18.8% NO
Gabon . . . IIIII IIIIIII 23.1% ↔ q
Gambia 10% — IIIIIII 46.3% YES p p q
Ghana 3% — I IIIIIIII 31.3% NO
Guinea . . . . . . . . . … … q
Guinea-Bissau . . . . . — — 6.8% ↔ q
Kenya 8% — IIIIIIIIII 52.3% NO
Lesotho 21% . . . — 50.9% NO
Liberia 6% — — 34.8% ↔ p
Madagascar 16% IIII IIIIIIIII 80.4% YES
Malawi 8% — — . . . . . .
Mali 10% — IIIIIII 27.7% NO
Mauritania . . . I 8 — 9.6% NO p p
Mauritius 16% IIIIII IIIIIIIII 83.5% YES p
Mozambique 11% IIIIIIIIII 28.5% YES p
Namibia 13% IIIIII IIIIIIIIII 44.1% ↔
Niger 5% III IIIIIIIII 31.3% ↔
Nigeria 3% — III 29.7% NO p
Rwanda 9% — IIIIIIII 55.9% NO q
Sao Tome and Principe 4% —	I IIIIIIIII 40.4% NO q
Senegal 6% IIII I IIIIII 38.2% YES
Seychelles 16% IIIIIIIIII IIIIIIIIII 70.1% ↔
Sierra Leone 19% — — 18.6% ↔
South Africa 17% — . . . 54.6% ↔ p
South Sudan . . . — — . . . . . .
Togo 6% IIIIIIIIII I IIIIIIIIII 22.0% ↔
Uganda 5% III IIIIIII 39.9% YES q
United Republic of Tanzania 8% — I . . . 32.1% ↔ q
Zambia 10% III — 41.2% ↔ p
Zimbabwe 11% IIII — 35.9% YES
ADULT DAILy SMOKING PREvALENCE: AGE-
STANDARDIZED* PREvALENCE RATES FOR ADULT DAILy 
SMOKERS OF TOBACCO (BOTH SExES COMBINED), 2017
. . . Estimates not available
30% or more 
From 20% to 29.9% 
From 15% to 19.9% 
Less than 15% 
*  The figures should be used strictly for the purpose of drawing 
comparisons across countries and must not be used to estimate 
absolute number of daily tobacco smokers in a country.
MONITORING: PREvALENCE DATA
No known data or no recent data or data 
that are not both recent and representative
recent and representative data for either 
adults or youth
recent and representative data for both 
adults and youth
recent, representative and periodic data for 
both adults and youth
SMOKE-FREE ENvIRONMENTS:
SMOKING BANS
Data not reported/not categorized
Complete absence of ban, or up to two public 
places completely smoke-free
Three to five public places completely smoke-free
Six to seven public places completely smoke-free
all public places completely smoke-free (or 
at least 90% of the population covered by 
complete subnational smoke-free legislation)
CESSATION PROGRAMMES:  
TREATMENT OF TOBACCO DEPENDENCE
Data not reported
None
NrT and/or some cessation services (neither 
cost-covered)
NrT and/or some cessation services (at least 
one of which is cost-covered)
National quit line, and both NrT and some 
cessation services cost-covered
HEALTH WARNINGS:  
HEALTH WARNINGS ON CIGARETTE PACKAGES
Data not reported
No warnings or small warnings
medium size warnings missing some or many 
appropriate characteristics Or large warnings 
missing many appropriate characteristics
medium size warnings with all appropriate 
characteristics Or large warnings missing 
some appropriate characteristics
Large warnings with all appropriate 
characteristics
MASS MEDIA:  
ANTI-TOBACCO CAMPAIGNS
Data not reported
No national campaign conducted between July 
2016 and June 2018 with duration of at least 
three weeks
National campaign conducted with one to four 
appropriate characteristics
National campaign conducted with five to 
six appropriate characteristics, or with seven 
characteristics excluding airing on television 
and/or radio
National campaign conducted with at least 
seven appropriate characteristics including 
airing on television and/or radio
ADvERTISING BANS:  
BANS ON ADvERTISING, PROMOTION AND SPONSORSHIP
Data not reported
Complete absence of ban, or ban that does not 
cover national television, radio and print media
Ban on national television, radio and print 
media only
Ban on national television, radio and print 
media as well as on some but not all other 
forms of direct and/or indirect advertising
Ban on all forms of direct and indirect 
advertising (or at least 90% of the population 
covered by subnational legislation completely 
banning tobacco advertising, promotion and 
sponsorship)
TAxATION: SHARE OF TOTAL TAxES IN THE RETAIL PRICE OF 
THE MOST WIDELy SOLD BRAND OF CIGARETTES
Data not reported
< 25% of retail price is tax 
≥25% and <50% of retail price is tax 
≥50% and <75% of retail price is tax 
≥75% of retail price is tax 
AFFORDABILITy OF CIGARETTES
YES
Cigarettes less affordable – per
capita GDP needed to buy 2000
cigarettes of the most sold brand
increased on average between 2008
and 2018
NO
Cigarettes more affordable – per
capita GDP needed to buy 2000
cigarettes of the most sold brand
declined on average between 2008
and 2018
↔
No trend change in affordability of cigarettes 
since 2008
. . . Insufficient data to conduct a trend analysis
COMPLIANCE: COMPLIANCE WITH BANS ON ADvERTISING, 
PROMOTION AND SPONSORSHIP, AND ADHERENCE TO 
SMOKE-FREE LAWS
||||||||||
|||||||||
||||||||
High compliance (8/10 to 10/10)
|||||||
||||||
|||||
||||
|||
moderate compliance (3/10 to 7/10)
||
| minimal compliance (0/10 to 2/10)
SyMBOLS LEGEND
I Country has one or more public places where 
designated smoking rooms (DSrs) are allowed. 
Separate, completely enclosed smoking rooms 
are allowed if they are separately ventilated 
to the outside and/or kept under negative air 
pressure in relation to the surrounding areas. 
Given the difficulty of meeting the very strict 
requirements delineated for such rooms, they 
appear to be a practical impossibility but 
no reliable empirical evidence is presently 
available to ascertain whether they have been 
constructed.
8 Policy adopted but not implemented by 
31 December 2018.
st Change in POWEr indicator group, up or down, 
between 2016 and 2018. Some 2016 data 
were revised in 2018. 2018 grouping rules 
were applied to both years. 
PLEASE REFER TO TECHNICAL NOTE I FOR DEFINITIONS OF 
CATEGORIES
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The Americas
Table 1.2 
Summary of 
MPOWER measures
. . . Data not reported/not available.
— Data not required/not applicable.
1  The Government of Canada has not 
implemented a nationwide mass 
media campaign during the reporting 
period. However, mass media 
campaigns have been implemented 
in three of Canada’s provinces.
2018 INDICATOR AND COMPLIANCE  CHANGE SINCE 2016
COUNTRy
ADULT DAILy 
SMOKING 
PREvALENCE 
(2017)
M
MONITORING
P 
SMOKE-FREE 
POLICIES
O 
CESSATION
W
WARNINGS
E 
ADvERTISING 
BANS
R P 
SMOKE-FREE 
POLICIES
O 
CESSATION 
PROGRAMMES
W 
HEALTH
WARNINGS
E 
ADvERTISING 
BANS
R 
TAxATION
LINES REPRESENT 
LEVEL OF 
COMPLIANCE
HEALTH
WARNINGS
MASS  
MEDIA
LINES REPRESENT 
LEVEL OF 
COMPLIANCE
TAXATION
CIGARETTES LESS 
AFFORDABLE 
SINCE 2008
CHANGE IN POWER INDICATOR GROUP, UP OR DOWN, SINCE 2016
Antigua and Barbuda . . . I — 13.3% ↔ p p p
Argentina 16% IIIIIIII IIIIIIII 76.2% YES
Bahamas 8% — . . . . . . . . .
Barbados 5% IIIIIIIIII — 47.1% YES p
Belize . . . — — 43.6% NO
Bolivia (Plurinational State of) . . . II II 36.8% ↔ q
Brazil 11% IIIIIIIIII IIIIIIIII 83.0% ↔ p
Canada1 10% IIIIIIIII IIIIIIIIII 64.3% YES
Chile 32% IIIIIIII IIIIIIIII 82.4% YES
Colombia 5% IIIIIII IIIIIII 78.4% ↔ p
Costa Rica 6% IIIII IIIIII 55.1% YES
Cuba 19% IIII — 70.2% . . .
Dominica . . . — — 23.6% ↔ q
Dominican Republic 7% III — 51.1% NO
Ecuador . . . IIIIIIII IIIIIII 70.0% YES
El Salvador 6% III IIIIIII 47.5% ↔ q
Grenada . . . — — 44.0% ↔
Guatemala . . . IIIII III 49.0% ↔
Guyana 11% IIIIIII 8 IIIIII 27.5% NO p p p p
Haiti 6% — — . . . . . .
Honduras . . . IIIIIIIIII IIIIII 33.4% YES p
Jamaica 8% IIIIIIII IIIIIIII 43.6% YES
Mexico 8% IIII I IIII IIIII 67.0% ↔
Nicaragua . . . IIIII IIIIIII 40.2% ↔
Panama 3% IIIIIII IIIIIII 56.5% ↔ q
Paraguay 9% IIIII IIIII 17.4% ↔ p
Peru 7% IIIIII IIIIII 49.0% YES
Saint Kitts and Nevis . . . — — 19.8% ↔
Saint Lucia . . . . . . — 51.2% ↔ p
Saint Vincent and the Grenadines . . . — — 16.9% ↔
Suriname . . . IIIII IIIIIIII 47.6% YES q
Trinidad and Tobago . . . IIIIIIIII 8 IIIIIIII 25.7% YES
United States of America 14% . . . . . . 43.0% ↔
Uruguay 18% IIIIIIIII IIIIIIII 66.1% ↔
Venezuela (Bolivarian Republic of) . . . IIIIIIII IIIIIIIIII 73.0% . . .
ADULT DAILy SMOKING PREvALENCE: AGE-
STANDARDIZED* PREvALENCE RATES FOR ADULT DAILy 
SMOKERS OF TOBACCO (BOTH SExES COMBINED), 2017
. . . Estimates not available
30% or more 
From 20% to 29.9% 
From 15% to 19.9% 
Less than 15% 
*  The figures should be used strictly for the purpose of drawing 
comparisons across countries and must not be used to estimate 
absolute number of daily tobacco smokers in a country.
MONITORING: PREvALENCE DATA
No known data or no recent data or data 
that are not both recent and representative
recent and representative data for either 
adults or youth
recent and representative data for both 
adults and youth
recent, representative and periodic data for 
both adults and youth
SMOKE-FREE ENvIRONMENTS:
SMOKING BANS
Data not reported/not categorized
Complete absence of ban, or up to two public 
places completely smoke-free
Three to five public places completely smoke-free
Six to seven public places completely smoke-free
all public places completely smoke-free (or 
at least 90% of the population covered by 
complete subnational smoke-free legislation)
CESSATION PROGRAMMES:  
TREATMENT OF TOBACCO DEPENDENCE
Data not reported
None
NrT and/or some cessation services (neither 
cost-covered)
NrT and/or some cessation services (at least 
one of which is cost-covered)
National quit line, and both NrT and some 
cessation services cost-covered
HEALTH WARNINGS:  
HEALTH WARNINGS ON CIGARETTE PACKAGES
Data not reported
No warnings or small warnings
medium size warnings missing some or many 
appropriate characteristics Or large warnings 
missing many appropriate characteristics
medium size warnings with all appropriate 
characteristics Or large warnings missing 
some appropriate characteristics
Large warnings with all appropriate 
characteristics
MASS MEDIA:  
ANTI-TOBACCO CAMPAIGNS
Data not reported
No national campaign conducted between July 
2016 and June 2018 with duration of at least 
three weeks
National campaign conducted with one to four 
appropriate characteristics
National campaign conducted with five to 
six appropriate characteristics, or with seven 
characteristics excluding airing on television 
and/or radio
National campaign conducted with at least 
seven appropriate characteristics including 
airing on television and/or radio
ADvERTISING BANS:  
BANS ON ADvERTISING, PROMOTION AND SPONSORSHIP
Data not reported
Complete absence of ban, or ban that does not 
cover national television, radio and print media
Ban on national television, radio and print 
media only
Ban on national television, radio and print 
media as well as on some but not all other 
forms of direct and/or indirect advertising
Ban on all forms of direct and indirect 
advertising (or at least 90% of the population 
covered by subnational legislation completely 
banning tobacco advertising, promotion and 
sponsorship)
TAxATION: SHARE OF TOTAL TAxES IN THE RETAIL PRICE OF 
THE MOST WIDELy SOLD BRAND OF CIGARETTES
Data not reported
< 25% of retail price is tax 
≥25% and <50% of retail price is tax 
≥50% and <75% of retail price is tax 
≥75% of retail price is tax 
AFFORDABILITy OF CIGARETTES
YES
Cigarettes less affordable – per
capita GDP needed to buy 2000
cigarettes of the most sold brand
increased on average between 2008
and 2018
NO
Cigarettes more affordable – per
capita GDP needed to buy 2000
cigarettes of the most sold brand
declined on average between 2008
and 2018
↔
No trend change in affordability of cigarettes 
since 2008
. . . Insufficient data to conduct a trend analysis
COMPLIANCE: COMPLIANCE WITH BANS ON ADvERTISING, 
PROMOTION AND SPONSORSHIP, AND ADHERENCE TO 
SMOKE-FREE LAWS
||||||||||
|||||||||
||||||||
High compliance (8/10 to 10/10)
|||||||
||||||
|||||
||||
|||
moderate compliance (3/10 to 7/10)
||
| minimal compliance (0/10 to 2/10)
SyMBOLS LEGEND
I Country has one or more public places where 
designated smoking rooms (DSrs) are allowed. 
Separate, completely enclosed smoking rooms 
are allowed if they are separately ventilated 
to the outside and/or kept under negative air 
pressure in relation to the surrounding areas. 
Given the difficulty of meeting the very strict 
requirements delineated for such rooms, they 
appear to be a practical impossibility but 
no reliable empirical evidence is presently 
available to ascertain whether they have been 
constructed.
8 Policy adopted but not implemented by 
31 December 2018.
st Change in POWEr indicator group, up or down, 
between 2016 and 2018. Some 2016 data 
were revised in 2018. 2018 grouping rules 
were applied to both years. 
PLEASE REFER TO TECHNICAL NOTE I FOR DEFINITIONS OF 
CATEGORIES
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Table 1.3 
Summary of 
MPOWER measures
. . . Data not reported/not available.
— Data not required/not applicable.
1  The manufacture and sale of tobacco 
products are banned. However 
all tobacco products imported for 
personal consumption shall show 
the country of origin and health 
warnings.
2018 INDICATOR AND COMPLIANCE  CHANGE SINCE 2016
COUNTRy
ADULT DAILy 
SMOKING 
PREvALENCE 
(2017)
M
MONITORING
P 
SMOKE-FREE 
POLICIES
O 
CESSATION
W
WARNINGS
E 
ADvERTISING 
BANS
R P 
SMOKE-FREE 
POLICIES
O 
CESSATION 
PROGRAMMES
W 
HEALTH
WARNINGS
E 
ADvERTISING 
BANS
R 
TAxATION
LINES REPRESENT 
LEVEL OF 
COMPLIANCE
HEALTH
WARNINGS
MASS  
MEDIA
LINES REPRESENT 
LEVEL OF 
COMPLIANCE
TAXATION
CIGARETTES LESS 
AFFORDABLE 
SINCE 2008
CHANGE IN POWER INDICATOR GROUP, UP OR DOWN, SINCE 2016
Bangladesh 19% IIIIII IIIIII 71.0% YES
Bhutan1 . . . IIIIIIIIII IIIIIIIIII — —
Democratic People's Republic 
of Korea 13% IIIII — 0.0% . . .
India 10% IIIIIII I IIIIIII 54.0% YES
Indonesia 28% IIII 58.5% ↔
Maldives . . . I IIII 68.7% YES
Myanmar 16% IIIII IIIIII 32.5% NO
Nepal 15% IIIII IIIIIIII 30.0% ↔
Sri Lanka 10% IIIIIIII IIIIIIIII 66.2% YES
Thailand 17% IIIII IIIIII 78.6% ↔ p
Timor-Leste 28% IIIIII IIIIIIII 21.8% YES p p q
ADULT DAILy SMOKING PREvALENCE: AGE-
STANDARDIZED* PREvALENCE RATES FOR ADULT DAILy 
SMOKERS OF TOBACCO (BOTH SExES COMBINED), 2017
. . . Estimates not available
30% or more 
From 20% to 29.9% 
From 15% to 19.9% 
Less than 15% 
*  The figures should be used strictly for the purpose of drawing 
comparisons across countries and must not be used to estimate 
absolute number of daily tobacco smokers in a country.
MONITORING: PREvALENCE DATA
No known data or no recent data or data 
that are not both recent and representative
recent and representative data for either 
adults or youth
recent and representative data for both 
adults and youth
recent, representative and periodic data for 
both adults and youth
SMOKE-FREE ENvIRONMENTS:
SMOKING BANS
Data not reported/not categorized
Complete absence of ban, or up to two public 
places completely smoke-free
Three to five public places completely smoke-free
Six to seven public places completely smoke-free
all public places completely smoke-free (or 
at least 90% of the population covered by 
complete subnational smoke-free legislation)
CESSATION PROGRAMMES:  
TREATMENT OF TOBACCO DEPENDENCE
Data not reported
None
NrT and/or some cessation services (neither 
cost-covered)
NrT and/or some cessation services (at least 
one of which is cost-covered)
National quit line, and both NrT and some 
cessation services cost-covered
HEALTH WARNINGS:  
HEALTH WARNINGS ON CIGARETTE PACKAGES
Data not reported
No warnings or small warnings
medium size warnings missing some or many 
appropriate characteristics Or large warnings 
missing many appropriate characteristics
medium size warnings with all appropriate 
characteristics Or large warnings missing 
some appropriate characteristics
Large warnings with all appropriate 
characteristics
MASS MEDIA:  
ANTI-TOBACCO CAMPAIGNS
Data not reported
No national campaign conducted between July 
2016 and June 2018 with duration of at least 
three weeks
National campaign conducted with one to four 
appropriate characteristics
National campaign conducted with five to 
six appropriate characteristics, or with seven 
characteristics excluding airing on television 
and/or radio
National campaign conducted with at least 
seven appropriate characteristics including 
airing on television and/or radio
ADvERTISING BANS:  
BANS ON ADvERTISING, PROMOTION AND SPONSORSHIP
Data not reported
Complete absence of ban, or ban that does not 
cover national television, radio and print media
Ban on national television, radio and print 
media only
Ban on national television, radio and print 
media as well as on some but not all other 
forms of direct and/or indirect advertising
Ban on all forms of direct and indirect 
advertising (or at least 90% of the population 
covered by subnational legislation completely 
banning tobacco advertising, promotion and 
sponsorship)
TAxATION: SHARE OF TOTAL TAxES IN THE RETAIL PRICE OF 
THE MOST WIDELy SOLD BRAND OF CIGARETTES
Data not reported
< 25% of retail price is tax 
≥25% and <50% of retail price is tax 
≥50% and <75% of retail price is tax 
≥75% of retail price is tax 
AFFORDABILITy OF CIGARETTES
YES
Cigarettes less affordable – per
capita GDP needed to buy 2000
cigarettes of the most sold brand
increased on average between 2008
and 2018
NO
Cigarettes more affordable – per
capita GDP needed to buy 2000
cigarettes of the most sold brand
declined on average between 2008
and 2018
↔
No trend change in affordability of cigarettes 
since 2008
. . . Insufficient data to conduct a trend analysis
COMPLIANCE: COMPLIANCE WITH BANS ON ADvERTISING, 
PROMOTION AND SPONSORSHIP, AND ADHERENCE TO 
SMOKE-FREE LAWS
||||||||||
|||||||||
||||||||
High compliance (8/10 to 10/10)
|||||||
||||||
|||||
||||
|||
moderate compliance (3/10 to 7/10)
||
| minimal compliance (0/10 to 2/10)
SyMBOLS LEGEND
I Country has one or more public places where 
designated smoking rooms (DSrs) are allowed. 
Separate, completely enclosed smoking rooms 
are allowed if they are separately ventilated 
to the outside and/or kept under negative air 
pressure in relation to the surrounding areas. 
Given the difficulty of meeting the very strict 
requirements delineated for such rooms, they 
appear to be a practical impossibility but 
no reliable empirical evidence is presently 
available to ascertain whether they have been 
constructed.
8 Policy adopted but not implemented by 
31 December 2018.
st Change in POWEr indicator group, up or down, 
between 2016 and 2018. Some 2016 data 
were revised in 2018. 2018 grouping rules 
were applied to both years. 
PLEASE REFER TO TECHNICAL NOTE I FOR DEFINITIONS OF 
CATEGORIES
150 151WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC, 2019 WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC, 2019
Europe
Table 1.4 
Summary of 
MPOWER measures
. . . Data not reported/not available.
— Data not required/not applicable.
1  The reported compliance is a 
calculated average of the assessment 
from two experts from the Federation 
of Bosnia and Herzegovina, and one 
expert from Republika Srpska.
2018 INDICATOR AND COMPLIANCE  CHANGE SINCE 2016
COUNTRy
ADULT DAILy 
SMOKING 
PREvALENCE 
(2017)
M
MONITORING
P 
SMOKE-FREE 
POLICIES
O 
CESSATION
W
WARNINGS
E 
ADvERTISING 
BANS
R P 
SMOKE-FREE 
POLICIES
O 
CESSATION 
PROGRAMMES
W 
HEALTH
WARNINGS
E 
ADvERTISING 
BANS
R 
TAxATION
LINES REPRESENT 
LEVEL OF 
COMPLIANCE
HEALTH
WARNINGS
MASS  
MEDIA
LINES REPRESENT 
LEVEL OF 
COMPLIANCE
TAXATION
CIGARETTES LESS 
AFFORDABLE 
SINCE 2008
CHANGE IN POWER INDICATOR GROUP, UP OR DOWN, SINCE 2016
Albania 23% IIIII IIIIIIIII 67.2% YES
Andorra 28% IIIIIII I — 79.3% . . . p
Armenia 25% III IIII 38.1% NO
Austria 23% IIIII IIIIIIIII 75.3% YES
Azerbaijan 17% III I IIIIIIII 35.3% ↔ p p
Belarus 24% — IIIIII 50.9% YES p
Belgium 21% IIIIIIII I IIIIIIIII 77.0% YES
Bosnia and Herzegovina1 32% — IIIIIII 83.8% YES
Bulgaria 31% IIIIIII IIIIIIII 83.6% ↔
Croatia 30% IIIIIIIII I IIIIIIIII 78.8% YES p p
Cyprus 30% . . . . . . 74.4% YES p q
Czechia 24% IIIIIIII IIIIIIIII 75.4% YES p
Denmark 15% IIIIIIII IIIIIII 74.1% ↔
Estonia 24% IIIIII IIIIIIII 79.4% YES q
Finland 15% IIIIIIIIII IIIIIIIIII 87.4% YES
France 28% IIII I IIIIIIIII 82.4% YES
Georgia 25% — IIIIIII 71.2% ↔ p p p
Germany 22% — IIIIIII 68.3% YES
Greece 31% IIIIIIIII IIIIIII 81.2% YES
Hungary 26% IIIIIIIIII IIIIIIIIII 72.3% YES
Iceland 11% IIIIIIIIII IIIIIIIIII 55.5% ↔
Ireland 20% IIIIIIIIII IIIIIIIII 78.4% ↔
Israel 21% . . . . . . 75.9% YES q
Italy 19% —	I IIIIIIII 76.0% YES
Kazakhstan 17% IIIIIIII IIIIIIII 52.4% YES p
Kyrgyzstan 21% II IIII 48.6% ↔
Latvia 31% IIIIIIIII IIIIIIIIII 80.0% ↔
Lithuania 22% IIIIIIII IIIIIIIIII 73.8% ↔ q
Luxembourg 17% IIIIIIIII I IIIIIIIIII 68.3% YES p p
Malta 20% IIIIIIII IIIIIIIIII 77.6% NO q
Monaco . . . . . .I IIII — . . . . . .
Montenegro . . . II IIIIII 81.4% YES q p
Netherlands 18% — IIIIIIIII 71.8% YES
North Macedonia . . . IIIIIII IIIIIIIII 81.3% ↔ p
Norway 13% IIIIIIIIII IIIIIIIIII 64.0% YES
Poland 23% … . . . 76.8% YES
Portugal 22% IIIIIII I IIIIII 71.7% YES
Republic of Moldova 21% IIIIIII IIIIIII 58.0% YES
Romania 23% IIIIIIII IIIIIIIII 68.6% ↔
Russian Federation 27% IIIIII IIIIIII 57.7% YES
San Marino . . . . . .  I . . . . . . . . . q
Serbia 33% IIII IIIIII 77.3% YES
Slovakia 24% IIIIIIII IIIIIIIIII 77.1% YES p
Slovenia 20% IIIIIIIII I IIIIIIIIII 79.2% YES p p
Spain 24% IIIIIIIII IIIIIIII 78.2% YES p
Sweden 10% — . . . 68.4% YES p
Switzerland 20% — IIIIII 60.3% YES
Tajikistan . . . IIII IIIIIII 42.3% ↔ p q p
Turkey 25% IIIIIII IIIIII 81.4% YES
Turkmenistan . . . IIIIIIII IIIIIIIIII 32.4% YES
Ukraine 23% IIIIIII IIIIIIII 74.7% YES q
United Kingdom of Great Britain 
and Northern Ireland 17% IIIIIIIIII . . . 79.4% YES
Uzbekistan 10% IIII IIIIIIII 44.7% ↔
ADULT DAILy SMOKING PREvALENCE: AGE-
STANDARDIZED* PREvALENCE RATES FOR ADULT DAILy 
SMOKERS OF TOBACCO (BOTH SExES COMBINED), 2017
. . . Estimates not available
30% or more 
From 20% to 29.9% 
From 15% to 19.9% 
Less than 15% 
*  The figures should be used strictly for the purpose of drawing 
comparisons across countries and must not be used to estimate 
absolute number of daily tobacco smokers in a country.
MONITORING: PREvALENCE DATA
No known data or no recent data or data 
that are not both recent and representative
recent and representative data for either 
adults or youth
recent and representative data for both 
adults and youth
recent, representative and periodic data for 
both adults and youth
SMOKE-FREE ENvIRONMENTS:
SMOKING BANS
Data not reported/not categorized
Complete absence of ban, or up to two public 
places completely smoke-free
Three to five public places completely smoke-free
Six to seven public places completely smoke-free
all public places completely smoke-free (or 
at least 90% of the population covered by 
complete subnational smoke-free legislation)
CESSATION PROGRAMMES:  
TREATMENT OF TOBACCO DEPENDENCE
Data not reported
None
NrT and/or some cessation services (neither 
cost-covered)
NrT and/or some cessation services (at least 
one of which is cost-covered)
National quit line, and both NrT and some 
cessation services cost-covered
HEALTH WARNINGS:  
HEALTH WARNINGS ON CIGARETTE PACKAGES
Data not reported
No warnings or small warnings
medium size warnings missing some or many 
appropriate characteristics Or large warnings 
missing many appropriate characteristics
medium size warnings with all appropriate 
characteristics Or large warnings missing 
some appropriate characteristics
Large warnings with all appropriate 
characteristics
MASS MEDIA:  
ANTI-TOBACCO CAMPAIGNS
Data not reported
No national campaign conducted between July 
2016 and June 2018 with duration of at least 
three weeks
National campaign conducted with one to four 
appropriate characteristics
National campaign conducted with five to 
six appropriate characteristics, or with seven 
characteristics excluding airing on television 
and/or radio
National campaign conducted with at least 
seven appropriate characteristics including 
airing on television and/or radio
ADvERTISING BANS:  
BANS ON ADvERTISING, PROMOTION AND SPONSORSHIP
Data not reported
Complete absence of ban, or ban that does not 
cover national television, radio and print media
Ban on national television, radio and print 
media only
Ban on national television, radio and print 
media as well as on some but not all other 
forms of direct and/or indirect advertising
Ban on all forms of direct and indirect 
advertising (or at least 90% of the population 
covered by subnational legislation completely 
banning tobacco advertising, promotion and 
sponsorship)
TAxATION: SHARE OF TOTAL TAxES IN THE RETAIL PRICE OF 
THE MOST WIDELy SOLD BRAND OF CIGARETTES
Data not reported
< 25% of retail price is tax 
≥25% and <50% of retail price is tax 
≥50% and <75% of retail price is tax 
≥75% of retail price is tax 
AFFORDABILITy OF CIGARETTES
YES
Cigarettes less affordable – per
capita GDP needed to buy 2000
cigarettes of the most sold brand
increased on average between 2008
and 2018
NO
Cigarettes more affordable – per
capita GDP needed to buy 2000
cigarettes of the most sold brand
declined on average between 2008
and 2018
↔
No trend change in affordability of cigarettes 
since 2008
. . . Insufficient data to conduct a trend analysis
COMPLIANCE: COMPLIANCE WITH BANS ON ADvERTISING, 
PROMOTION AND SPONSORSHIP, AND ADHERENCE TO 
SMOKE-FREE LAWS
||||||||||
|||||||||
||||||||
High compliance (8/10 to 10/10)
|||||||
||||||
|||||
||||
|||
moderate compliance (3/10 to 7/10)
||
| minimal compliance (0/10 to 2/10)
SyMBOLS LEGEND
I Country has one or more public places where 
designated smoking rooms (DSrs) are allowed. 
Separate, completely enclosed smoking rooms 
are allowed if they are separately ventilated 
to the outside and/or kept under negative air 
pressure in relation to the surrounding areas. 
Given the difficulty of meeting the very strict 
requirements delineated for such rooms, they 
appear to be a practical impossibility but 
no reliable empirical evidence is presently 
available to ascertain whether they have been 
constructed.
8 Policy adopted but not implemented by 
31 December 2018.
st Change in POWEr indicator group, up or down, 
between 2016 and 2018. Some 2016 data 
were revised in 2018. 2018 grouping rules 
were applied to both years. 
PLEASE REFER TO TECHNICAL NOTE I FOR DEFINITIONS OF 
CATEGORIES
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Table 1.5 
Summary of 
MPOWER measures
. . . Data not reported/not available.
— Data not required/not applicable.
< The term West Bank and Gaza Strip 
is used as a synonym to refer to 
the occupied Palestinian territory, 
including east Jerusalem.
1  The reported compliance is a 
calculated average of the assessment 
from experts from the West Bank.
2018 INDICATOR AND COMPLIANCE  CHANGE SINCE 2016
COUNTRy
ADULT DAILy 
SMOKING 
PREvALENCE 
(2017)
M
MONITORING
P 
SMOKE-FREE 
POLICIES
O 
CESSATION
W
WARNINGS
E 
ADvERTISING 
BANS
R P 
SMOKE-FREE 
POLICIES
O 
CESSATION 
PROGRAMMES
W 
HEALTH
WARNINGS
E 
ADvERTISING 
BANS
R 
TAxATION
LINES REPRESENT 
LEVEL OF 
COMPLIANCE
HEALTH
WARNINGS
MASS  
MEDIA
LINES REPRESENT 
LEVEL OF 
COMPLIANCE
TAXATION
CIGARETTES LESS 
AFFORDABLE 
SINCE 2008
CHANGE IN POWER INDICATOR GROUP, UP OR DOWN, SINCE 2016
Afghanistan . . . IIIIII 4.1% YES q
Bahrain 15% — I IIIIIIIII 64.5% YES p
Djibouti . . . . . . . . . . . . . . . q
Egypt 19% III IIIIIII 77.2% YES p
Iran (Islamic Republic of) 9% IIIIIIII IIIIIIIIII 21.7% YES q q
Iraq 16% III IIII 7.6% ↔
Jordan . . . III IIIII 80.5% YES
Kuwait 16% . . . . . . 21.2% YES
Lebanon 24% III IIIIII 45.6% ↔
Libya . . . III IIIIIIII 12.6% YES
Morocco 12% III IIIIII 71.2% NO
Oman 6% — IIIIIIII 25.0% YES q p
Pakistan 13% III 8 IIIII 56.4% ↔ p
Qatar 11% — IIIIIIIIII 40.0% YES p
Saudi Arabia 11% IIIIIII I 8 IIIIIII 68.1% YES p p p p
Somalia . . . — — 4.5% . . .
Sudan . . . — IIIIIIIII 69.8% ↔ p
Syrian Arab Republic . . . III IIIIIIIIII 41.8% . . .
Tunisia 20% — IIIIIIII 72.0% ↔
United Arab Emirates 12% IIIIIIIII I 
IIIIIIIIIII IIIIIIIII 73.5% YES p
West Bank and Gaza Strip <1 . . . III IIIIIIII 83.5% . . .
Yemen 13% IIIII IIIIII 50.6% YES
ADULT DAILy SMOKING PREvALENCE: AGE-
STANDARDIZED* PREvALENCE RATES FOR ADULT DAILy 
SMOKERS OF TOBACCO (BOTH SExES COMBINED), 2017
. . . Estimates not available
30% or more 
From 20% to 29.9% 
From 15% to 19.9% 
Less than 15% 
*  The figures should be used strictly for the purpose of drawing 
comparisons across countries and must not be used to estimate 
absolute number of daily tobacco smokers in a country.
MONITORING: PREvALENCE DATA
No known data or no recent data or data 
that are not both recent and representative
recent and representative data for either 
adults or youth
recent and representative data for both 
adults and youth
recent, representative and periodic data for 
both adults and youth
SMOKE-FREE ENvIRONMENTS:
SMOKING BANS
Data not reported/not categorized
Complete absence of ban, or up to two public 
places completely smoke-free
Three to five public places completely smoke-free
Six to seven public places completely smoke-free
all public places completely smoke-free (or 
at least 90% of the population covered by 
complete subnational smoke-free legislation)
CESSATION PROGRAMMES:  
TREATMENT OF TOBACCO DEPENDENCE
Data not reported
None
NrT and/or some cessation services (neither 
cost-covered)
NrT and/or some cessation services (at least 
one of which is cost-covered)
National quit line, and both NrT and some 
cessation services cost-covered
HEALTH WARNINGS:  
HEALTH WARNINGS ON CIGARETTE PACKAGES
Data not reported
No warnings or small warnings
medium size warnings missing some or many 
appropriate characteristics Or large warnings 
missing many appropriate characteristics
medium size warnings with all appropriate 
characteristics Or large warnings missing 
some appropriate characteristics
Large warnings with all appropriate 
characteristics
MASS MEDIA:  
ANTI-TOBACCO CAMPAIGNS
Data not reported
No national campaign conducted between July 
2016 and June 2018 with duration of at least 
three weeks
National campaign conducted with one to four 
appropriate characteristics
National campaign conducted with five to 
six appropriate characteristics, or with seven 
characteristics excluding airing on television 
and/or radio
National campaign conducted with at least 
seven appropriate characteristics including 
airing on television and/or radio
ADvERTISING BANS:  
BANS ON ADvERTISING, PROMOTION AND SPONSORSHIP
Data not reported
Complete absence of ban, or ban that does not 
cover national television, radio and print media
Ban on national television, radio and print 
media only
Ban on national television, radio and print 
media as well as on some but not all other 
forms of direct and/or indirect advertising
Ban on all forms of direct and indirect 
advertising (or at least 90% of the population 
covered by subnational legislation completely 
banning tobacco advertising, promotion and 
sponsorship)
TAxATION: SHARE OF TOTAL TAxES IN THE RETAIL PRICE OF 
THE MOST WIDELy SOLD BRAND OF CIGARETTES
Data not reported
< 25% of retail price is tax 
≥25% and <50% of retail price is tax 
≥50% and <75% of retail price is tax 
≥75% of retail price is tax 
AFFORDABILITy OF CIGARETTES
YES
Cigarettes less affordable – per
capita GDP needed to buy 2000
cigarettes of the most sold brand
increased on average between 2008
and 2018
NO
Cigarettes more affordable – per
capita GDP needed to buy 2000
cigarettes of the most sold brand
declined on average between 2008
and 2018
↔
No trend change in affordability of cigarettes 
since 2008
. . . Insufficient data to conduct a trend analysis
COMPLIANCE: COMPLIANCE WITH BANS ON ADvERTISING, 
PROMOTION AND SPONSORSHIP, AND ADHERENCE TO 
SMOKE-FREE LAWS
||||||||||
|||||||||
||||||||
High compliance (8/10 to 10/10)
|||||||
||||||
|||||
||||
|||
moderate compliance (3/10 to 7/10)
||
| minimal compliance (0/10 to 2/10)
SyMBOLS LEGEND
I Country has one or more public places where 
designated smoking rooms (DSrs) are allowed. 
Separate, completely enclosed smoking rooms 
are allowed if they are separately ventilated 
to the outside and/or kept under negative air 
pressure in relation to the surrounding areas. 
Given the difficulty of meeting the very strict 
requirements delineated for such rooms, they 
appear to be a practical impossibility but 
no reliable empirical evidence is presently 
available to ascertain whether they have been 
constructed.
8 Policy adopted but not implemented by 
31 December 2018.
st Change in POWEr indicator group, up or down, 
between 2016 and 2018. Some 2016 data 
were revised in 2018. 2018 grouping rules 
were applied to both years. 
PLEASE REFER TO TECHNICAL NOTE I FOR DEFINITIONS OF 
CATEGORIES
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Table 1.6 
Summary of 
MPOWER measures
. . . Data not reported/not available.
— Data not required/not applicable.
2018 INDICATOR AND COMPLIANCE  CHANGE SINCE 2016
COUNTRy
ADULT DAILy 
SMOKING 
PREvALENCE 
(2017)
M
MONITORING
P 
SMOKE-FREE 
POLICIES
O 
CESSATION
W
WARNINGS
E 
ADvERTISING 
BANS
R P 
SMOKE-FREE 
POLICIES
O 
CESSATION 
PROGRAMMES
W 
HEALTH
WARNINGS
E 
ADvERTISING 
BANS
R 
TAxATION
LINES REPRESENT 
LEVEL OF 
COMPLIANCE
HEALTH
WARNINGS
MASS  
MEDIA
LINES REPRESENT 
LEVEL OF 
COMPLIANCE
TAXATION
CIGARETTES LESS 
AFFORDABLE 
SINCE 2008
CHANGE IN POWER INDICATOR GROUP, UP OR DOWN, SINCE 2016
Australia 13% . . . IIIIIIIIII 77.5% YES p
Brunei Darussalam 12% IIIIIII IIIIIIIIII — — q
Cambodia 16% III IIIIIIIII 25.1% NO
China 22% IIIII IIIIIII 55.7% NO
Cook Islands 19% IIIIIIIIII IIIIIIIIII 70.3% YES
Fiji 17% IIIIIIII IIIIIIIII 42.1% YES
Japan 19% — 8 — 63.1% YES p
Kiribati 45% IIIII IIIIIIIII 41.7% NO
Lao People's Democratic 
Republic 24% IIIII IIIIIIII 18.8% NO
Malaysia 18% — IIIII 58.6% YES
Marshall Islands . . . IIIIIII IIIIIIIIII 54.1% NO
Micronesia (Federated States of) . . . IIIIIIII — 48.6% YES q
Mongolia 22% IIIII IIIIIIII 47.4% ↔ q
Nauru 38% . . . . . . 48.3% YES q
New Zealand 14% IIIIIIIIII IIIIIIIIII 82.2% YES p
Niue . . . — 8 8 — 8 87.7% . . . p p p
Palau 15% IIIIIII IIIIIIIII 73.0% ↔
Papua New Guinea . . . . . . . . . 54.2% ↔ p p p
Philippines 19% IIIII IIIII 71.3% YES
Republic of Korea 21% IIIIIIII . . . 73.8% ↔
Samoa 23% III IIIIIIIII 49.5% YES q
Singapore 13% IIIIIIII I IIIIIIIIII 67.1% NO
Solomon Islands 30% IIIIIIIIII 34.1% ↔
Tonga 26% IIIIIII IIIIIIIIII 62.4% YES
Tuvalu 30% IIIIIII IIIIIIII 29.5% ↔ q q
Vanuatu 13% — IIIIIIIII 58.6% NO
Viet Nam . . . III IIIIIIII 36.7% NO p
ADULT DAILy SMOKING PREvALENCE: AGE-
STANDARDIZED* PREvALENCE RATES FOR ADULT DAILy 
SMOKERS OF TOBACCO (BOTH SExES COMBINED), 2017
. . . Estimates not available
30% or more 
From 20% to 29.9% 
From 15% to 19.9% 
Less than 15% 
*  The figures should be used strictly for the purpose of drawing 
comparisons across countries and must not be used to estimate 
absolute number of daily tobacco smokers in a country.
MONITORING: PREvALENCE DATA
No known data or no recent data or data 
that are not both recent and representative
recent and representative data for either 
adults or youth
recent and representative data for both 
adults and youth
recent, representative and periodic data for 
both adults and youth
SMOKE-FREE ENvIRONMENTS:
SMOKING BANS
Data not reported/not categorized
Complete absence of ban, or up to two public 
places completely smoke-free
Three to five public places completely smoke-free
Six to seven public places completely smoke-free
all public places completely smoke-free (or 
at least 90% of the population covered by 
complete subnational smoke-free legislation)
CESSATION PROGRAMMES:  
TREATMENT OF TOBACCO DEPENDENCE
Data not reported
None
NrT and/or some cessation services (neither 
cost-covered)
NrT and/or some cessation services (at least 
one of which is cost-covered)
National quit line, and both NrT and some 
cessation services cost-covered
HEALTH WARNINGS:  
HEALTH WARNINGS ON CIGARETTE PACKAGES
Data not reported
No warnings or small warnings
medium size warnings missing some or many 
appropriate characteristics Or large warnings 
missing many appropriate characteristics
medium size warnings with all appropriate 
characteristics Or large warnings missing 
some appropriate characteristics
Large warnings with all appropriate 
characteristics
MASS MEDIA:  
ANTI-TOBACCO CAMPAIGNS
Data not reported
No national campaign conducted between July 
2016 and June 2018 with duration of at least 
three weeks
National campaign conducted with one to four 
appropriate characteristics
National campaign conducted with five to 
six appropriate characteristics, or with seven 
characteristics excluding airing on television 
and/or radio
National campaign conducted with at least 
seven appropriate characteristics including 
airing on television and/or radio
ADvERTISING BANS:  
BANS ON ADvERTISING, PROMOTION AND SPONSORSHIP
Data not reported
Complete absence of ban, or ban that does not 
cover national television, radio and print media
Ban on national television, radio and print 
media only
Ban on national television, radio and print 
media as well as on some but not all other 
forms of direct and/or indirect advertising
Ban on all forms of direct and indirect 
advertising (or at least 90% of the population 
covered by subnational legislation completely 
banning tobacco advertising, promotion and 
sponsorship)
TAxATION: SHARE OF TOTAL TAxES IN THE RETAIL PRICE OF 
THE MOST WIDELy SOLD BRAND OF CIGARETTES
Data not reported
< 25% of retail price is tax 
≥25% and <50% of retail price is tax 
≥50% and <75% of retail price is tax 
≥75% of retail price is tax 
AFFORDABILITy OF CIGARETTES
YES
Cigarettes less affordable – per
capita GDP needed to buy 2000
cigarettes of the most sold brand
increased on average between 2008
and 2018
NO
Cigarettes more affordable – per
capita GDP needed to buy 2000
cigarettes of the most sold brand
declined on average between 2008
and 2018
↔
No trend change in affordability of cigarettes 
since 2008
. . . Insufficient data to conduct a trend analysis
COMPLIANCE: COMPLIANCE WITH BANS ON ADvERTISING, 
PROMOTION AND SPONSORSHIP, AND ADHERENCE TO 
SMOKE-FREE LAWS
||||||||||
|||||||||
||||||||
High compliance (8/10 to 10/10)
|||||||
||||||
|||||
||||
|||
moderate compliance (3/10 to 7/10)
||
| minimal compliance (0/10 to 2/10)
SyMBOLS LEGEND
I Country has one or more public places where 
designated smoking rooms (DSrs) are allowed. 
Separate, completely enclosed smoking rooms 
are allowed if they are separately ventilated 
to the outside and/or kept under negative air 
pressure in relation to the surrounding areas. 
Given the difficulty of meeting the very strict 
requirements delineated for such rooms, they 
appear to be a practical impossibility but 
no reliable empirical evidence is presently 
available to ascertain whether they have been 
constructed.
8 Policy adopted but not implemented by 
31 December 2018.
st Change in POWEr indicator group, up or down, 
between 2016 and 2018. Some 2016 data 
were revised in 2018. 2018 grouping rules 
were applied to both years. 
PLEASE REFER TO TECHNICAL NOTE I FOR DEFINITIONS OF 
CATEGORIES
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Appendix II provides detailed 
information on tobacco dependence 
treatment availability in WHO Member 
States for each WHO region. Data in the 
appendix were provided by Member 
States and were reviewed by WHO. 
The following data are reported in this 
appendix:
The available support for 
the treatment of tobacco 
dependence:
l	 The existence of a national toll-free 
quit line
l	 The existence of smoking cessation 
support in health facilities and 
other settings, and whether it is 
provided as a cost-covered service
l	 The availability of nicotine 
replacement therapy and whether it 
is cost-covered
TOBACCO DEPENDENCE TREATMENTAppendix ii: 
Policies and guidelines: The 
availability of national policies and 
clinical guidelines on tobacco cessation 
Integrating cessation into other 
tobacco control approaches: The 
integration of national toll-free quit 
lines into mass media campaigns and 
tobacco-related health warnings
structural capacity: The existence of 
regular training programmes in tobacco 
cessation for primary care providers and 
the routine recording of tobacco use 
status in medical records
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Africa
COUNTRy NATIONAL 
TOLL-FREE 
qUIT LINE
NICOTINE REPLACEMENT THERAPy
PLACE AvAILABLE§ COST-COvERED INCLUDED IN
ESSENTIAL MEDICINES 
LIST
AvAILABLE* COST-COvERED AvAILABLE*
COST-
COvERED AvAILABLE*
COST-
COvERED AvAILABLE*
COST-
COvERED AvAILABLE*
COST-
COvERED
Algeria No Pharmacy No Yes Yes in some No Yes in some No Yes in some No No — No —
Angola No Not available — — Yes in some Fully Yes in some Fully Yes in some Fully No — No —
Benin No Not available — No No — No — No — No — No —
Botswana No Pharmacy with Rx No . . . Yes in some Fully No — No — Yes in some No Yes in some No
Burkina Faso No Not available — No No — No — No — Yes in some . . . No —
Burundi No Not available — No No — No — No — No — No —
Cabo Verde No Not available — No No — No — No — Yes in some . . . Yes in some Partially
Cameroon Yes . . . No No No — No — Yes in some Partially No — Yes in some Partially
Central African Republic No Not available — No No — No — No — No — No —
Chad No . . . No No No — No — No — Yes in some No No —
Comoros No Not available — No No — No — Yes in some No . . . . . . Yes in some No
Congo No Pharmacy Partially No No — Yes in some No Yes in some No Yes in some No Yes in some No
Côte d'Ivoire Yes Pharmacy Partially No Yes in some No Yes in some No No — Yes in some No Yes in some No
Democratic Republic of the Congo No Pharmacy No No No — No — Yes in some No No — No —
Equatorial Guinea No Not available — . . . No — No — No — No — No —
Eritrea No Not available — No No — No — No — No — No —
Eswatini No Pharmacy with Rx Fully No No — No — No — No — No —
Ethiopia No . . . Partially Yes No — No — No — No — Yes in some Partially
Gabon No Pharmacy No No No — No — No — No — No —
Gambia No Not available — No No — No — No — No — . . . . . .
Ghana No Not available — No No — Yes in some Partially Yes in some No No — No —
Guinea No Not available — No No — No — No — No — No —
Guinea-Bissau No Not available — No No — No — No — No — No —
Kenya Yes Pharmacy No No No — Yes in some Partially No — Yes in some . . . Yes in some Partially
Lesotho No Pharmacy with Rx No No No — No — Yes in most Fully Yes in some No Yes in most Partially
Liberia No Not available — No Yes in some No No — Yes in some No No — No —
Madagascar No Pharmacy No No Yes in some No Yes in some No Yes in some No Yes in some No Yes in some No
Malawi No Not available — No No — No — No — No — No —
Mali No Not available — No Yes in some Partially Yes in some Partially Yes in some Partially No — No —
Mauritania No Not available — No No — No — No — No — No —
Mauritius No Pharmacy Fully No No — No — Yes in most No No — Yes in some Fully
Mozambique No Not available — . . . Yes in some Partially Yes in some Partially No — Yes in some . . . No —
Namibia No Pharmacy No . . . Yes in some Partially Yes in some No Yes in some No No — Yes in some Partially
Niger No Pharmacy No No No — No — No — No — No —
Nigeria No Pharmacy Partially No No — Yes in some Partially Yes in some Partially No — Yes in some Partially
Rwanda No Not available — No No — No — No — No — No —
Sao Tome and Principe No Not available — No No — No — No — No — No —
Senegal Yes Pharmacy with Rx Partially No Yes in some Partially No — Yes in some Partially Yes in some No No —
Seychelles No Pharmacy Fully No No — No — No — No — Yes in some Fully
Sierra Leone No Not available — No No — No — No — No — No —
South Africa No Pharmacy No Yes No — No — No — Yes in most No Yes in some Fully
South Sudan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Togo No Not available — No No — No — No — No — No —
Uganda No Pharmacy No No No — No — No — No — Yes in most No
United Republic of Tanzania No Not available — No No — No — No — Yes in some No No —
Zambia No Pharmacy with Rx Partially No Yes in some Fully Yes in some Fully Yes in some Fully Yes in some No No —
Zimbabwe No Pharmacy with Rx No No No — No — Yes in some Partially No — Yes in some . . .
Table 2.1.1 
Support for 
treatment 
of tobacco 
dependence 
in Africa
§ “Pharmacy with Rx” means that a  
prescription is required.
* “Most” means in more than half. 
“Some” means in less than half. 
“No” means in none at all.
. . . Data not reported/not available.
 — Data not required/not applicable.
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The Americas
COUNTRy NATIONAL 
TOLL-FREE 
qUIT LINE
NICOTINE REPLACEMENT THERAPy
PLACE AvAILABLE§ COST-COvERED INCLUDED IN
ESSENTIAL MEDICINES 
LIST
AvAILABLE* COST-COvERED AvAILABLE*
COST-
COvERED AvAILABLE*
COST-
COvERED AvAILABLE*
COST-
COvERED AvAILABLE*
COST-
COvERED
Antigua and Barbuda No Pharmacy No No No — No — Yes in some No No — No —
Argentina Yes Pharmacy No No Yes in most Fully Yes in most Fully Yes in some Partially Yes in some Partially No —
Bahamas No Pharmacy No No Yes in some Fully Yes in some Fully No — No — Yes in some Fully
Barbados No Pharmacy No Yes No — No — Yes in some No Yes in some No Yes in some Fully
Belize No Not available — No Yes in some Partially Yes in some No No — No — Yes in some Partially
Bolivia (Plurinational State of) No Not available — No No — No — No — No — No —
Brazil Yes Pharmacy Fully Yes Yes in some Fully Yes in some Fully No — Yes in some No No —
Canada Yes Pharmacy Partially No Yes in most Partially Yes in most Partially Yes in most Partially Yes in some No Yes in some Partially
Chile Yes Pharmacy No No No — No — No — No — Yes in some No
Colombia No Pharmacy Partially No Yes in some Partially Yes in some Partially Yes in some Partially No — Yes in some No
Costa Rica No Pharmacy Fully No Yes in some Fully Yes in most Fully Yes in some Fully Yes in some Fully Yes in some Partially
Cuba Yes Not available — No Yes in most Fully Yes in most Fully Yes in most Fully Yes in most Fully Yes in some Fully
Dominica No Not available — No No — No — No — No — No —
Dominican Republic No Pharmacy No No No — No — Yes in most No No — Yes in some No
Ecuador Yes Not available — No Yes in some Fully Yes in some Fully Yes in some Fully No — No —
El Salvador Yes Pharmacy with Rx Fully No No — No — No — No — Yes in some Fully
Grenada No Not available — No Yes in some Partially No — Yes in some No No — No —
Guatemala No Pharmacy No No No — Yes in some Partially Yes in some No No — Yes in some No
Guyana No . . . No Yes Yes in some Fully Yes in some Fully No — No — Yes in some Fully
Haiti No Not available — No No — No — No — No — No —
Honduras Yes Not available — No Yes in some Fully Yes in some Partially Yes in some Partially No — Yes in some Partially
Jamaica Yes Pharmacy with Rx Fully Yes Yes in most Fully Yes in most Fully Yes in some Partially Yes in some No Yes in some Partially
Mexico Yes Pharmacy Partially Yes Yes in most Fully Yes in some Partially Yes in some Partially Yes in some Partially Yes in some No
Nicaragua No Pharmacy No Yes No — No — No — No — No —
Panama No Pharmacy Fully Yes Yes in some Partially Yes in some Partially Yes in some Partially No — Yes in some Partially
Paraguay No Not available — Yes No — Yes in some Fully Yes in some Fully No — Yes in some Partially
Peru Yes Pharmacy with Rx No No No — Yes in some Fully No — No — No —
Saint Kitts and Nevis No Pharmacy No No No — No — No — No — No —
Saint Lucia No . . . No No No — No — No — No — Yes in some Partially
Saint Vincent and the Grenadines No Not available — No No — No — No — Yes in some . . . No —
Suriname No Pharmacy No Yes Yes in most Fully No — No — Yes in some No Yes in some No
Trinidad and Tobago No Pharmacy Fully Yes Yes in some Fully Yes in some Partially Yes in some No No — No —
United States of America Yes General store Partially No Yes in some Partially Yes in some Partially Yes in some Partially Yes in some Partially No —
Uruguay No Pharmacy Fully Yes Yes in most Fully Yes in most Fully Yes in some Fully Yes in some No Yes in some Fully
Venezuela (Bolivarian Republic of) No Pharmacy Fully No Yes in some Fully Yes in some Fully Yes in some Fully No — Yes in some Partially
Table 2.1.2 
Support for 
treatment 
of tobacco 
dependence in 
the Americas
§ “Pharmacy with Rx” means that a  
prescription is required.
* “Most” means in more than half. 
“Some” means in less than half. 
“No” means in none at all.
. . . Data not reported/not available.
 — Data not required/not applicable.
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COUNTRy NATIONAL 
TOLL-FREE 
qUIT LINE
NICOTINE REPLACEMENT THERAPy
PLACE AvAILABLE§ COST-COvERED INCLUDED IN
ESSENTIAL MEDICINES 
LIST
AvAILABLE* COST-COvERED AvAILABLE*
COST-
COvERED AvAILABLE*
COST-
COvERED AvAILABLE*
COST-
COvERED AvAILABLE*
COST-
COvERED
Bangladesh No Not available — No Yes in some No Yes in some No No — Yes in some No No —
Bhutan Yes Not available — . . . Yes in most Partially Yes in some Partially No — No — Yes in some No
Democratic People's Republic of Korea No . . . Partially . . . Yes in most Fully Yes in most Fully Yes in most Fully Yes in most Partially Yes in most Fully
India Yes General store Fully No Yes in some Fully Yes in some Fully Yes in some . . . Yes in some . . . Yes in some Fully
Indonesia Yes Pharmacy No No Yes in some Fully Yes in some Fully Yes in some No Yes in some No No —
Maldives No Pharmacy with Rx Fully Yes Yes in most Fully Yes in most Fully Yes in some Partially No — Yes in some Fully
Myanmar No Not available — No Yes in some Partially Yes in some Partially Yes in some Partially Yes in some No No —
Nepal No Not available — No Yes in some No Yes in some Fully No — No — No —
Sri Lanka Yes Not available — No No — No — Yes in most Fully Yes in some Partially Yes in some Partially
Thailand Yes Pharmacy No No Yes in most Fully Yes in most Fully Yes in some Fully Yes in most Partially Yes in some Fully
Timor-Leste Yes Not available — Yes Yes in some Partially Yes in some Partially Yes in some Fully No — No —
Table 2.1.3 
Support for 
treatment 
of tobacco 
dependence in 
South-East Asia
§ “Pharmacy with Rx” means that a  
prescription is required.
* “Most” means in more than half. 
“Some” means in less than half. 
“No” means in none at all.
. . . Data not reported/not available.
 — Data not required/not applicable.
South-East Asia
SMOKING CESSATION SUPPORT 
PRIMARy CARE FACILITIES HOSPITALS THE COMMUNITy OTHER SETTINGSOFFICES OF HEALTH 
PROFESSIONALS
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Europe
COUNTRy NATIONAL 
TOLL-FREE 
qUIT LINE
NICOTINE REPLACEMENT THERAPy
PLACE AvAILABLE§ COST-COvERED INCLUDED IN
ESSENTIAL MEDICINES 
LIST
AvAILABLE* COST-COvERED AvAILABLE*
COST-
COvERED AvAILABLE*
COST-
COvERED AvAILABLE*
COST-
COvERED AvAILABLE*
COST-
COvERED
Albania No Not available — No Yes in some Fully No — No — No — No —
Andorra No Pharmacy No No No — Yes in some Partially Yes in some Partially . . . . . . . . . . . .
Armenia No Pharmacy No No Yes in some Fully No — No — . . . . . . No —
Austria Yes Pharmacy No No Yes in some Partially Yes in some Partially Yes in some Partially Yes in some . . . Yes in some Partially
Azerbaijan Yes Not available — No No — No — No — No — Yes in some No
Belarus Yes Pharmacy No No Yes in most Partially Yes in most Partially Yes in some Partially No — No —
Belgium Yes Pharmacy No No Yes in some Partially Yes in some Partially Yes in some Partially No — Yes in some Partially
Bosnia and Herzegovina No Pharmacy No No Yes in most Fully No — No — No — Yes in some No
Bulgaria Yes Pharmacy No Yes Yes in some Partially No — Yes in some No Yes in some Partially Yes in some Fully
Croatia Yes Pharmacy No No Yes in some Fully Yes in some Fully No — Yes in some No Yes in some Partially
Cyprus No Pharmacy Fully Yes Yes in some Fully Yes in some Fully No — No — Yes in some Fully
Czechia Yes Pharmacy Partially — Yes in some Partially Yes in some Partially Yes in some Partially No — Yes in some Partially
Denmark Yes Pharmacy Partially . . . Yes in some No No — No — Yes in most Fully Yes in some Fully
Estonia Yes Pharmacy No No Yes in some Fully Yes in some Fully No — No — Yes in some Fully
Finland Yes General store No No Yes in most Partially Yes in most Partially Yes in some Partially Yes in some . . . Yes in some Partially
France No Pharmacy Partially No Yes in some Partially Yes in most Partially Yes in some Partially . . . . . . Yes in some Partially
Georgia Yes Pharmacy No — Yes in some Partially No — No — No — No —
Germany Yes Pharmacy No No Yes in some Partially Yes in some Partially Yes in some Partially Yes in some Partially Yes in some Partially
Greece No Pharmacy No No Yes in some Partially Yes in some Partially Yes in some Partially No — Yes in some Partially
Hungary Yes Pharmacy No No Yes in some Partially Yes in some Partially Yes in some Partially Yes in some . . . Yes in some Partially
Iceland Yes General store No Yes No — No — No — Yes in some . . . No —
Ireland Yes General store Partially Yes Yes in some Fully Yes in some Fully Yes in some Fully Yes in some Partially Yes in some Partially
Israel No Pharmacy No No Yes in some Fully Yes in some Fully No — Yes in some Partially Yes in some Fully
Italy Yes Pharmacy No No Yes in some Fully Yes in some Partially Yes in some Partially Yes in some No Yes in some Partially
Kazakhstan No Pharmacy No No Yes in some Fully No — Yes in some No Yes in some No Yes in some No
Kyrgyzstan Yes Not available — No Yes in most Partially No — Yes in most Partially Yes in some No Yes in some Partially
Latvia Yes Pharmacy No Yes Yes in some Partially Yes in some Partially Yes in some Partially Yes in some No Yes in some Partially
Lithuania No Pharmacy No Yes Yes in some Fully No — No — . . . . . . Yes in some No
Luxembourg Yes Pharmacy Partially Yes Yes in some Partially Yes in some Partially Yes in some Partially . . . . . . Yes in some Partially
Malta Yes Pharmacy No No Yes in some Fully Yes in some Fully No — Yes in some Fully No —
Monaco No Pharmacy Fully . . . . . . . . . Yes in most Partially Yes in most Partially . . . . . . . . . . . .
Montenegro No Not available — No No — No — No — No — No —
Netherlands Yes Pharmacy Fully Yes Yes in most Fully Yes in most Fully Yes in most Fully Yes in some Partially Yes in some Partially
North Macedonia No Pharmacy No No No — Yes in some Fully Yes in some Fully No — Yes in some Fully
Norway No General store No No Yes in some Partially Yes in some Fully Yes in some Fully Yes in some No Yes in some Partially
Poland Yes Pharmacy No No Yes in some Partially No — Yes in some Partially Yes in some No Yes in some Partially
Portugal No Not available — No Yes in some Fully Yes in some Fully No — Yes in some Partially Yes in some Partially
Republic of Moldova Yes Not available — No Yes in some Fully No — No — . . . . . . Yes in some Partially
Romania Yes Pharmacy No No Yes in some No Yes in some No Yes in some Partially Yes in some No Yes in some Partially
Russian Federation Yes Not available — Yes Yes in some Fully No — No — No — No —
San Marino No Not available — No No — No — No — . . . . . . No —
Serbia No Pharmacy No No Yes in some Fully Yes in some Fully Yes in some Fully No — Yes in some Partially
Slovakia Yes Pharmacy Partially No No — No — Yes in some Partially No — Yes in some Fully
Slovenia Yes Pharmacy No Yes Yes in some Fully No — No — Yes in some Partially Yes in some Fully
Spain No Pharmacy No No Yes in some Fully Yes in some Fully Yes in some Fully Yes in some Partially Yes in some Partially
Sweden Yes General store Partially Yes Yes in most Partially Yes in most Partially Yes in some Partially No — Yes in some Partially
Switzerland Yes Pharmacy No No Yes in some Partially Yes in some No Yes in most Partially Yes in some No . . . . . .
Tajikistan No Not available — Yes No — No — No — . . . . . . No —
Turkey Yes Pharmacy Fully Yes Yes in some Fully Yes in some Fully No — Yes in some Partially Yes in some Partially
Turkmenistan Yes Pharmacy No Yes Yes in most Fully Yes in some Fully Yes in most Fully No — Yes in some Fully
Ukraine Yes Pharmacy No No Yes in some No No — No — No — No —
United Kingdom of Great Britain and 
Northern Ireland No General store Partially . . . Yes in most Fully Yes in most Fully Yes in most Fully Yes in most Fully Yes in some Fully
Uzbekistan No Pharmacy No No Yes in some Partially Yes in some Partially No — No — No —
Table 2.1.4 
Support for 
treatment 
of tobacco 
dependence in 
Europe
§ “Pharmacy with Rx” means that a  
prescription is required.
* “Most” means in more than half. 
“Some” means in less than half. 
“No” means in none at all.
. . . Data not reported/not available.
 — Data not required/not applicable.
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Eastern Mediterranean
COUNTRy NATIONAL 
TOLL-FREE 
qUIT LINE
NICOTINE REPLACEMENT THERAPy
PLACE AvAILABLE§ COST-COvERED INCLUDED IN
ESSENTIAL MEDICINES 
LIST
AvAILABLE* COST-COvERED AvAILABLE*
COST-
COvERED AvAILABLE*
COST-
COvERED AvAILABLE*
COST-
COvERED AvAILABLE*
COST-
COvERED
Afghanistan No Pharmacy No No Yes in some No No — No — No — No —
Bahrain No Pharmacy Fully Yes Yes in some Fully Yes in some Fully No — No — No —
Djibouti No Not available — No No — No — No — No — No —
Egypt Yes Not available — No No — No — No — No — Yes in some Partially
Iran (Islamic Republic of) Yes Pharmacy No Yes Yes in some Partially Yes in some Partially Yes in some No Yes in some No Yes in some No
Iraq No Pharmacy Partially Yes Yes in some Partially No — No — No — No —
Jordan No Pharmacy Fully No Yes in some Fully Yes in some Partially Yes in some Partially Yes in some Partially Yes in some Partially
Kuwait Yes Pharmacy Fully Yes Yes in some Fully No — No — Yes in most Partially Yes in some Fully
Lebanon No Not available — No Yes in some Partially No — No — Yes in some Partially No —
Libya No Not available — No Yes in some Partially No — No — No — Yes in some Partially
Morocco No Pharmacy with Rx No No Yes in most No Yes in some No Yes in some No No — No —
Oman No Pharmacy No No No — No — No — No — No —
Pakistan No . . . No No No — No — No — Yes in some Partially Yes in some Partially
Qatar No Pharmacy with Rx Fully Yes Yes in some Fully Yes in some Fully Yes in some . . . No — Yes in some Partially
Saudi Arabia Yes Pharmacy Fully Yes Yes in most Fully Yes in some Fully No — Yes in most No Yes in some Fully
Somalia No Not available — No No — No — No — No — No —
Sudan No Not available — No Yes in some No No — No — No — No —
Syrian Arab Republic No Not available — No Yes in most Partially Yes in most Partially Yes in most Partially No — No —
Tunisia No Pharmacy with Rx Fully No Yes in most Partially Yes in most Partially Yes in some Partially No — Yes in some Partially
United Arab Emirates Yes Pharmacy Partially . . . Yes in some Partially No — Yes in some . . . Yes in some Partially Yes in some Fully
West Bank and Gaza Strip < No Pharmacy No No Yes in some No Yes in some No Yes in some No Yes in some No Yes in some No
Yemen No Not available — No No — No — No — Yes in some No No —
Table 2.1.5 
Support for 
treatment 
of tobacco 
dependence 
in the Eastern 
Mediterranean
§ “Pharmacy with Rx” means that a  
prescription is required.
* “Most” means in more than half. 
“Some” means in less than half. 
“No” means in none at all.
. . . Data not reported/not available.
 — Data not required/not applicable.
<  The term West Bank and Gaza Strip 
is used as a synonym to refer to 
the occupied Palestinian territory, 
including east Jerusalem.
SMOKING CESSATION SUPPORT 
PRIMARy CARE FACILITIES HOSPITALS THE COMMUNITy OTHER SETTINGSOFFICES OF HEALTH 
PROFESSIONALS
168 169WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC, 2019 WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC, 2019
Western Pacific
COUNTRy NATIONAL 
TOLL-FREE 
qUIT LINE
NICOTINE REPLACEMENT THERAPy
PLACE AvAILABLE§ COST-COvERED INCLUDED IN
ESSENTIAL MEDICINES 
LIST
AvAILABLE* COST-COvERED AvAILABLE*
COST-
COvERED AvAILABLE*
COST-
COvERED AvAILABLE*
COST-
COvERED AvAILABLE*
COST-
COvERED
Australia Yes General store Partially Yes Yes in most Partially Yes in most Partially Yes in most Partially Yes in some . . . Yes in some Partially
Brunei Darussalam No Pharmacy Fully Yes Yes in some Fully Yes in some Fully No — Yes in some Fully No —
Cambodia No Not available — No No — No — No — Yes in some No No —
China No Not available — No Yes in some Partially Yes in some Partially Yes in some Partially Yes in some No Yes in some Partially
Cook Islands No Pharmacy Fully No Yes in most Fully Yes in most Fully No — Yes in most Partially No —
Fiji No Pharmacy No No Yes in some Fully Yes in some Fully No — No — No —
Japan No Pharmacy Partially Yes Yes in some Partially Yes in some Partially No — Yes in some Partially No —
Kiribati No Not available — No Yes in most Fully Yes in some Fully No — No — No —
Lao People's Democratic Republic No Not available — No No — No — No — No — No —
Malaysia No Pharmacy Fully Yes Yes in some Fully Yes in some Fully Yes in some Fully Yes in some No No —
Marshall Islands No Pharmacy Partially Yes No — No — No — No — No —
Micronesia (Federated States of) Yes . . . No No Yes in most Fully No — Yes in some Fully Yes in some No Yes in some No
Mongolia No Pharmacy Partially Yes Yes in some Partially Yes in some No No — No — No —
Nauru No Not available — No No — Yes in some No No — No — No —
New Zealand Yes General store Fully Yes Yes in most Partially Yes in most Fully Yes in most Partially Yes in most Partially Yes in some Fully
Niue No Pharmacy Fully No No — No — No — No — No —
Palau No General store Partially No Yes in some Fully Yes in some Fully No — No — No —
Papua New Guinea No Pharmacy No No No — No — No — No — No —
Philippines No Pharmacy with Rx No Yes Yes in some Partially Yes in some Partially Yes in some No No — Yes in some Fully
Republic of Korea Yes Pharmacy Partially No Yes in some Fully Yes in some Fully Yes in some Fully . . . . . . Yes in most Fully
Samoa No Pharmacy No No No — No — No — Yes in some Fully No —
Singapore Yes Pharmacy Partially No Yes in most Partially Yes in most Partially Yes in some Partially Yes in some Partially Yes in some Partially
Solomon Islands No . . . No No Yes in some Fully No — No — No — No —
Tonga Yes Pharmacy No No Yes in most Fully Yes in some Fully No — No — No —
Tuvalu No Not available — No No — No — No — Yes in some No No —
Vanuatu No Pharmacy No Yes No — No — No — No — No —
Viet Nam Yes Pharmacy No No Yes in some Partially Yes in some Partially No — No — No —
Table 2.1.6 
Support for 
treatment 
of tobacco 
dependence in 
the Western Pacific
§ “Pharmacy with Rx” means that a  
prescription is required.
* “Most” means in more than half. 
“Some” means in less than half. 
“No” means in none at all.
. . . Data not reported/not available.
 — Data not required/not applicable.
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Africa
Table 2.2.1 
Tobacco cessation 
support, 
supplementary 
information in 
Africa
COUNTRy THE COUNTRy HAS A NATIONAL 
TOBACCO CESSATION STRATEGy
THE COUNTRy HAS NATIONAL TOBACCO 
CESSATION CLINICAL GUIDELINES
TOBACCO CESSATION IS INCLUDED 
IN AT LEAST ONE NATIONAL DISEASE 
SPECIFIC TREATMENT GUIDELINE
TOBACCO USE STATUS OF PATIENTS IS 
ROUTINELy RECORDED ON MEDICAL 
RECORDS
NATIONAL TOLL-FREE qUIT LINES ARE 
INCLUDED ON HEALTH WARNINGS OR 
MASS MEDIA CAMPAIGNS
TRAINING IN TOBACCO CESSATION IS 
INCLUDED IN HEALTH CARE DEGREE 
CURRICULA OR PRIMARy CARE 
PROvIDERS ARE REGULARLy TRAINED 
IN BRIEF TOBACCO INTERvENTIONS
Algeria Yes Yes Yes No No No
Angola . . . . . . . . . . . . . . . . . .
Benin No Yes Yes No No No
Botswana No No Yes No No No
Burkina Faso No No No No No No
Burundi No No Yes No No No
Cabo Verde No No Yes No No No
Cameroon No No No No No No
Central African Republic No No No No No Yes
Chad No No No No No No
Comoros No No No No No No
Congo No No Yes No No No
Côte d'Ivoire Yes Yes No No No No
Democratic Republic of the Congo No No No No No No
Equatorial Guinea . . . . . . . . . . . . . . . . . .
Eritrea No No Yes No No No
Eswatini No No No No No No
Ethiopia Yes Yes Yes No No No
Gabon No No No No No No
Gambia No Yes Yes No No No
Ghana Yes Yes Yes No No No
Guinea No Yes Yes No No No
Guinea-Bissau No No No No No No
Kenya Yes Yes No Yes No No
Lesotho No No No No No No
Liberia No No No No No No
Madagascar No Yes Yes No No No
Malawi No No No No No No
Mali No No Yes No No No
Mauritania No No No No No No
Mauritius Yes No Yes No No No
Mozambique No No No No No No
Namibia Yes No Yes No No No
Niger No No No No No No
Nigeria No No No Yes No No
Rwanda No No Yes No No No
Sao Tome and Principe No No No No No No
Senegal No No Yes No No No
Seychelles No No Yes Yes No No
Sierra Leone No No No No No No
South Africa . . . . . . . . . . . . . . . . . .
South Sudan No No No No No No
Togo Yes Yes Yes No No No
Uganda No Yes Yes No No No
United Republic of Tanzania No No No No No No
Zambia No No No No No No
Zimbabwe No No Yes No No No
. . . Data not reported/not available. 
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The Americas
Table 2.2.2 
Tobacco cessation 
support, 
supplementary 
information in 
the Americas
. . . Data not reported/not available. 
COUNTRy THE COUNTRy HAS A NATIONAL 
TOBACCO CESSATION STRATEGy
THE COUNTRy HAS NATIONAL TOBACCO 
CESSATION CLINICAL GUIDELINES
TOBACCO CESSATION IS INCLUDED 
IN AT LEAST ONE NATIONAL DISEASE 
SPECIFIC TREATMENT GUIDELINE
TOBACCO USE STATUS OF PATIENTS IS 
ROUTINELy RECORDED ON MEDICAL 
RECORDS
NATIONAL TOLL-FREE qUIT LINES ARE 
INCLUDED ON HEALTH WARNINGS OR 
MASS MEDIA CAMPAIGNS
TRAINING IN TOBACCO CESSATION IS 
INCLUDED IN HEALTH CARE DEGREE 
CURRICULA OR PRIMARy CARE 
PROvIDERS ARE REGULARLy TRAINED 
IN BRIEF TOBACCO INTERvENTIONS
Antigua and Barbuda No No Yes No No No
Argentina No Yes Yes No Yes Yes
Bahamas . . . . . . . . . . . . . . . . . .
Barbados No No Yes No No No
Belize No No Yes No No No
Bolivia (Plurinational State of) No No No No No No
Brazil Yes Yes Yes No Yes No
Canada No Yes Yes No Yes Yes
Chile No Yes Yes No No Yes
Colombia Yes No Yes No No Yes
Costa Rica No Yes Yes Yes No Yes
Cuba Yes Yes Yes Yes No Yes
Dominica No No Yes No No No
Dominican Republic No No Yes No No No
Ecuador No Yes Yes No Yes Yes
El Salvador No No Yes No No No
Grenada No No Yes No No No
Guatemala No Yes Yes No No No
Guyana No Yes Yes No No No
Haiti No No No No No No
Honduras Yes Yes Yes Yes No No
Jamaica No Yes Yes No No No
Mexico Yes Yes Yes Yes Yes No
Nicaragua No No Yes No No No
Panama Yes Yes Yes Yes No No
Paraguay No No Yes No No No
Peru No No Yes No No No
Saint Kitts and Nevis No No Yes No No No
Saint Lucia No No Yes No No No
Saint Vincent and the Grenadines No No No No No No
Suriname No No Yes No No No
Trinidad and Tobago Yes No Yes No No No
United States of America Yes Yes Yes No Yes Yes
Uruguay Yes Yes Yes Yes No Yes
Venezuela (Bolivarian Republic of) Yes No No No No No
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Table 2.2.3 
Tobacco cessation 
support, 
supplementary 
information in 
South-East Asia
South-East Asia
COUNTRy THE COUNTRy HAS A NATIONAL 
TOBACCO CESSATION STRATEGy
THE COUNTRy HAS NATIONAL TOBACCO 
CESSATION CLINICAL GUIDELINES
TOBACCO CESSATION IS INCLUDED 
IN AT LEAST ONE NATIONAL DISEASE 
SPECIFIC TREATMENT GUIDELINE
TOBACCO USE STATUS OF PATIENTS IS 
ROUTINELy RECORDED ON MEDICAL 
RECORDS
NATIONAL TOLL-FREE qUIT LINES ARE 
INCLUDED ON HEALTH WARNINGS OR 
MASS MEDIA CAMPAIGNS
TRAINING IN TOBACCO CESSATION IS 
INCLUDED IN HEALTH CARE DEGREE 
CURRICULA OR PRIMARy CARE 
PROvIDERS ARE REGULARLy TRAINED 
IN BRIEF TOBACCO INTERvENTIONS
Bangladesh No No Yes No No No
Bhutan No Yes Yes Yes No No
Democratic People's Republic of Korea No Yes Yes No No No
India Yes Yes Yes No Yes Yes
Indonesia Yes Yes Yes No Yes Yes
Maldives No Yes No No No No
Myanmar Yes No No Yes No Yes
Nepal No No No No No No
Sri Lanka Yes No Yes No Yes No
Thailand Yes Yes Yes Yes Yes Yes
Timor-Leste No No No No No No
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. . . Data not reported/not available.
Europe
Table 2.2.4 
Tobacco cessation 
support, 
supplementary 
information in 
Europe
COUNTRy THE COUNTRy HAS A NATIONAL 
TOBACCO CESSATION STRATEGy
THE COUNTRy HAS NATIONAL TOBACCO 
CESSATION CLINICAL GUIDELINES
TOBACCO CESSATION IS INCLUDED 
IN AT LEAST ONE NATIONAL DISEASE 
SPECIFIC TREATMENT GUIDELINE
TOBACCO USE STATUS OF PATIENTS IS 
ROUTINELy RECORDED ON MEDICAL 
RECORDS
NATIONAL TOLL-FREE qUIT LINES ARE 
INCLUDED ON HEALTH WARNINGS OR 
MASS MEDIA CAMPAIGNS
TRAINING IN TOBACCO CESSATION IS 
INCLUDED IN HEALTH CARE DEGREE 
CURRICULA OR PRIMARy CARE 
PROvIDERS ARE REGULARLy TRAINED 
IN BRIEF TOBACCO INTERvENTIONS
Albania No No Yes No No No
Andorra No No Yes No No No
Armenia Yes Yes Yes No No No
Austria No No Yes No Yes Yes
Azerbaijan No Yes Yes Yes No No
Belarus No Yes Yes No Yes No
Belgium Yes Yes Yes No No Yes
Bosnia and Herzegovina . . . . . . . . . . . . . . . . . .
Bulgaria Yes Yes Yes Yes No Yes
Croatia No Yes Yes Yes Yes No
Cyprus Yes Yes Yes No No Yes
Czechia No Yes Yes Yes Yes No
Denmark No Yes Yes No Yes No
Estonia Yes Yes Yes Yes No No
Finland No Yes Yes No No No
France Yes Yes Yes Yes No Yes
Georgia Yes Yes Yes Yes Yes Yes
Germany No Yes Yes No Yes Yes
Greece Yes No Yes No No Yes
Hungary No Yes No Yes Yes Yes
Iceland No No No No Yes Yes
Ireland Yes No Yes No Yes Yes
Israel . . . . . . . . . . . . . . . . . .
Italy Yes Yes Yes No Yes No
Kazakhstan Yes Yes Yes Yes No No
Kyrgyzstan No Yes Yes No Yes No
Latvia Yes No Yes Yes Yes No
Lithuania No No Yes No No Yes
Luxembourg Yes Yes Yes No Yes No
Malta No No No No Yes Yes
Monaco No No No No No No
Montenegro No No Yes No No No
Netherlands Yes Yes Yes No Yes Yes
North Macedonia No No Yes Yes No No
Norway Yes Yes Yes No No No
Poland Yes No Yes No Yes Yes
Portugal Yes Yes Yes No No No
Republic of Moldova Yes No Yes Yes Yes No
Romania No No Yes No Yes Yes
Russian Federation No Yes Yes Yes Yes Yes
San Marino Yes No Yes No Yes No
Serbia No No Yes No No No
Slovakia Yes Yes No No Yes No
Slovenia Yes No No Yes Yes Yes
Spain Yes Yes Yes No No Yes
Sweden Yes Yes Yes No Yes Yes
Switzerland Yes Yes Yes No Yes Yes
Tajikistan No Yes Yes Yes No No
Turkey Yes Yes Yes No Yes No
Turkmenistan No Yes Yes No Yes No
Ukraine No Yes Yes No No No
United Kingdom of Great Britain and 
Northern Ireland Yes Yes Yes Yes No Yes
Uzbekistan No No Yes No No Yes
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. . . Data not reported/not available. 
< The term West Bank and Gaza Strip 
is used as a synonym to refer to 
the occupied Palestinian territory, 
including east Jerusalem.
Eastern Mediterranean
Table 2.2.5 
Tobacco cessation 
support, 
supplementary 
information 
in the Eastern 
Mediterranean
COUNTRy THE COUNTRy HAS A NATIONAL 
TOBACCO CESSATION STRATEGy
THE COUNTRy HAS NATIONAL TOBACCO 
CESSATION CLINICAL GUIDELINES
TOBACCO CESSATION IS INCLUDED 
IN AT LEAST ONE NATIONAL DISEASE 
SPECIFIC TREATMENT GUIDELINE
TOBACCO USE STATUS OF PATIENTS IS 
ROUTINELy RECORDED ON MEDICAL 
RECORDS
NATIONAL TOLL-FREE qUIT LINES ARE 
INCLUDED ON HEALTH WARNINGS OR 
MASS MEDIA CAMPAIGNS
TRAINING IN TOBACCO CESSATION IS 
INCLUDED IN HEALTH CARE DEGREE 
CURRICULA OR PRIMARy CARE 
PROvIDERS ARE REGULARLy TRAINED 
IN BRIEF TOBACCO INTERvENTIONS
Afghanistan Yes No No No No No
Bahrain Yes Yes Yes No No Yes
Djibouti . . . . . . . . . . . . . . . . . .
Egypt No Yes Yes No Yes No
Iran (Islamic Republic of) Yes Yes No Yes No Yes
Iraq Yes Yes Yes Yes No No
Jordan Yes No No No No No
Kuwait Yes Yes Yes Yes No No
Lebanon Yes No Yes No No No
Libya No No No No No No
Morocco Yes Yes Yes No No No
Oman Yes No Yes No No No
Pakistan No No No No No No
Qatar No Yes Yes No No Yes
Saudi Arabia Yes Yes Yes Yes No No
Somalia . . . . . . . . . . . . . . . . . .
Sudan No No No No No No
Syrian Arab Republic No No No No No Yes
Tunisia Yes Yes No No No Yes
United Arab Emirates Yes No Yes Yes Yes Yes
West Bank and Gaza Strip < Yes No Yes No No No
Yemen Yes No No No No No
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Table 2.2.6 
Tobacco cessation 
support, 
supplementary 
information in the 
Western Pacific
Western Pacific
COUNTRy THE COUNTRy HAS A NATIONAL 
TOBACCO CESSATION STRATEGy
THE COUNTRy HAS NATIONAL TOBACCO 
CESSATION CLINICAL GUIDELINES
TOBACCO CESSATION IS INCLUDED 
IN AT LEAST ONE NATIONAL DISEASE 
SPECIFIC TREATMENT GUIDELINE
TOBACCO USE STATUS OF PATIENTS IS 
ROUTINELy RECORDED ON MEDICAL 
RECORDS
NATIONAL TOLL-FREE qUIT LINES ARE 
INCLUDED ON HEALTH WARNINGS OR 
MASS MEDIA CAMPAIGNS
TRAINING IN TOBACCO CESSATION IS 
INCLUDED IN HEALTH CARE DEGREE 
CURRICULA OR PRIMARy CARE 
PROvIDERS ARE REGULARLy TRAINED 
IN BRIEF TOBACCO INTERvENTIONS
Australia Yes Yes Yes Yes Yes Yes
Brunei Darussalam No Yes Yes No No No
Cambodia Yes No No No No No
China Yes Yes Yes No No Yes
Cook Islands Yes Yes Yes No No No
Fiji No No Yes No No No
Japan No No No No No Yes
Kiribati No No Yes No No No
Lao People's Democratic Republic No No Yes No No No
Malaysia Yes Yes Yes No No No
Marshall Islands No No Yes No No No
Micronesia (Federated States of) No No Yes No No No
Mongolia No No Yes No No No
Nauru No No No No No No
New Zealand No Yes Yes Yes Yes Yes
Niue No No No No No No
Palau No No Yes No No No
Papua New Guinea Yes No Yes No No No
Philippines Yes Yes Yes No No No
Republic of Korea Yes No Yes No Yes Yes
Samoa No No No No No No
Singapore Yes Yes Yes No Yes No
Solomon Islands No No Yes No No No
Tonga No No Yes No Yes Yes
Tuvalu No No Yes No No No
Vanuatu Yes No Yes No No No
Viet Nam No Yes Yes Yes Yes No
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Appendix III provides information on 
the year in which respective countries 
attained the highest level of achievement 
for five of the MPOWER measures. Data 
are shown separately for each WHO 
region.
For Monitoring tobacco use the earliest 
year assessed is 2007. However, it is 
possible that while 2007 is reported as 
the year of highest achievement for some 
countries, they actually may have reached 
this level earlier.
yEAR OF HIGHEST lEvEl OF 
ACHIEvEMENT IN SElECTED TOBACCO 
CONTROl MEASURES 
Appendix iii:
Years of highest level achievement 
of the MPOWER measure Raise taxes 
on tobacco are not included in this 
appendix. The share of taxes in product 
price depends both on tax policy and 
on demand and supply factors that 
affect manufacturing and retail prices. 
Countries with tax increases might have 
seen the share of tax remain unchanged 
or even decline if the non-tax share of 
price rose at the same, or a higher rate, 
complicating the interpretation of the 
year of highest level of achievement. 
See Technical Note III for details on the 
calculation of tax shares.
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Note: an empty cell indicates that the population is not covered by the 
measure at the highest level of achievement.
8 Policy adopted but not implemented by 31 December 2018.
Table 3.1 
Year of highest level of achievement 
in selected tobacco control measures 
in Africa
Africa
COUNTRy yEAR THE HIGHEST LEvEL OF ACHIEvEMENT WAS ATTAINED
MONITOR TOBACCO USE PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO qUIT TOBACCO 
USE
WARN ABOUT THE DANGERS OF 
TOBACCO
ENFORCE BANS ON TOBACCO 
ADvERTISING, PROMOTION AND 
SPONSORSHIP
Algeria
Angola
Benin 2017 2017
Botswana
Burkina Faso 2010 2015
Burundi 2018
Cabo Verde
Cameroon 2018 8
Central African Republic
Chad 2010 2015 2010
Comoros
Congo 2012 2018
Côte d'Ivoire
Democratic Republic of the Congo 2018 8
Equatorial Guinea
Eritrea 2004
Eswatini
Ethiopia
Gabon
Gambia 2018 2018
Ghana 2012
Guinea 2012
Guinea-Bissau
Kenya 2007
Lesotho
Liberia
Madagascar 2013 2012 2003
Malawi
Mali
Mauritania
Mauritius 2008 2008
Mozambique
Namibia 2010 2013
Niger 2006
Nigeria 2015
Rwanda
Sao Tome and Principe
Senegal 2016 2016 2016
Seychelles 2009 2012 2009
Sierra Leone
South Africa
South Sudan
Togo 2012
Uganda 2015 2015
United Republic of Tanzania
Zambia
Zimbabwe
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Note: an empty cell indicates that the population is not covered by the 
measure at the highest level of achievement.
*  Or earlier year.
8	Policy adopted but not implemented by 31 December 2018.
Table 3.2 
Year of highest level of achievement 
in selected tobacco control measures 
in the Americas
The Americas
COUNTRy yEAR THE HIGHEST LEvEL OF ACHIEvEMENT WAS ATTAINED
MONITOR TOBACCO USE PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO qUIT TOBACCO 
USE
WARN ABOUT THE DANGERS OF 
TOBACCO
ENFORCE BANS ON TOBACCO 
ADvERTISING, PROMOTION AND 
SPONSORSHIP
Antigua and Barbuda 2018 2018
Argentina 2011 2012
Bahamas 2018
Barbados 2010 2017
Belize
Bolivia (Plurinational State of) 2009
Brazil 2015 2011 2002 2003 2011
Canada 2007* 2007 2008 2011
Chile 2007* 2013 2006
Colombia 2008 2009
Costa Rica 2007* 2012 2013
Cuba
Dominica
Dominican Republic
Ecuador 2016 2011 2012
El Salvador 2015 2016 2011
Grenada
Guatemala 2008
Guyana 2017 2018 8 2017
Haiti
Honduras 2010 2017
Jamaica 2013 2016 2013
Mexico 2013 2009
Nicaragua
Panama 2012 2008 2005 2008
Paraguay
Peru 2007* 2010 2011
Saint Kitts and Nevis
Saint Lucia 2017
Saint Vincent and the Grenadines
Suriname 2018 2013 2016 2013
Trinidad and Tobago 2009 2013 8
United States of America 2007* 2008
Uruguay 2007* 2005 2005 2014
Venezuela (Bolivarian Republic of) 2011 2004
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Note: an empty cell indicates that the population is not covered by the 
measure at the highest level of achievement.
*  Or earlier year.
Table 3.3 
Year of highest level of achievement 
in selected tobacco control measures 
in South-East Asia
South-East Asia
COUNTRy yEAR THE HIGHEST LEvEL OF ACHIEvEMENT WAS ATTAINED
MONITOR TOBACCO USE PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO qUIT TOBACCO 
USE
WARN ABOUT THE DANGERS OF 
TOBACCO
ENFORCE BANS ON TOBACCO 
ADvERTISING, PROMOTION AND 
SPONSORSHIP
Bangladesh 2014 2015
Bhutan 2014
Democratic People's Republic of Korea
India 2016 2016
Indonesia 2015
Maldives 2010
Myanmar 2015
Nepal 2011 2011 2014
Sri Lanka 2012
Thailand 2007* 2010 2005
Timor-Leste 2018
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Note: an empty cell indicates that the population is not covered by the 
measure at the highest level of achievement.
*  Or earlier year.
Table 3.4 
Year of highest level of achievement 
in selected tobacco control measures 
in Europe
Europe
COUNTRy yEAR THE HIGHEST LEvEL OF ACHIEvEMENT WAS ATTAINED
MONITOR TOBACCO USE PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO qUIT TOBACCO 
USE
WARN ABOUT THE DANGERS OF 
TOBACCO
ENFORCE BANS ON TOBACCO 
ADvERTISING, PROMOTION AND 
SPONSORSHIP
Albania 2006 2006
Andorra
Armenia 2007* 2016
Austria 2007* 2016
Azerbaijan 2016 2017
Belarus 2016
Belgium 2007* 2016
Bosnia and Herzegovina
Bulgaria 2007* 2012 2016
Croatia 2007* 2017
Cyprus 2017
Czechia 2007* 2018 2016
Denmark 2007* 2011 2016
Estonia 2007* 2016
Finland 2007* 2016
France 2007* 2016
Georgia 2007* 2018
Germany 2007* 2016
Greece 2007* 2010 2016
Hungary 2007* 2016
Iceland 2007*
Ireland 2007* 2004 2003 2016
Israel
Italy 2007* 2016
Kazakhstan 2007* 2014
Kyrgyzstan 2014
Latvia 2007* 2016
Lithuania 2007* 2016
Luxembourg 2007* 2016 2017
Malta 2007* 2010 2016
Monaco
Montenegro
Netherlands 2007* 2014 2016
North Macedonia 2008
Norway 2007* 2013
Poland 2007* 2016
Portugal 2007* 2015
Republic of Moldova 2013 2016 2016
Romania 2007* 2015 2016
Russian Federation 2007* 2013 2014 2013
San Marino
Serbia 2007*
Slovakia 2007* 2018 2016
Slovenia 2007* 2017 2017
Spain 2007* 2010 2017 2010
Sweden 2007* 2018 2016
Switzerland 2007*
Tajikistan 2018
Turkey 2008 2010 2012 2012
Turkmenistan 2000 2014
Ukraine 2007* 2009
United Kingdom of Great Britain and Northern Ireland 2007* 2006 2016
Uzbekistan
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Note: an empty cell indicates that the population is not covered by the 
measure at the highest level of achievement.
*   Or earlier year.
8 Policy adopted but not implemented by 31 December 2018.
<  The term West Bank and Gaza Strip is used as a synonym to refer to the 
occupied Palestinian territory, including east Jerusalem.
Table 3.5 
Year of highest level of achievement 
in selected tobacco control measures 
in the Eastern Mediterranean
Eastern Mediterranean
COUNTRy yEAR THE HIGHEST LEvEL OF ACHIEvEMENT WAS ATTAINED
MONITOR TOBACCO USE PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO qUIT TOBACCO 
USE
WARN ABOUT THE DANGERS OF 
TOBACCO
ENFORCE BANS ON TOBACCO 
ADvERTISING, PROMOTION AND 
SPONSORSHIP
Afghanistan 2015 2015
Bahrain 2011
Djibouti 2008 2007
Egypt 2007* 2010 2008
Iran (Islamic Republic of) 2007* 2007 2008 2007
Iraq
Jordan
Kuwait 2007* 2012 2016
Lebanon 2013 2011
Libya 2009 2009
Morocco
Oman
Pakistan 2014 2009 2017 8
Qatar 2014 2016
Saudi Arabia 2018 2017 8 2017
Somalia
Sudan
Syrian Arab Republic
Tunisia
United Arab Emirates 2008 2013
West Bank and Gaza Strip < 2011
Yemen 2013
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Note: an empty cell indicates that the population is not covered by the 
measure at the highest level of achievement.
*   Or earlier year.
8	Policy adopted but not implemented by 31 December 2018.
Table 3.6 
Year of highest level of achievement 
in selected tobacco control measures 
in the Western Pacific
Western Pacific
COUNTRy yEAR THE HIGHEST LEvEL OF ACHIEvEMENT WAS ATTAINED
MONITOR TOBACCO USE PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO qUIT TOBACCO 
USE
WARN ABOUT THE DANGERS OF 
TOBACCO
ENFORCE BANS ON TOBACCO 
ADvERTISING, PROMOTION AND 
SPONSORSHIP
Australia 2007* 2005 2011 2004
Brunei Darussalam 2014 2012 2007
Cambodia 2014 2016 2016
China
Cook Islands 2007*
Fiji 2013
Japan 2007*
Kiribati 2013
Lao People's Democratic Republic 2015 2016 2016
Malaysia 2012 2008
Marshall Islands 2006
Micronesia (Federated States of)
Mongolia 2007* 2012 2012
Nauru 2009
New Zealand 2007* 2003 2000 2007
Niue 2018 8 2018 8
Palau 2010
Papua New Guinea 2012
Philippines 2007* 2014
Republic of Korea 2007* 2006
Samoa 2013
Singapore 2007* 1999 2012
Solomon Islands 2013
Tonga
Tuvalu 2008
Vanuatu 2013 2008
Viet Nam 2014 2013
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Appendix IV provides information on 
whether the populations of the world’s 
100 biggest cities are covered by selected 
tobacco control measures at the highest 
level of achievement.
Cities are listed alphabetically. There 
are many ways to define geographically 
and measure the size of “a city”. For the 
purposes of this report, we focused on 
the jurisdictional boundaries of cities, 
since subnational laws will apply to 
populations within jurisdictions. Where a 
large “city” includes several jurisdictions 
or parts of jurisdictions, it is possible 
that not everyone in the entire “city” is 
covered by the same laws. We therefore 
use the list of cities and their populations 
published in the United Nations Statistics 
Division Demographic Yearbook, since 
these are defined jurisdictionally. Please 
refer to Table 8 at https://unstats.un.org/
unsd/demographic-social/products/dyb/
dyb_2016/ for the source data.
HIGHEST lEvEl OF ACHIEvEMENT 
IN SElECTED TOBACCO CONTROl 
MEASURES IN THE 100 BIGGEST CITIES 
IN THE WORlD 
Appendix iV:
A number of countries do not appear in 
Table 8 of the Demographic Yearbook 
because they did not report data.
Countries missing from the list because 
they did not report data, but large 
enough to potentially qualify for the 
100 biggest cities list are: Angola, Chad, 
Democratic Republic of the Congo, 
Nigeria, Sudan and Viet Nam.
Refer to Technical Note I for definitions 
of highest level of achievement.
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Table 4.1 
Highest level of achievement in 
selected tobacco control measures 
in the 100 biggest cities in the world
CITy * POPULATION (2016) COUNTRy
PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO qUIT 
TOBACCO USE
WARN ABOUT THE 
DANGERS OF TOBACCO
ENFORCE BANS ON 
TOBACCO ADvERTISING, 
PROMOTION AND 
SPONSORSHIP
RAISE TAxES ON 
TOBACCO
Abidjan 4 395 243 Côte d'Ivoire
Adana 2 183 167 N N N N N Turkey
Addis Ababa 2 979 086 N Ethiopia
Ahmedabad 5 633 927 N N India
Aleppo 4 450 000 Syrian Arab Republic
Alexandria 4 358 439 N N N Egypt
Algiers 2 712 944 Algeria
Amman 3 752 644 N N Jordan
Ankara 5 270 575 N N N N N Turkey
Antalya 2 288 456 N N N N N Turkey
Baku 2 215 034 N N Azerbaijan
Bandung 2 497 938 C Indonesia
Bangalore 8 495 492 N N India
Bangkok 8 305 218 N N Thailand
Beijing 19 610 000 N China
Belo Horizonte 2 513 451 N N N N N Brazil
Berlin 3 520 031 N Germany
Bogotá 7 980 001 N N N Colombia
Brasília 2 977 216 N N N N N Brazil
Brisbane 2 209 453 S N N N Australia
Buenos Aires 13 879 707 N N N Argentina
Bursa 2 842 547 N N N N N Turkey
Busan 3 388 631 N Republic of Korea
Cairo 7 248 671 N N N Egypt
Cali 2 394 925 N N N Colombia
Casablanca 3 352 399 Morocco
Chennai 4 646 732 N N India
Chicago 2 704 958 N United States of America
Chittagong 2 591 681 N Bangladesh
Daegu 2 449 667 N Republic of Korea
Damasus Rural 2 529 000 Syrian Arab Republic
Dar es Salaam 4 364 541 United Republic of Tanzania
Delhi 11 034 555 N N India
Dhaka 8 906 035 N Bangladesh
Douala 2 948 464 N Cameroon
Fortaleza 2 609 716 N N N N N Brazil
Giza 3 122 041 N N N Egypt
Guadalajara 4 853 425 N N Mexico
Guayaquil 2 531 371 N N Ecuador
Hong Kong SAR 7 336 600 C C C China, Hong Kong SAR
Houston 2 303 482 N United States of America
Hyderabad 6 993 262 S N N India
Incheon 2 914 455 N Republic of Korea
Istanbul 14 657 434 N N N N N Turkey
Izmir 4 168 415 N N N N N Turkey
Jaipur 3 046 163 N N India
Jakarta 10 374 235 N Indonesia
Jiddah 3 430 697 N N Saudi Arabia
Kabul 3 817 241 N N Afghanistan
Kanpur 2 768 057 N N India
Karachi 9 339 023 N N Pakistan
Kiev 2 803 716 N Ukraine
Kolkata 4 496 694 N N India
Konya 2 130 544 N N N N N Turkey
COvERAGE AT THE HIGHEST LEvEL OF ACHIEvEMENT
City’s population covered by national legislation or 
policy at the highest level of achievement
City’s population covered by state-level legislation or 
policy at the highest level of achievement
City’s population covered by city-level legislation or 
policy at the highest level of achievement
N
S
C
Notes: An empty cell indicates that the population in the respective city is 
not covered by the measure at the highest level of achievement.
Refer to Technical Note I for definitions of highest level of achievement of 
the respective measure.
* Only cities which appear among the top 100 cities sorted by 
population size, according to the United Nations Statistics Division 
Demographic Yearbook 2016 (available at: https://unstats.un.org/
unsd/demographic-social/products/dyb/documents/dyb2016/ 
table08.xls).
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Table 4.1 
Highest level of achievement in 
selected tobacco control measures 
in the 100 biggest cities in the world 
(continued)
COvERAGE AT THE HIGHEST LEvEL OF ACHIEvEMENT
City’s population covered by national legislation or 
policy at the highest level of achievement
City’s population covered by state-level legislation or 
policy at the highest level of achievement
City’s population covered by city-level legislation or 
policy at the highest level of achievement
N
S
C
CITy * POPULATION (2016) COUNTRy
PROTECT PEOPLE FROM 
TOBACCO SMOKE
OFFER HELP TO qUIT 
TOBACCO USE
WARN ABOUT THE 
DANGERS OF TOBACCO
ENFORCE BANS ON 
TOBACCO ADvERTISING, 
PROMOTION AND 
SPONSORSHIP
RAISE TAxES ON 
TOBACCO
Lahore 5 143 495 N     N 8 Pakistan
Lima 10 039 455 N N Peru
London 8 135 667 N C N N United Kingdom of Great Brit-
ain and Northern Ireland
Los Angeles 3 976 322 S N United States of America
Lucknow 2 817 105 N N India
Madrid 3 186 241 N N N N Spain
Mashhad 2 766 258 N N N Iran (Islamic Republic of)
Medan 2 247 425 C Indonesia
Medellín 2 486 723 N N N Colombia
Melbourne 4 353 514 S N N N Australia
Mexico City 21 497 029 S N N Mexico
Monterrey 4 540 429 S N N Mexico
Moscow 11 918 057 N N N Russian Federation
Mumbai 12 442 373 N N India
Mwanza 2 772 509 United Republic of Tanzania
Nagoya 2 295 638 Japan
Nagpur 2 405 665 N N India
Nairobi 3 133 518 N Kenya
New York 8 537 673 N United States of America
Osaka 2 691 185 Japan
Paris 2 243 833 N N N France
Puebla-Tlaxcala 2 986 825 N N Mexico
Pune 3 124 458 N N India
Pyongyang 2 581 076 Democratic People's Republic 
of Korea
Quezon City 2 936 116 N Philippines
Rio De Janeiro 6 498 837 N N N N N Brazil
Riyadh 5 188 286 N N Saudi Arabia
Rome 2 867 672 N N N Italy
Saint Petersburg 4 990 602 N N N Russian Federation
Salvador 2 938 092 N N N N N Brazil
Santiago 5 561 252 N N N Chile
São Paulo 12 038 175 N N N N N Brazil
Seoul 9 834 687 N Republic of Korea
Singapore 5 607 283 N N Singapore
Surabaya 2 874 699 Indonesia
Surat 4 501 610 N N India
Sydney 4 526 479 N N N N Australia
Tangerang 2 139 891 Indonesia
Tashkent 2 393 176 Uzbekistan
Tehran 8 154 051 N N N Iran (Islamic Republic of)
Tokyo 9 272 740 Japan
Toluca 2 225 286 S N N Mexico
Toronto 2 876 095 N N N Canada
Yangon 5 209 541 Myanmar
Yaounde 2 873 567     N 8 Cameroon
Yokohama 3 724 844 Japan
COvERAGE AT THE HIGHEST LEvEL OF ACHIEvEMENT
Notes: An empty cell indicates that the population in the respective city is 
not covered by the measure at the highest level of achievement.
Refer to Technical Note I for definitions of highest level of achievement of 
the respective measure.
* Only cities which appear among the top 100 cities sorted by 
population size, according to the United Nations Statistics Division 
Demographic Yearbook 2016 (available at: https://unstats.un.org/
unsd/demographic-social/products/dyb/documents/dyb2016/ 
table08.xls).
8 Policy adopted but not implemented by 31 December 2018.
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Appendix V shows the status of the 
WHO Framework Convention on 
Tobacco Control (WHO FCTC).
Ratification is the international act 
by which countries that have already 
signed a convention formally state their 
consent to be bound by it. Accession is 
the international act by which countries 
that have not signed a treaty/convention 
formally state their consent to be bound 
by it. Acceptance and approval are the 
legal equivalent to ratification. Signature 
of a convention indicates that a country 
is not legally bound by the treaty but 
is committed not to undermine its 
provisions.
STATUS OF THE WHO FRAMEWORK 
CONvENTION ON TOBACCO CONTROl
Appendix V:
The WHO FCTC entered into force on 
27 February 2005. The treaty remains 
open for ratification, acceptance, 
approval, formal confirmation and 
accession indefinitely for States and 
eligible regional economic integration 
organizations wishing to become Parties 
to it.
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Table 5.1 
Status of the WHO 
Framework Convention 
on Tobacco Control, as 
of 8 May 2019
COUNTRy DATE OF SIGNATURE DATE OF RATIFICATION*  
(OR LEGAL EqUIvALENT) 
Afghanistan 29 June 2004 13 August 2010
Albania 29 June 2004 26 April 2006
Algeria 20 June 2003 30 June 2006
Andorra    
Angola 29 June 2004 20 September 2007
Antigua and Barbuda 28 June 2004 5 June 2006
Argentina 25 September 2003  
Armenia   29 November 2004 a
Australia 5 December 2003 27 October 2004
Austria 28 August 2003 15 September 2005
Azerbaijan   1 November 2005 a
Bahamas 29 June 2004 3 November 2009
Bahrain   20 March 2007 a
Bangladesh 16 June 2003 14 June 2004
Barbados 28 June 2004 3 November 2005
Belarus 17 June 2004 8 September 2005
Belgium 22 January 2004 1 November 2005
Belize 26 September 2003 15 December 2005
Benin 18 June 2004 3 November 2005
Bhutan 9 December 2003 23 August 2004
Bolivia (Plurinational State of) 27 February 2004 15 September 2005
Bosnia and Herzegovina   10 July 2009 a
Botswana 16 June 2003 31 January 2005
Brazil 16 June 2003 3 November 2005
Brunei Darussalam 3 June 2004 3 June 2004
Bulgaria 22 December 2003 7 November 2005
Burkina Faso 22 December 2003 31 July 2006
Burundi 16 June 2003 22 November 2005
Cabo Verde 17 February 2004 4 October 2005
Cambodia 25 May 2004 15 November 2005
Cameroon 13 May 2004 3 February 2006
Canada 15 July 2003 26 November 2004
Central African Republic 29 December 2003 7 November 2005
Chad 22 June 2004 30 January 2006
Chile 25 September 2003 13 June 2005
China 10 November 2003 11 October 2005
Colombia   10 April 2008 a
Comoros 27 February 2004 24 January 2006
Congo 23 March 2004 6 February 2007
Cook Islands 14 May 2004 14 May 2004
Costa Rica 3 July 2003 21 August 2008
Côte d’Ivoire 24 July 2003 13 August 2010
Croatia 2 June 2004 14 July 2008
Cuba 29 June 2004  
Cyprus 24 May 2004 26 October 2005
Czechia 16 June 2003 1 June 2012
Democratic People’s Republic of Korea 17 June 2003 27 April 2005
Democratic Republic of the Congo 28 June 2004 28 October 2005
Denmark 16 June 2003 16 December 2004
Djibouti 13 May 2004 31 July 2005
Dominica 29 June 2004 24 July 2006
COUNTRy DATE OF SIGNATURE DATE OF RATIFICATION*  
(OR LEGAL EqUIvALENT) 
Dominican Republic
Ecuador  22 March 2004  25 July 2006 
Egypt  17 June 2003  25 February 2005
El Salvador  18 March 2004  21 July 2014 
Equatorial Guinea   17 September 2005 a
Eritrea
Estonia  8 June 2004  27 July 2005
Eswatini  29 June 2004  13 January 2006 
Ethiopia  25 February 2004  25 March 2014 
European Union  16 June 2003  30 June 2005 c
Fiji  3 October 2003  3 October 2003 
Finland  16 June 2003  24 January 2005 
France  16 June 2003  19 October 2004 AA
Gabon  22 August 2003  20 February 2009 
Gambia  16 June 2003  18 September 2007 
Georgia  20 February 2004  14 February 2006 
Germany  24 October 2003  16 December 2004 
Ghana  20 June 2003  29 November 2004 
Greece  16 June 2003  27 January 2006 
Grenada  29 June 2004  14 August 2007 
Guatemala  25 September 2003  16 November 2005  
Guinea  1 April 2004  7 November 2007 
Guinea-Bissau   7 November 2008 a
Guyana   15 September 2005 a
Haiti  23 July 2003  
Honduras  18 June 2004  16 February 2005 
Hungary  16 June 2003  7 April 2004 
Iceland  16 June 2003  14 June 2004 
India  10 September 2003  5 February 2004
Indonesia 
Iran (Islamic Republic of)  16 June 2003  6 November 2005 
Iraq  29 June 2004  17 March 2008 
Ireland  16 September 2003  7 November 2005 
Israel  20 June 2003  24 August 2005 
Italy  16 June 2003  2 July 2008 
Jamaica  24 September 2003  7 July 2005 
Japan   9 March 2004  8 June 2004 A
Jordan  28 May 2004  19 August 2004 
Kazakhstan  21 June 2004  22 January 2007 
Kenya  25 June 2004  25 June 2004 
Kiribati  27 April 2004  15 September 2005 
Kuwait  16 June 2003  12 May 2006 
Kyrgyzstan  18 February 2004  25 May 2006 
Lao People’s Democratic Republic  29 June 2004  6 September 2006 
Latvia  10 May 2004  10 February 2005 
Lebanon  4 March 2004  7 December 2005 
Lesotho  23 June 2004  14 January 2005 
Liberia  25 June 2004  15 September 2009 
Libya  18 June 2004  7 June 2005 
Lithuania  22 September 2003  16 December 2004 
Luxembourg  16 June 2003  30 June 2005 
* Ratification is the international act by 
which countries that have already signed 
a treaty or convention formally state their 
consent to be bound by it.
a Accession is the international act by which 
countries that have not signed a treaty/
convention formally state their consent to 
be bound by it.
A Acceptance is the international act, similar 
to ratification, by which countries that 
have already signed a treaty/convention 
formally state their consent to be bound 
by it.
AA Approval is the international act, similar 
to ratification, by which countries that 
have already signed a treaty/convention 
formally state their consent to be bound 
by it.
c Formal confirmation is the international 
act corresponding to ratification by 
a State, whereby an international 
organization (in the case of the WHO 
FCTC, competent regional economic 
integration organizations) formally state 
their consent to be bound by a treaty/
convention.
d Succession is the international act, 
however phrased or named, by which 
successor States formally state their 
consent to be bound by treaties/
conventions originally entered into by 
their predecessor State.
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COUNTRy DATE OF SIGNATURE DATE OF RATIFICATION*  
(OR LEGAL EqUIvALENT) Table 5.1 
Status of the WHO 
Framework Convention 
on Tobacco Control, as 
of 8 May 2019 
(continued)
Madagascar 24 September 2003  22 September 2004 
Malawi 
Malaysia 23 September 2003  16 September 2005
Maldives 17 May 2004  20 May 2004 
Mali 23 September 2003  19 October 2005 
Malta 16 June 2003  24 September 2003 
Marshall Islands 16 June 2003  8 December 2004 
Mauritania 24 June 2004  28 October 2005 
Mauritius 17 June 2003  17 May 2004 
Mexico 12 August 2003  28 May 2004 
Micronesia (Federated States of) 28 June 2004  18 March 2005
Monaco 
Mongolia 16 June 2003  27 January 2004 
Montenegro  23 October 2006 d
Morocco 16 April 2004  
Mozambique 18 June 2003  14 July 2017
Myanmar 23 October 2003  21 April 2004 
Namibia 29 January 2004  7 November 2005 
Nauru  29 June 2004 a
Nepal 3 December 2003  7 November 2006 
Netherlands 16 June 2003  27 January 2005 A
New Zealand  16 June 2003  27 January 2004  
Nicaragua 7 June 2004  9 April 2008 
Niger 28 June 2004  25 August 2005 
Nigeria 28 June 2004  20 October 2005 
Niue 18 June 2004  3 June 2005 
North Macedonia   30 June 2006 a 
Norway 16 June 2003  16 June 2003 AA
Oman  9 March 2005 a
Pakistan 18 May 2004  3 November 2004 
Palau 16 June 2003  12 February 2004 
Panama 26 September 2003  16 August 2004 
Papua New Guinea 22 June 2004  25 May 2006 
Paraguay 16 June 2003  26 September 2006 
Peru 21 April 2004  30 November 2004 
Philippines 23 September 2003  6 June 2005 
Poland 14 June 2004  15 September 2006 
Portugal 9 January 2004  8 November 2005 AA
Qatar 17 June 2003  23 July 2004 
Republic of Korea 21 July 2003  16 May 2005
Republic of Moldova 29 June 2004  3 February 2009 
Romania 25 June 2004  27 January 2006 
Russian Federation  3 June 2008 a
Rwanda 2 June 2004  19 October 2005 
Saint Kitts and Nevis       29 June 2004  21 June 2011
Saint Lucia       29 June 2004  7 November 2005
Saint Vincent and the Grenadines  14 June 2004  29 October 2010 
Samoa 25 September 2003  3 November 2005 
San Marino 26 September 2003  7 July 2004 
Sao Tome and Principe 18 June 2004  12 April 2006 
Saudi Arabia 24 June 2004  9 May 2005 
COUNTRy DATE OF SIGNATURE DATE OF RATIFICATION*  
(OR LEGAL EqUIvALENT) 
Source: United Nations Treaty Collection web site https://treaties.un.org/pages/ViewDetails.aspx?src=TREATY&mtdsg_no=IX-
4&chapter=9&lang=en, accessed 8 May 2019).
Though not a Member State of WHO, as a Member State of the United Nations, Liechtenstein is also eligible to become Party to the 
WHO FCTC, though it has taken no action to do so.
On submitting instruments to become Party to the WHO FCTC, some Parties have included notes and/or declarations. All notes can be 
viewed at https://treaties.un.org/pages/ViewDetails.aspx?src=TREATY&mtdsg_no=IX-4&chapter=9&lang=en
Senegal 19 June 2003  27 January 2005 
Serbia 28 June 2004  8 February 2006 
Seychelles 11 September 2003  12 November 2003 
Sierra Leone  22 May 2009 a
Singapore 29 December 2003  14 May 2004 
Slovakia 19 December 2003  4 May 2004 
Slovenia 25 September 2003  15 March 2005 
Solomon Islands 18 June 2004  10 August 2004
Somalia 
South Africa 16 June 2003  19 April 2005
South Sudan 
Spain 16 June 2003  11 January 2005 
Sri Lanka 23 September 2003  11 November 2003 
Sudan  10 June 2004  31 October 2005 
Suriname  24 June 2004  16 December 2008 
Sweden  16 June 2003  7 July 2005 
Switzerland  25 June 2004  
Syrian Arab Republic  11 July 2003  22 November 2004  
Tajikistan   21 June 2013 a
Thailand  20 June 2003 8 November 2004 
Timor-Leste  25 May 2004  22 December 2004 
Togo  12 May 2004  15 November 2005 
Tonga  25 September 2003 8 April 2005 
Trinidad and Tobago  27 August 2003  19 August 2004 
Tunisia  22 August 2003  7 June 2010 
Turkey  28 April 2004  31 December 2004 
Turkmenistan   13 May 2011 a
Tuvalu  10 June 2004  26 September 2005 
Uganda   5 March 2004  20 June 2007 
Ukraine  25 June 2004 6 June 2006 
United Arab Emirates  24 June 2004 7 November 2005 
United Kingdom of Great Britain and Northern Ireland 16 June 2003  16 December 2004 
United Republic of Tanzania  27 January 2004  30 April 2007 
United States of America  10 May 2004  
Uruguay  19 June 2003 9 September 2004  
Uzbekistan   15 May 2012 a
Vanuatu  22 April 2004  16 September 2005 
Venezuela (Bolivarian Republic of)  22 September 2003  27 June 2006 
Viet Nam   3 September 2003  17 December 2004  
Yemen  20 June 2003  22 February 2007
Zambia   23 May 2008 a
Zimbabwe   4 December 2014 a
* Ratification is the international act by 
which countries that have already signed 
a treaty or convention formally state their 
consent to be bound by it.
a Accession is the international act by which 
countries that have not signed a treaty/
convention formally state their consent to 
be bound by it.
A Acceptance is the international act, similar 
to ratification, by which countries that 
have already signed a treaty/convention 
formally state their consent to be bound 
by it.
AA Approval is the international act, similar 
to ratification, by which countries that 
have already signed a treaty/convention 
formally state their consent to be bound 
by it.
c Formal confirmation is the international 
act corresponding to ratification by 
a State, whereby an international 
organization (in the case of the WHO 
FCTC, competent regional economic 
integration organizations) formally state 
their consent to be bound by a treaty/
convention.
d Succession is the international act, 
however phrased or named, by which 
successor States formally state their 
consent to be bound by treaties/
conventions originally entered into by 
their predecessor State.
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